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Abstract 
Prion diseases are fatal transmissible neurological disorders afflicting a variety 
of mammalian species and include scrapie in sheep, bovine spongiform 
encephalopathy in cattle and Creutzfeldt-Jakob disease in humans. The prion protein 
(PrP') is a normal host-encoded glycoprotein which accumulates as a disease specific 
protease-resistant isoform (PrP) in the brains of infected hosts. In a number of 
species PrP polymorphisms and germline mutations are associated with the 
modulation of disease phenotype and the occurrence of familial prion disease. 
To investigate the biological consequences of manipulation of the prion 
protein in mice a flexible two step double replacement gene targeting strategy was 
developed. This method can be used to generate a series of mouse lines with 
alterations to the mouse prion protein gene (Prn-p). To facilitate gene targeting 
studies a restriction map of the 129/01a Pm-p locus was constructed and a series of 
overlapping genomic clones were retrieved from a ? DASH II bacteriophage 129/01a 
library. 
The double replacement strategy was used to generate PrP deficient mice and 
mice with subtle alterations to PrP codons 108 and 189. Murine PrP 1 08L/F and 
189T/V dimorphisms give rise to 2 distinct PrP protein allotypes, PrP A and PrP B 
and these are postulated to be responsible for the control of incubation time following 
challenge with a wide range of prion inocula. To test this proposal the endogenous 
129/01a PrP A allotype [1 08L1 89T] was converted by gene targeting to encode the 
PrP-B allotype [108F 189V]. Mice bearing codon 108 and 189 alterations were 
challenged with mouse adapted BSE isolate 301V. Gene targeting in 129/01a derived 
HIM-1 ES cells and breeding with 129/01a mice enabled the investigation of the effect 
of PrP alterations in the absence of PrP overexpression artefacts or the influence of 
non-Pm-p genes. The dramatic acceleration of incubation time in PrP gtB/gtB mice 
homozygous for the Pm-p a[108F_189V]  gene targeted allele confirmed the major role of 
codons 108 and 189 in the control ofBSE isolate 301V incubation time -and probably 
other prion isolates. This data provides the strongest evidence yet that the incubation 
xl 
time control long attributed to the action of different alleles of Sinc (Pm-i) are 
determined by PrP codon 1 08L/F and 1 89T/V dimorphisms. 
XII 
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Section 1: The biology of prion diseases 
Section 1.1: Introduction 
Prion diseases are transmissible degenerative encephalopathies of the central 
nervous system and occur in a number of mammalian species (Table 1. 1, p4). The 
molecular nature of the infectious agent remains controversial, however there is good 
evidence that it is associated with ppSc  a protease resistant isoform of a host-
encoded glycoprotein, PrP' (Bolton et al., 1982; McKinley et al., 1983). Prusiner has 
proposed that PrPSC  may be the major (or sole) component of a novel agent, or prion 
(Prusiner, 1982a), which may "replicate" in the absence of nucleic acid': if this is 
correct then prions are without precedent in the history of biology or medicine. 
A large and growing body of evidence derived from biophysical, biochemical 
and transgenic experiments confirm that PrP is of central importance to this disease 
class (Prusiner, 1997). PrP amino acid sequence variations mediate a number of 
aspects of these diseases. For example, germline mutations in humans are linked, or 
associated with, the occurrence of familial prion diseases (Table 1.2, Ps)  and PrP 
interspecies sequence variation between hosts is at least one major determinant of the 
species barrier effect. Mice are the main experimental hosts for a range of prion 
diseases including BSE, scrapie and Creutzfeldt-Jakob disease. This thesis describes 
mapping and gene targeted modification of the mouse prion protein gene and, 
specifically, investigates the role of murine PrP codon 108 and 189 polymorphisms in 
the control of incubation time following experimental challenge. The fundamental 
importance of these residues is underlined by the following observations i) despite 
numerous PrP amino acid sequence differences between mice and natural hosts for 
these diseases (sheep, cattle, humans), murine PrP dimorphisms at codons 108 and 
189 are consistently associated with large differences in incubation time following 
primary passage with a variety of inocula and ii) mouse adapted scrapie, BSE and 
CJD isolates retain large differences in incubation times between mice with dimorphic 
codon 108 and 189 residues. However, the relationship between PrP and mouse genes 
However there are alternative models of the infectious agent including the virino hypothesis (Dickinson and 
Outram, 1988). 
2 	 Chapter 1: Introduction 
Sine and Pm-i, which are known to modulate incubation times, remains uncertain. 
The use of gene targeting to modify PrP codon 108 and 189 sequence dimorphisms is 
explored in an attempt to delineate the relationship between PrP and these incubation 
time control genes. 
Section 1.1.2: The spectrum of prion diseases 
Sheep scrapie has been documented in the UK for in excess of 250 years 
(M'Gowan, 1914) and its transmissibility was demonstrated in 1936 (Cuille and 
Chelle, 1936). Epidemiological analysis indicates that the spread of natural scrapie is 
mainly by maternal transmission (Dickinson, 1976), although horizontal transmission 
also occurs. Related disorders have been described in other species based upon 
transmission to experimental hosts and clinical and neuropathological similarities to 
scrapie. For example, transmissible mink encephalopathy (TME) was first described in 
the 1960's in ranched mink (Hartsough and Burger, 1965) and was subsequently 
shown to be transmissible (Marsh, 1976; Marsh and Hanson, 1979). Bovine 
spongiform encephalopathy was first described in dairy cattle in 1987 (BSE: Wells et 
al., 1987) and was transmitted to mice in 1988 (Fraser et al., 1988). The origin of 
BSE is presumed to be a scrapie-like agent contaminating meat and bone meal feed 
supplements (Wilesmith et al., 1988). 
Human prion diseases include Kuru (Gadjusek and Zigas, 1957), Gerstmann-
Straussler-Scheinker disease (GSS: Gerstmann et al., 1936), Creutzfeldt-Jakob 
disease (CJD: Creutzfeldt, 1920; Jakob, 192 1)2  and Fatal Familial Insomnia (FF1: 
Lugaresi et al., 1986). Kuru is an epidemic prion disease transmitted by 
endocaimibalism amongst members of the Fore linguistic group in the highlands of 
Papua New Guinea (Gadjusek, 1985). Kuru has been responsible for a large number 
of deaths since 1950 -although the incidence of disease has declined markedly in 
recent years, partly as a result of government intervention and the erosion of Fore 
traditional culture. Creutzfeldt-Jakob disease has several epidemiological 
manifestations: sporadic, familial and iatrogenic. Sporadic CJD has an incidence of 
2  See Creutzfeldt, (1989) and Jakob, (1989) for recent English translations 
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Scrapie Field scrapie; experimentally transmitted to sheep, goats, mice, rats ,hamsters and cattle (Gibbs et al., 1990). 
Scrapie 	 Natural cases rare 
Transmissible mink 	Infection in farmed mink; source of infection probably scrapie infected offal. Experimentally transmitted to hamsters. 	North America; Europe 
encephalopathy 
Chronic wasting disease 	Infection of farmed deer probably from scrapie contaminated feed. Experimentally transmitted to other deer. 	 North America 
Chronic wasting disease 	Infection in farmed elk, probably derived from scrapie infected feed. 	 North America 
Bovine spongiform 	UK BSE epidemic mostly in Holstein Friesian dairy cattle; scrapie contamination of feed. Experimentally transmitted 
encephalopathy to mice (Fraser et al., 1988), pigs (Dawson et al., 1990), monkeys (Lazxnesaa et al, 1996). 
Cuille and Chelle, 1936 
Wood, Lund and Done, 1992 
Cuille and Chelle, 1939; Pattison and Millson, 
1960 
Marsh and Kimberlin, 1975; McKenzie et al., 
1996 
Williams and Young, 1980; Williams, Young 
and Marsh, 1982 
Williams and Young, 1982 
UK; Republic of Ireland; 	Wells et al., 1987 
Europe1' 
a Infection in a zoo specimen. UK Kirkwood et al., 1990 
a Infection in a zoo specimen. UK Jeffrey and Wells, 1988; HMSO, 1987 
a Infection in a zoo specimen. UK Kirkwood et al., 1990 
a Infection in a zoo specimen. UK Fleetwood and Furley, 1993 
a Infection in a zoo specimen. UK Jeffrey and Wells, 1988 
a Infection in >75 domestic cats. Transmitted to mice (Bruce et al, 1994). UK, Norway Wyatt et al., 1990; Bratberg,Ueland and Wells, 
a Infection ins zoo specimen UK 1995; Willoughby et al., 1992 
a Infection in a zoo specimen UK 
Creutzfeldt-Jakob Disease Sporadic: 106  incidence; not associated with prion protein (PrP) mutations. Experimentally transmitted to Worldwide Creutzfeldt, 1920; Jakob, 1921 
(sCJD) chimpanzees (Gibbs et al, 1968), monkeys, cats and mice 
iCJD latrogenic: transmission following neurosurgery, comeal transplant and dura mater waft. Worldwide Gadjusek, 1985; Buchanan Cl al, 1991 ;Lane et 
al., 1994 
ltJt) Familial: linked to mutations in prion protein (PrP); autosomal dominant, some have variable penetrance. Worldwide for review, see Prusiner, 1994 
Gerstmann- Straussler Familial disorder tightly linked to mutations in the prion protein (PrP) Worldwide Gerstmann et al., 1936, Hsaio et al., 1989 
Scheinker- syndrome 
Fatal Familial Insomnia Familial disorder linked to germline mutation in prion protein (PrP) in association with a common PrP polymorphism. Worldwide For review see Gambetti et al., 1993 
Kuru Sporadic Cii) spread and maintained by cannibalism; endemic to a remote highland region of Papua New Guinea, Papua New Guinea Gadjusek and Zigas, 1957; Gadjusek, 1985 
Experimentally transmitted to goats, primates and rodents. 
CID new variant (nvCID) Unusual CID variant in UK (20 cases) and France (1 case) with early onset (<49yrs), unusual clinical presentation and UK and France Will et al., 1996; Chazot 01 al., 1996 
neuropathology. PrP' from nvCJt) cases has similar SDS-PAGE banding pattern to BSE PrP` (Collinge et al, 1996). 
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:familial; nv:new vca 
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Table 1.2: Human familial prion diseases associated with PrP mutations 
Disease Mutation Onset/Duration Clinkalfeatures Neuropathology Reference 
yr:year/m:months 
fCID 120bp insertion 31-45yr / 5-15 yr Dementia with myoclonus Spongiosis, neuronal loss and reactive gliosis Goldfarb et al., 1991a 
fEll) 144bp insertion 22-52 yr/ 1-13 yr Early personality changes Widespread atrophy with PrP amyloid plaques Poulter et al., 1992 
progressing to dementia with 
ataxia and myoclonus 
1)31) 168bp insertion 23-35 yr/ >10 yr Similar to 144bp insertion Widespread atrophy with spongiosis. Brown et al., 1992 
IEID 196bp insertion 35-54 yr/ 3 m- I 3yr Abnormal behaviour, ataxia, Widespread atrophy with mild spongiosis. PrP amyloid plaques in cerebrum and cerebellum. Owen et al., 1992 
mutism, myoclonus 
GSS 102 Pro-Leu 1 5-4Oyr / 2-1 Oyr Cerebellar ataxia, extra/pyramidal PrP amyloid plaques in cerebral and cerebellar cortex., also in white matter of basal ganglia and Hsaio et al., 1989 
signs with late onset dementia thalamus. 
GSS 105 Pro-Leu 42yr / 9yrs Clumsiness, gait disturbance, Kitamoto et al., 1993 
decline in intellectual function. 
GSS 117 Ala-Val 35yr/ - Dementing form Dementing form (telancephalic GSS) no cerebellar pathology. Doh-ura et at, 1989 
Ataxic form Ataxic form: widespread cerebellar pathology with PrP amyloid plaques Mastrianni et al., 1995 
Atypical Prion 145 Tyr -stop [amber 38 yr/death at 59 yrs Slowly progressive Alzheimer's- Numerous Kum plaques and neurofibrillary tangles but little spongiform change. Plaques Kitamoto et al. 1993 
Disease mutation] like disease ma single Japanese 
woman. 
contained only truncated PrP derived from the mutant allele. 
fEuD 178 Arg-Asn in phase 26-56 yr/ 9-51 m Similar to sCJD. Spongiosis of cerebral cortex, little thalamic pathology (see FF1). Goldfarb et al., 1991b 
with 129 Val 
FF1 178 Arg.Asn in phase 20-71 yr / 6-32 m Untreatable insomnia, endocrine Minimal cortical spongiosis. Selective thalamic atrophy; neuronal loss and gliosis in inferior Goldfarb et al., 1992b; Gambetti et al., 
with 129 Met abnormalities, olive. 1993 
CII) 18OVal-Ile Similar tosCiD Similar tosCifl Kitainotoetal., 1993 
GSS I 98Phe-Ser 34-71 yr/ 3-I1 m Similar to codon 102 mutation but Similar to codon 102 mutation but with widespread Alzheimer's type rseumfibrillaiy tangles Hsaio et al., 1992; Dloughy et al., 1992 
with NFT with early dementia. (NFT) in cerebral cortex. 
ICJD 200Gln-Lys 35-66yr / 2-41 m Similar to sporadic CID. Widespread spongiosis which extends to deep brain nuclei, cerebellum and brain stem. Goldfarb et al., 1990; Goldfarb et al., 
Penetrance estimated at 0.56 1991c 
1)JD 208Arg-His Mastrianni et al., 1996 
iDID 21OVal-Ile Incomplete penetrance. Pocchiari et al., 1993 
GSS 217Glu-Arg PrP amyloid plaques and occasional neocortical NFT Ikeda et al., 1991 
Cli) 232Met-Arg Codon 1 8OIle/232Arg double mutant genotype described in a single Japanese man of 84 years Kitamoto et al., 1993 
with a sporadic CID-like presentation (Hitcahi et al, 1993). 
FF1: fatal familial insomnia; NFT: neurofibrillary tangles 
10-6  and an average onset age of 65 years (Masters et al., 1979; Brown et al., 1987). 
Approximately 10% of CJD cases (and all GSS and FF1 cases) are autosomal 
dominant familial disorders with tight linkage to mutations in the prion protein gene 
(See Table 1.2, p5; for review see Prusiner, 1994). A small number of iatrogenic CJD 
cases have arisen as a result of transmission from contaminated neurosurgical 
instruments, dura mater grafts (Lane et al., 1994), cornea! transplants (Gadjusek, 
1985), contaminated cadaver-derived pituitary growth hormone and gonadotrophin 
(Buchanan et al., 1991). In The UK, much interest has been generated by the possible 
association between consumption of B SE-infected food products and the recent 
emergence of a new variant of CJD, (nvCJD) with an earlier age of onset and a novel 
clinico-pathological phenotype (Will et al., 1996; Chazot et al., 1996). 
Section 1.1.3: Clinical manifestations and neuropathology 
The effects of prion diseases are generally limited to the CNS and the clinical 
signs are almost entirely neurological. Gross neuropathology can include reduced 
brain weight, cortical atrophy and enlargement of the ventricles, whilst histological 
CNS abnormalities include spongiform degeneration, neuronal perikaryal vacuolation, 
conspicuous neuronal loss, amyloid plaques and astroglial hypertrophy (Bell and 
Ironside, 1993; DeArmond and Prusiner, 1997). A florid CNS microglial response has 
been described in CJD and scrapie, which may represent a modified form of 
inflammatory response (Ironside et al., 1993; Williams et al., 1994). Widespread 
apoptosis has been described in the brains of sheep, mice and humans with these 
disorders and may be a major mode of cell death (Fairbairn et al., 1994; Lucassen et 
al., 1995; Giese et al., 1995). 
Natural scrapie in sheep can appear in a number of distinct syndromes 
including a scratching disorder or as a general paralysis (Pattison and Millson, 1960) 
and has been attributed to the actions of distinct strains (see section 1.1.5). BSE signs 
include apprehension, pelvic gait ataxia and hyperaesthesia (Wells et al., 1987; 
Cranwell et al., 1988; Gilmour et al., 1988) with post mortem diagnosis made from 
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characteristic vacuolar neuropathology in the medulla oblongata (Wells et al., 1989). 
The clinical signs of human prion diseases are variable but include progressive 
dementia, ataxia and behavioural disturbances. The clinical presentation of Kuru is 
comparatively uniform and consists of a progressive cerebellar disorder leading to 
recumbency, often with sparing of higher cortical function, but is invariably fatal 
within 3 to 12 months of onset (Gadjusek, 1985; Liberski and Gadjusek, 1997). 
Successful transmission of Kuru' to chimpanzees was reported in 1966 (Gadjusek, 
Gibbs and Alpers, 1966) following an incubation time of 18 months. 
Sporadic CJD results in dementia often with cerebellar and visual deficits. 
Many patients are in their fifth or sixth decade at onset4. CJD was first shown to be 
transmissible in 1968 following transmission to chimpanzees (Gibbs et al., 1968) and 
has subsequently been transmitted to a wide range of non-human primates. The 
recently described novel variant of CJD, nvCJD (Will et al., 1996; Chazot et al., 
1996), is unusual in that it occurs at a much earlier age than sCJD and has a number 
of unusual features including prominent early psychiatric manifestations. 
GSS generally presents as a progressive cerebellar ataxia with Parkinsonism 
and nystagmus leading to dementia and has three recognised manifestations: ataxic, 
telencephalic and dementing with pathologic quantities of neurofibrillary tangles. GSS 
subtypes are associated with germline PrP mutations at codons 102, 117 and 198 
respectively (reviewed by DeArmond and Prusiner, 1997). The first successful 
transmission of GSS was reported in 1981 (Masters et at., 1981). 
Fatal Familial Insomnia is a familial prion disease linked to a PrP germline 
mutation in association with codon 129 met (Table 1.2, p5) and characterised by 
intractable insomnia, dysautonomia, multiple endocrine abnormalities and severe 
selective atrophy of the thalamic nuclei (Lugaresi et at., 1986; Gambetti et al., 1992, 
1993) The first successful transmission of FF1 was reported in 1995 (Tateishi et al., 
1995). 
Hadlow first noted the clinical and histopathological similarities between Kuru and scrapie and suggested that 
Kuru brain material be tested for transmissibility (Hadlow, 1959). 
Although there are a limited number of documented cases of teenagers with sCJD (Berman, Davidson and 
Becker, 1988; Brown etal., 1985; Britton et al., 1995). 
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Section 1.1.4: Prion diseases are transmissible following long incubation times 
The transmission of scrapie and other prion diseases to rodents, especially 
mice (Chandler, 1961) has enabled the detailed investigation of many features of 
pathogenesis. The response to experimental inoculation is characterised by a long 
asymptomatic pre-clinical phase which is followed by a relatively short clinical illness 
and death. An intriguing feature of scrapie is precise timing of disease onset under 
controlled conditions: if inbred mice are given the same dose of agent by the same 
route, all can die within days of each other following a prolonged incubation period of 
up to 1 year or considerably longer (Scott, 1993). The small standard error and 
reproducibility of incubation times has enabled the estimation of agent titre by 
endpoint titration (Chandler, 1961; Dougherty, 1964) and incubation time interval 
assay (Prusiner et al., 1980; Prusiner et al., 1982b) in mice and hamsters'. Intracranial 
inoculation is commonly used for titration (and thus titres are expressed as i.c. m50) 
but other routes are available, and include intragastric, intravenous, subcutaneous, 
intraocular6 . 
There is evidence that this precise timing can be a feature of human prion 
disease -analysis of a number of Kuru cases whose illness is attributable to 
participation in the same cannibalistic meal7, has shown that disease can develop 
within months of each other following an incubation period of 25-30 years (Klitzman, 
Alpers and Gadjusek, 1984). 
End point titration is a quantal assay which requires the inoculation of groups of susceptible animals (usually 
mice or hamsters) with tenfold serial dilutions of crude brain homogenate. The titre is determined by the 
highest dilution at which 50% of the animals develop scrapie and is expressed as 11)50 or LD50 (ID=LD here 
because these diseases are always fatal). The incubation interval assay estimates the infectious dose based upon 
the incubation time alone and is based upon observations that the incubation time was related to the dose of 
agent (Dickinson et al., 1969; Elkund, Kennedy and Hadlow, 1965). Estimates of scrapie titre using this method 
are very similar to those made by endpoint titration (Prusiner et al., 1992b) and have a number of advantages 
over end-point titration, most notably being much faster titration experiments and the reduced number of 
animals required. 
6  Each inoculation route is associated with a different LD50 (the effective dose) and gives an estimate of the 
relative efficiency of each route (Kimberlin and Walker, 1978b; Kimberlin and Walker, 1979). It has also been 
shown that application of infectious material directly onto skin which has been mildly scarified is as effective a 
route as intraperitoneal inoculation (Scott, 1993). The most efficient route is via the spinal cord (Kimberlin et 
al., 1987). 
Exposure to the infectious agent is thought to have occurred during cannibalistic mourning rites in which 
women, young females and males under 6 years eat the lightly cooked tissues of recently deceased relatives. 
The limited involvement of males in these practices may explain the predominately female incidence of kuru. 
Kuru is considered to be an epidemic form of CJD (reviewed by Gadjusek, 1977, 1985). 
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Whilst it is clear that incubation times are influenced by route and dose, 
incubation times are also determined by scrapie strain properties as illustrated by the 
large differences noted in the same inbred mouse host for different isolates (Figure 
1. 1, p12) (Dickinson and Fraser, 1977; Bruce et al., 1991). However, it is clear that 
host genes modulate the incubation time because the same strain can have very 
different incubation times in different inbred mouse strains (Table 1.4, p3  1) 
(Dickinson, Meikie and Fraser, 1968; Carlson et al., 1986; Carlson et al., 1988; Race 
et al., 1990). The role of host genotype in incubation time control is the main subject 
of this thesis and is discussed at length in section 1.3 and thereafter. 
Section 1.1.5: Strains 
Heterogeneity in the clinical presentation of natural scrapie in sheep was long 
thought to indicate that there may be different "strains" of scrapie. Evidence for the 
existence of multiple strains was provided upon transmission of scrapie to goats -this 
gave rise to two distinct clinical syndromes called "drowsy" and "scratching" which 
could be serially passaged in goats, retaining their distinct properties (Pattison, 1960; 
Pattison and Milison, 1960, 1961). In the last 30 years many strains of sheep scrapie 
have been transmitted and propagated in mice (see Figure 1.1, p12; Foster and 
Dickinson, 1988) and hamsters (Kimberlin and Walker, 1978a; Kimberlin et al., 
1989a). A number of other prion diseases with distinct strains have also been 
transmitted to mice including TME (Marsh and Kimberlin, 1975) and CJD (Mohri and 
Tateishi, 1989; Kitamoto, Mohri and Tateishi, 1990). 
Strains can be differentiated or "typed" on the basis of their different but 
remarkably reproducible incubation times and neuropathology in inbred mouse strains 
such as C57 and VMIDk. Pathological changes in brain can be quantified in standard 
brain areas and displayed graphically as "lesion profiles" (Fraser and Dickinson, 1968; 
Fraser and Dickinson, 1973). Lesion profiles are highly reproducible over a large dose 
range provided the major experimental variables of agent strain, host strain and route 
of inoculation remain constant. Differing lesion profiles arise from the effects of 
strain-specific propagation in predilection sites. A number of other strain properties 
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have been described including differential susceptibility to thermal inactivation 
(Dickinson and Taylor, 1978) and the ease of transmission to other species (Kimberlin 
and Walker, 1978a, 1989a). Strains differ with respect to their CNS replication sites 
(Bruce, McBride and Farquar, 1989) but differ also in the timing and distribution of 
ppSC and infectivity in non-CNS organs such as pancreas and lymphoreticular system 
(Farquar et al., 1994a; Farquar et al., 1996). 
The existence of multiple strains argues that the agent carries biological 
information capable of specifying strain properties. The biological diversity of scrapie 
strain characteristics together with the ability to "clone" strains with stable biological 
properties from mixtures (Kimberlin and Walker, 1978a; Kimberlin, Walker and 
Fraser, 1989) is also considered by some to be evidence that the agent carries 
information encoded by a nucleic acid (Bruce, 1993). In contrast to the stability of 
strain properties, scrapie strain characteristics have also been shown to "mutate" 
under certain circumstances and this is also considered by some workers to be strong 
evidence that the scrapie agent has an independent genome (Bruce and Dickinson, 
1987) -possibly a nucleic acid. However there is no direct evidence for a nucleic acid 
component in the agent despite several decades of searching (for review, see Liberski, 
1994)8. Indeed, efforts to detect scrapie specific nucleic acids have identified a 
number of host genes differentially expressed during scrapie infection 9 . 
8  Although, one must bear in mind Carl Sagan's dictum that "absence of evidence is not evidence of absence. 
A number of gene products whose expression is increased during scrapie infection have been identified by 
subtractive hybridisation and include polyubiquitin C, hsp 70, transferrin, aB crystallin, metallothionein II, 
vimentin, 32 inicroglobulin, apolipoprotein B, cathepsin D and sulphated glycoprotein 2 (Duguid and 
Dinauer, 1989). GFAP, a putative PrP' ligand (Oesch et al., 1990), is also increased during scrapie infection 
(Diedrich et al., 1987). However, it is likely that many of these genes are involved in tissue response to 
damage and are not of primary importance to prion diseases per se e.g GFAP overexpression is unsurprising-
given 
g
 that glial hypertrophy is a feature of prion diseases - indeed GFAP null mice are viable and have a 
normal scrapie incubation time (Gomi et al., 1995). It has been proposed that Apo E has a significant role in 
CJD because carriers of the E4 allele have an earlier age of onset and a more rapid clinical progression than 
those with the E2 allele (Pickering-Brown et al., 1995) however Apo E null mice have unaltered scrapie 
incubation times and neuropathology (Tatzelt et al., 1996). 
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Figure 1.1: Scrapie strains 
A number of TSE or prion strains have been isolated in mice from a range of sources 
including sheep scrapie and BSE. These have characteristic lesion profiles and 
incubation times in standard mouse strains such as C57BL, VMIDk and 
F1[C57xVM]. Incubation times are controlled by Sine, a gene with two alleles, s7 and 
p7 (Dickinson, Meikle and Fraser, 1968). The pattern of allelic interaction observed 
between Sine and the agent is strain dependent. Strains such as 22C, 22L, 79A and 
139A are similar to ME7 in that they have short incubation times in Sine 
7,7 mice. 
However, in a number of strains (22A and 301V), Sine 17
p7  mice have the shorter 
incubation times. Additional complexity is apparent in Sine 
s7p7 mice which reveal a 
range of dominance patterns including co-dominance with ME7, almost complete 
dominance with 79A and 301V and overdominance with 22A, 139A and 301C (not 
shown). Adapted from Bruce et al., 1991 and Bruce et al., 1994. 









ME7 22C 22L 79A 139A 22A 301V 
Agent strain 
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Section 1.2: The prion protein 
Section 1.2.1: SAF, prion rods and the prion protein, PrP. 
Prusiner and co-workers enriched the scrapie agent 100-1000 fold with 
respect to protein and found a protease resistant protein (PrP) of 27-3OkDa 
copurifying with infectious fractions, called PrP27-30 (Prusiner et al., 1982a). 
Prolonged proteinase K digestion was found to reduce the agent titre and this was 
paralleled by the digestion kinetics of PrP27-30, suggesting that this protein was a 
component of the infectious agent (Bolton et al., 1982; McKinley et al., 1983). 
Purification of hamster PrP27-30 to near homogeneity by a combination of 
detergent extraction, proteinase digestion and sucrose density gradient sedimentation 
enabled the N-terminal peptide sequence of PrP 27-30 to be determined (Prusiner et 
al., 1984). This led to the cloning of partial PrP cDNA clones from scrapie infected 
hamster (Oesch et al., 1985) and mouse brain (Chesebro et al., 1985). Later, the full 
length PrP cDNA clones were retrieved (Basler et al., 1986; Locht et al., 1986) and it 
was subsequently found that both infected and uninfected animals have an endogenous 
gene encoding PrP27-30 (Basler et al., 1986), indicating that PrP 27-30 was not the 
gene product of a viral pathogen but is the product of the host PrP gene. PrP 27-30 
was found to be a protease resistant core derived from frill length PrP33-35 kDa by 
partial proteolysis during purification. Thus it became apparent that both infected and 
normal animals contained a full length PrP33-35 but that PrP33-35 from diseased 
animals was resistant to protease digestion and insoluble in detergents. PrP from 
healthy animals was found to be completely hydrolysed by mild protease digestion and 
was soluble in non-denaturing detergents. Normal (i.e. protease sensitive) PrP was 
termed PrP' and the protease resistant infection specific isoform was denoted by PrPSC 
-although some authors refer to these PrP isoforms as PrP sen  and PrP res  respectively 
(Caughey and Chesebro, 1997). 
Unique scrapie-associated fibrils (SAF) were described in scrapie and CJD 
infected brains (Merz et al., 1981) and are composed of paired helical filaments of 
100-1 000nm in length. Prion rods were described in preparations of detergent treated 
PrP 27-30 and are heterogeneous 100-200nm long flattened amyloid rods (Bolton et 
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al., 1982) which are probably an artefact of the purification procedure. Further 
analysis of prion rods (Prusiner et al., 1983) and SAF (Hope et al., 1986) 
demonstrated that PrP27-30 was a major component of these structures. 
The in vivo relevance of PrP27-30, or rather PrPSC,  was confirmed by the 
observation that antisera raised against PrP 27-30 stained amyloid plaques in the brain 
of scrapie infected mice (DeArmond et al., 1985). PrP antisera have subsequently 
been used to detect PrP accumulation in the brains of humans with CJD (Bockman et 
al., 1985), GSS and Kuru (Brown et al., 1986). PrPSC  has also been described in 
natural and experimental scrapie in sheep (Rubenstein et al., 1987), BSE (Hope et al., 
1988b) and range of experimental murine scrapie strains (Kascsak et al., 1985; 
Kascsak et al., 1986; Hope et al., 1986; Hope et al, 1988a). 
PrPS accumulates in the brains of infected animals although PrP mRNA levels 
do not change throughout the course of scrapie infection (Oesch et al., 1985; 
Chesebro et al., 1985) suggesting that the accumulation of PrPS  occurs as a 
consequence of alterations to protein turnover. Supporting evidence is provided by 
metabolic labelling studies in scrapie infected mouse neuroblastoma cells which show 
that, whilst PrP' has a half life of -3-6 hours, PrPSC  is synthesised slowly (-1 Shours), 
is derived from PrPC  post translationally (Borchelt et al., 1990; Caughey et al., 1991) 
and accumulates within the cytoplasm of scrapie infected cells (Taraboulos et al., 
1990). 
Section 1.2.2: Tissue distribution and expression levels of PrP' 
PrPC is most abundant in the CNS but is found at lower levels in a range of 
non-CNS tissues in mice, hamsters and sheep (Horiuchi et al., 1995). PrP' is also 
found in glia (Moser et al., 1995) and in epithelial cells of the choroid plexus (Brown 
et al., 1990). PrP' has been localised to the synaptic boutons of hamster hippocampus 
where it colocalises with synaptophysin (Fournier et al., 1995) and has been detected 
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in the postsynaptic domain of the neuromuscular junction where it colocalises with 13-
APP (Sarkozi, Askanas and Engel, 1994) suggesting a physiological role in muscle'0 . 
In situ hybridisation of mouse brain indicates that PrP mRNA is widely expressed, 
being present at highest levels in the pyramidal neurons of the hippocampus, 
cerebellar Purkinje neurons and in large neurones in the thalamus and neocortex 
(Manson, McBride and Hope, 1992). Intermediate levels of mRNA expression are 
found in cardiac myocytes and lung septal interstitial cells (Oesch et al., 1985). Low 
levels of PrP mRNA are found in skeletal muscle, spleen (Westaway et al., 1987) 
kidney and liver (Kretzschmar et al., 1986). PrP mRNA and f3-APP have been 
detected in human muscle macrophages (Askanas et al., 1995). PrP' is also expressed 
by lymphocytes (Cashman et al., 1990), follicular dendritic cells in the spleen and in 
lymph nodes (McBride et al., 1992; Bendheim et al., 1992). 
Immunohistochemical detection of PrP' in adult mouse brain demonstrates 
that only a subset of cells expressing PrP mRNA actually produce PrP' (Manson, 
McBride and Hope, 1992). This discrepancy suggests translational control of PrP 
expression. The factors involved in the control of PrP expression are poorly defined 
although NGF has been shown to increase PrP mRNA levels both in vivo (Mobley et 
al., 1988) and in vitro (Wion et al., 1988; Lasmesas et al., 1993). Recombinant 
growth hormone and one of its in vivo effectors, insulin-like growth factor-1, can 
induce PrP expression in PC 12 cells" (Lasmesas et al., 1993). Cultured human muscle 
tissue expresses both 13-APP and PrP and the mRNA level of both is significantly 
reduced by glucocorticoids (Askanas et al., 1995). 
10 
 The detection of PrP' in muscle is interesting given that mice overexpressing hamster, sheep and mouse PrP 
in a number of tissues, including muscle, develop a late onset neuromyopathy (Westaway et al., 1994b). A 
necrotising myopathy was described in a wide range of skeletal muscles (but not smooth muscles) which was 
detectable as early as 90 days of age. This is well before the development of pathology in the PNS and CNS, 
arguing that PrP overexpression in muscle causes a primary muscle disorder (DeArmond and Prusiner, 1997). 
11  Although it is not known whether the expression of PrP is increased by growth hormone in humans, GH-
mediated upregulation of PrP expression in recipients of CJD contaminated growth hormone may have 
contributed to the the susceptibility of recipients to infection. 
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Section 1.2.3: PrPC  structure and function 
The peptide backbone of all mammalian PrP' molecules studied so far is 
predicted to be 252-254 amino acids in length. PrP' is post translationally modified 
(Figure 1.2, p19) by the removal of a 22 amino acid N-terminal signal sequence 
following translocation into the endoplasmic reticulum where it is modified by the 
addition of complex N-linked polysaccharides at 2 asparagine residues (Endo et al., 
1989) and a single intrachain disulphide bond (Basler et al., 1986; Turk et al., 1988). 
Nascent PrP' is further modified by the addition of a sialated glycosylinositol 
phospholipid (GPI) anchor at residue 231 (Stahl et al., 1987, 1992) enabling 
attachment of PrP' to the surface of neurons (Stahl et al., 1987). A soluble form of 
PrP' has been detected in human cerebrospinal fluid (Tagliavini et al., 1992) and there 
is evidence also of truncated forms of human PrP in brain which are C-terminal 
fragments from His-i 11 and Met-1 12 (Chen et al., 1995). 
PrP' has a number of features including a stretch of 5 gly/pro rich octapeptide 
repeats between codons 45 and 84 (Liao et al., 1986) and a non-hydrophobic stop 
transfer effector (STE) sequence (Yost et al., 1990; Lopez et al., 1990) between 
codons 96 and 112 12  which determines PrP topology in in vitro translation systems - 
although its in vivo relevance remains uncertain. The microheterogeneity of PrP 33-35 
observed with SDS-PAGE is attributable to varying degrees of N-linked glycosylation 
and indeed PNGase F deglycosylated PrP' runs as a single band of —16 kDa (Endo et 
al., 1989; Somerville and Ritchie, 1990). 
Sequence data from a wide variety of mammals indicates a high degree of 
conservation at the amino acid level (Figure 1.3, p21) which, together with the tight 
spatial and temporal control of PrP expression during embryonic development 
(Manson et al., 1992), suggests an important role for PrP. However PrP null mice 
were reported to be fertile and had no overt neurological phenotype (Bueler et al., 
12  Note that the GSS PI02L mutation occurs in this region. 
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1992). Subsequently a number of other groups have independently generated PrP 
nulls (Manson et al., 1994a; Moore et al., 1995; Sakaguchi et al., 1995) and a number 
of differences with wildtype mice have been found and are discussed in chapter 4. 
Section 1.2.4: PrP accumulates in the CNS during infection 
Following the purification of PrP27-30 and the generation of PrP antisera it 
became apparent that PrP localised to amyloid plaques in scrapie infected brains 
(Bendheim et al., 1984) and can accumulate to levels --10-20 fold higher than in 
uninfected brains (Meyer et al., 1986). PrP immunostaining of normal and infected 
brains indicated that PrP localisation altered from that of around neuronal cell bodies 
to staining of the neuropil (DeArmond et al., 1985). A wide variety of PrP 
immunostaining patterns are now known to occur in prion diseases and it is evident 
that a number of factors control the localisation of most forms of known 
neuropathology including agent strain and host genotype (Bruce, McBride and 
Farquar, 1989; Jeffrey et al., 1994). Extracellular PrP amyloid plaques are a feature of 
some human and experimental mouse prion diseases. There is good evidence that 
strains differ with respect to the formation of PrP amyloid plaques, although host 
genetic control of plaque frequency has been described in the mouse (Bruce and 
Dickinson, 1985; Carlson et al., 1994). 
Co-localisation of PrP immunostaining and neuropathology has been described 
in a number of prion diseases and the observation that PrP"  accumulation precedes 
vacuolation argues for a causative role for PrP (Reviewed by DeArmond and 
Prusiner, 1997). However, observations in the mouse and in human Cifi cases 
suggest that there is not necessarily a strict association between amyloid plaques and 
neuropathology (Jeffrey et al., 1994). The level and distribution of PrP in uninfected 
rodent brain does not always correspond to infectious titre or to levels of PrPSC  in 
terminal brains (Kitamoto et al., 1989; Taraboulos et al., 1992). For example, regions 
which normally produce low levels of PrP' may ultimately exhibit large accumulations 
of PrP in terminal brains. These observations suggest that cell-type specific factors 
may be required for the entry and/or replication of agent 
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Figure 1.2: PrP primary and secondary structure 
Diagram of PrP' indicating primary amino acid sequence, secondary structural 
features and post translational modifications. Hamster PrP is used as an example as it 
is has been most thoroughly studied of all mammalian PrP molecules. The position of 
known post translational modifications are marked and include: the removal of N and 
C terminal signal peptides following translocation into the endoplasmic reticulum, the 
addition of a GPI anchor at ser 231, addition of complex N-linked glycosylation at asn 
181 and asn 197 and the formation of an intrachain disulphide bond between cys 179 
and cys 214. A five octapeptide repeat structure is a prominent feature of the N-
terminus between residues 51 and 90 and is similar to pro/gly rich repeat structures 
found in fibrillar proteins such as the collagens and keratins. A number of regions of 
secondary structure have been predicted including 5 putative (X-helices (H1-4 and 
helix 2.5) (Reviewed by Harrison et al., 1997). Helices 2.5, 3 and 4 have been 
observed in NMR structures obtained from a fragment of PrP expressed in E.coli 
(Rieketal., 1996). 
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1 	......... 40 	 80 
IN-terminal signal peptide 	 I I 
MANLSWLLA LFVAMWTDVG LCKKRPKPGG WNTGGSRYPG QGSPGGNRYP PQGGGTWQP HGGGWGQPHG GGQPHGGG 
/repeat 1 /repeat 2 	/repeat 3 /repeat 4 
PK cleavage 
.........................2O 	.....................................160 
W6QPHGGG QGGGTHNQWN KPSKPKTHMK HMAGAAAAGA VVGGLGGYML GSAMSRPMMH FGNDWEDRYY RENMNYPNQ 
/repeat 5 
109 	 122 120 	 140 143 	 150 
HELIX 1 	 HELIX 2 	 HELIX 2.5 
170 	 214 	
GPI anchor 
161 .......................................200 ........................................240 
VYYRPVDQYH NQNNFVH6CV NITIKQHTVT ±TTKGE8FTE TbIKIMERVV EQMCVTQYQK ESQAYYDGRR SSAVLSSPP 
I 	I 
178 	101 	 191 197 	202 	 217 	 231 
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Figure 1.3: Multiple sequence alignment of PrP amino acid sequences from a 
number of mammalian species. 
This illustrates the high degree of amino acid sequence conservation of mammalian 
PrP. Dimorphic mouse codons 108L/F and 189T/V linked to differences in 
experimental prion disease incubation time control (Westaway et al., 1987) are 
indicated in bold and are boxed. The position of putative a-helices are indicated by 
open boxes. Helices 2.5, 3 and 4 have been confirmed by NMR (Riek et al., 1996). 
This alignment was generated by the Genetics Computer Group Wisconsin 
package, gcg8 using translate, pileup then pretty -con -duff (plurality: 8.00, threshold: 
1.50, aveweight 1.00). The consensus sequence is indicated in upper case, divergent 
residues are indicated in lower case and gaps introduced to optimise the alignment are 
indicated by ".". 
Genbank accession numbers of PrP sequences used are as follows: 






Human (129met allele) M13899 
Gorilla U08300 
Chimpanzee U08296 
PrP-ANZW mouse M18070 
PrP-B ILnIJ mouse M18071 
Chinese hamster M33958 
Armenian hamster M33959 
Syrian hamster K02234 
Rat M202313 
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Residue 	 1 	 60 
	
Suffolk sheep) mvkshi s i 	m 	 g 
Goat) mvkshi 5 i m g 
Cow) mvkshi 5 i 	in 	 g 	 gggw 
Kudu) mvkshi s i m a 	g s gggw 
Mink) mvkshi 5 1 	t 	i f g 
Pig) mvkshi g i a i 	 g 
Human 129Met) . .manl c is 	 t 	1 . 
Human 129Val) - .manl C a t 1 	 . 
Gorilla) . .manl C m 	t 	1 . 
Chimpanzee) - .manl C is t 1 
PrP-A 55W mouse) . .manl y 1 a 	tin t 	 . 
PrP-B Iln/J mouse) . .manl y 1 a tin t . 
Chinese hamster) . manlsy 1 a 	t t 
Armenian hamster) . manlsy 1 a t t 	 . 
Syriac hamster) 	.......... ...... m t 
Rat) .......... .......... .......... . s... 
Consensus ------G-W-- LVLFVA-WSD VGLCKKRPXP -GGWNTGGSR YPGQGSPGGN RYPPQG--- 
61 	 120 
Suffolk sheep) . . .. 	 g 	. s a 
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(Horiuchi et al., 1995). However, PrP may be transported to such areas from 
regions expressing high levels of PrP' and producing large quantities of PrPSC. 
Retrograde transport of infectivity along axons has been described in experimental 
scrapie models (Kimberlin, Field and Walker, 1983; Fraser and Dickinson, 1985) and 
may be a common mechanism for the movement of infectivity within the CNS and 
between the CNS, PNS and peripheral organs. 
Section 1.2.5: PrP gene structure and location 
PrP is encoded by a single copy gene (Liao et al., 1986). Mouse and human 
PrP are encoded by the Pm-p and PRNP loci respectively. Pm-p is located on 
chromosome 2 (Figure 1.4, p24) and PRNP on chromosome 20pter-p12 (Sparkes et 
al., 1986). Pm-p has been mapped between II-1a and Pax-] (Carlson et al., 1993) and 
lies within an area of extensive synteny with the region of human chromosome 20 
bearing the human PRNP locus (Siracusa et al., 1990). Six alleles of the murine Pm-p 
gene have been described but most are similar to the Prnp' allele (see Figure 1.6a, 
p32) which spans approximately 23kb. The first PrP gene structure to be elucidated 
was hamster which was shown to consist of two exons -one upstream untranslated 
region and one coding exon separated by a large intron (Basler et al., 1986). 
However, the murine Pm-p gene consists of three exons of which, exons 1 and 2 are 
untranslated, the entire coding region being limited to exon 3. The murine promoter, 
exons 1 and 2 are sited approximately 18 kb upstream of exon 3. Human, sheep and 
mouse PrP genes have a GC rich TATA -less promoter bearing consensus binding 
sites for AP-1, AP-2, Sp-1 and a number of undefined repeats (Westaway et al., 
1994a; Herbert Baybutt, personal communication) and are similar to promoters 
described in so-called "house keeping" genes such as HPRT. 
22 	 Chapter 1. Introduction 
Figure 1.4: A genetic map of mouse chromosome 2 
A genetic map of mouse chromosome 2 showing the location of the Pm-p locus. 
Areas of extensive synteny with humans shown in black and mapping distances are 
shown in cM (centimorgans). Mapping data was compiled from Siracusa et al., (1990) 
and Carlson et al., (1993). 
Note on physical mapping: Analysis of a YAC spanning Pm-p indicates that Evi-4 is 
300Kb downstream of the Pm-p locus (Westaway et al., 1994a). 
Gene abbreviations are as follows: 
Spna-2, brain a-spectrin; Abi, Abelson proto-oncogene; Ass, arginosuccinate 
synthetase; CS, complement component 5; Gcg, glucagon; Acra, muscle nicotinic 
acetylcholine receptor a-chain; Hox 5-1, homeobox gene 5.1; Cas-1, catalase 1; Sey, 
small eye; Actc, cardiac actin ; Ltk, leukocyte tyrosine kinase ; B2m, b2 microglobulin; 
fl-la/b, interleukin 1 a and b; Pmn-p, prion protein; D2Hss-1, anonymous marker; Pax-
1 paired box-containing gene 1(also known as un -undulated); Ada, adenosine 
deaminase; Cenpb, centromere protein b; we wellhaarig; Evi-4, ecotrophic virus 
integration site-4; Scg-1, secretogranin 1 
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Section 1.3: The genetics of incubation time control 
Section 1.3.1: Introduction 
Early investigation into the role of genetics in sheep demonstrated a strong 
genetic influence, however the cost, long generation times, extended incubation times 
and absence of inbred strains in these species generated the requirement for a rodent 
model. Following the transmission of sheep scrapie to mice in 1961 (Chandler, 1961) 
and work performed by Dickinson and colleagues with ME7 and other scrapie strains 
clearly demonstrated that susceptibility in the mouse was under genetic control 
(Dickinson and MacKay, 1964). 
Section 1.3.2: Experimental scrapie incubation time control in mice 
Dickinson and MacKay investigated the response of a number of inbred and 
partially inbred mouse strains to M1E7 scrapie and found that whilst the incubation 
time for most strains was between 22 to 25 weeks, one partially inbred strain, VM (or 
SM), had a prolonged incubation time of 40 weeks (Dickinson and MacKay, 1964). 
This suggested that this strain was distinct from the others with respect to genes 
controlling scrapie incubation time. Following further inbreeding of the YM line they 
identified a single autosomal gene, Sinc, with 2 codominant alleles, s7 and p7 
(Dickinson, Meikie and Fraser, 1968). In subsequent work with inbred mouse strains 
it was confirmed that Sinc is the major gene controlling the incubation time of mice to 
a wide range of scrapie isolates (Dickinson and Fraser, 1977; Bruce et al., 1991) and 
BSE isolates (Fraser et al., 1992; Bruce et al., 1994). 
Classical genetic analysis using the Chandler scrapie strain identified a single 
autosomal gene Pm-i, with 2 alleles, N and I, which control scrapie incubation time 
(Carlson et al., 1986). These workers used IfLnJ (Kingsbury et al., 1983), a mouse 
strain with a prolonged Chandler incubation time of -255 days homozygous for the 
Pm-i' allele. In contrast, NZW/LacJ mice with a shorter incubation time of —113 days 
were designated as Pm-i N  homozygotes. The Fl cross of these stains had a long 
incubation time of —222 days suggesting that the Pm-i' allele was partially dominant. 
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Important clues to the identity of both Pm-i and Sine followed the discovery 
of linkage of Pm-i and Sine to PrP using a Pm-p Xba I RFLP (Carlson et al., 1986; 
Hunter et al., 1987). This Xba I RFLP defined two Pm-p variants Pm-p a  and Pm-p b 
and, in a search for the molecular basis of Pm-p allelism, mouse strains with differing 
Xba I RFLPs were investigated for differences in their PrP gene sequences and 
expression levels (Westaway et al., 1987). Whilst no significant differences in PrP 
mRNA or protein levels were apparent, protein coding dimorphisms were found at 
codons 108 and 189 which gave rise to distinct prion proteins in mice with the Pm-p a 
and Pm-p b  alleles and were termed the PrP A and PrP B allotypes respectively. 
Pm-p a  homozygous NZW mice with short Chandler scrapie strain incubation 
times encode the PrP A allotype with leucine and threonine at codons 108 and 189 
respectively. The IILnJ strain with a long Chandler scrapie incubation time are 
homozygous for the Pm-p b  allele and encode phenylalanine and valine at codons 108 
and 189 (the PrP B allotype). 
Although there are a number of Pm-p RFLPs which define six alleles (Carlson 
et al., 1988), only mice with the Pm-p b  allele encode the PrP B allotype and have 
long Chandler and MIE7 incubation times. A BstE II RFLP provides a marker for the 
PrP allotype. This RFLP arises from the codon 189 threonine/valine dimorphism. A 
valine at this position results in loss of the BstEII site, present in mice encoding 
threonine and expressing the PrP A allotype (Westaway et al., 1987). To date, all 
mice lacking this exon 3 BstEII site encode the PrP B allotype. Only three mouse 
strains are known to encode the Pm-p b  allele and express the PrP B allotype: 
VMIDk, ILn/J and P/J. All have long Chandler and/or ME7 incubation times. 
Section 1.3.3: The relationship between Pm -p and Sinc/Prn-i 
Whilst it is likely that Sine and Pm-i are identical loci, much effort has been 
directed towards determining whether the Prn complex includes two distinct genes 
(i.e. Pm-p and Pmn-i/Sinc) or whether Pm-p and Prn-i/Sinc are in fact the same gene. 
Sinc/Prn-i and Pm-p are closely linked (Carlson et al., 1986; Carlson et al., 1988) and 
in a study of mice with meiotic crossovers near Pm-p (Carlson et al., 1993) the 
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location of Pm-i was mapped to between 0.67cM proximal and 0.22cM distal to Pm-
p. 
However, the unambiguous delineation of the relationship between these 
genes is lacking, not least because tight linkage between Pm-p and an incubation time 
locus only demonstrates a correlative rather than a causal relationship but also 
because four independent test crosses have yielded small numbers of progeny with 
discordant PrP genotype and scrapie incubation time phenotype (Carlson et al., 1986; 
Carlson et al., 1988; Race et al., 1990). In these experiments, Pm-p a  and Pm-p b  mice 
were crossed and the F1 progeny were backcrossed onto a Pm-p a  strain. Ina number 
of experiments, four F2 mice with a Pm-p Xba I RFLP characteristic of the Pm-p aib 
genotype were observed to have Chandler incubation times characteristic of the Pm-p 
a  genotype. These observations could indicate recombination between Pm-p and a 
closely linked (estimated at 4.3+1-1.3 (S.E) cM, Carlson et al., 1993) incubation time 
control locus. A convincing demonstration of recombination between Sinc/Pmn-i and 
Pm-p would be highly significant as it would demonstrate that incubation times for 
murine scrapie, and perhaps other prion diseases, are controlled by a tightly linked but 
distinct locus from that encoding the prion protein. The lethal nature of the 
backcrossing experiments has frustrated attempts to determine whether discordant 
mice are true meiotic recombinants or whether the discordant incubation times are 
simply due to the reproducible co-segregation of other genes which, in combination, 
have a large effect upon incubation time. 
A different approach to the delineation of the relationship between SinclPmn-i 
and Pm-p utilised congenic \M./Dk and VMfDkSincs7s7  mouse lines (Figure 1.5a, 
p30). These VMIDk based mouse lines encode distinct Sinc alleles, distinct Pm-p 
alleles, distinct PrP allotypes and have dramatically different scrapie incubation times 
(Hunter et al., 1987; Hunter et al., 1992). These mice demonstrated the co-transfer of 
the Pm-p a  allele and the Sinc s7 allele onto the VM!Dk background. However, this 
cannot provide formal proof for the congruence between S/nc/Pm-i and Pm-p 
because these experiments were performed on congenic mice at the 19  1h  backcross. 
The size of the differential chromosomal segment at this stage of the construction of 
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any congenic line is around 10cM13, or roughly 10Mb. Thus the incubation time 
alteration generated by the transfer of the S/nc s7 allele could be due to the effects of 
a linked gene. Therefore it remains formally possible that S/nc and Pm-p could still be 
linked but discrete genes. 
Westaway, using a transgenic approach (Figure 1.5b, p30) constructed mice in 
which a 40Kb cosmid Pm-p b  transgene from ILn/J mice had been introduced to wild 
type mice (Westaway et al., 1991). Thus the transgenic mice had two copies of the 
endogenous Pm-p a  allele in addition to the Pm-p b  transgene. The rationale of this 
approach was based on the observation that in F1 crosses between NZW and ILn/J, 
Pm-p a/b  heterozygous mice encoding both Pm-p a  and Pm-p b  alleles had Chandler 
scrapie incubation times almost as long as Pm-p b  ILn/J mice. This indicated that the 
Pm-p b  allele was dominant. Thus if the Pm-p b  allele was the determinant of long 
incubation times in ILn/J mice then adding a Pm-p b  allele onto a Pm-p a  short 
incubation time should exert its dominant action by prolonging the scrapie incubation 
time. Carrying this argument one step further one might imagine that the higher the 
Tg[Prn-p b]  copy number and the greater the Pm-p b  (i.e. PrP B) expression level, the 
longer the incubation time. However the transgenic mice had accelerated rather than 
prolonged Chandler scrapie incubation times. 
A number of other transgenic mouse lines with multiple copies of cosmid Pm-
p transgenes overexpressing PrP have accelerated scrapie incubation times. These 
include mice overexpressing Syrian hamster PrP (Scott et al., 1989; Prusiner et al., 
1990) and the mice overexpressing the PrP A allotype from a Pm-p a  transgene 
(Fischer et al., 1996; Telling et al., 1996). This suggests that accelerated Chandler 
scrapie incubation times are an artefact of PrP overexpression (Carlson et al., 1994). 
13 the size of the differential chromosomal segment in congenic lines is theoretically 200/t cM, where t is the 
number of backcrosses (Falconer, 1989). 
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Figure 1.5: Investigation of the relationship between Pm-p and Sinc/Prn-i. 
Two experiments exploring the relationship between SinclPrn-i and Pm-p are depicted. Sine 
congenics a). were constructed by repeatedly backcrossing F1[C57xVMIDk] Sincs7 P7  progeny onto 
VM/DK Sine p7p7  with selection for short incubation times at each of 19 backcross generations (Bruce 
et al., 1991). Sine congenics enable the comparison of VM/Dk congenic lines in which the genetic 
variation is limited to the Sine locus. However, after 19 backcross generations the Sine s7 allele from 
the C57 donor strain carries a .-.lOcM chromosomal segment bearing multiple linked genes. Pm-p 
Xba I RFLP analysis of these mice (Hunter et al., 1992) demonstrated the co-transfer of the Pm-p 
8 
allele and rapid ME7 incubation times of .-175 days in \TMIDkSi flC9787  mice, close to that of C57 
mice bearing the Sine s7 allele (-...167 days), however this cannot exclude the possibility that Sine and 
Pm-p are distinct but tightly linked loci -they could be as much as much as 10cM distant. A 
transgenic approach b) in which the Pm-p b  allele was introduced onto a Pm-p 
8 background 
(Westaway et al., 1991). The dominance of the Pm-p 
b  allele with Chandler scrapie was expected to 
result in prolonged incubation times in Tg[Pmn-p 
b]  mice, however the transgene actually accelerated 
Chandler scrapie incubation times (Table 1.3, below). The accelerated incubation time in Tg[Prn-p 
b1  
mice may have resulted from selection for a rapidly replicating component from the (uncloned) 
Chandler isolate 14  (Bruce and Dickinson, 1987), however serial passage from Tg [93 H] in CD-1 
mice indicated that the properties of the inoculum were unaltered. This indicates that the accelerated 
incubation times were the result of raised PrPC expression levels. 
Table 1.3: Raised expression levels of Pm-p b  accelerate 
Chandler incubation times. [Adapted from Westaway et al., 19911 
Transgenic line 	Incubation time8 (+1-SE days) 	[PrPd] 
b 
Tg[94] 	 75 	(+1-1.8, n=15) 8 x 
Tg [117] 	78.5 	(+1-1.9, n13) 8 x 
Tg [93H] 	79.4 	(+1-2.9, n=14) ND 
Tg [93L] 	96.7 	(+1-3.0, n=12) 2-4 x 
Non Tg 	125.3-137 (n61) 1 x 
littermates 
incubation time to onset of clinical signs of scrapie; 
whole brain PrPC expression levels were compared to 
wildtype mice; 
ND, not determined 
14 Bruce et al., (1991) indicated that the Chandler isolate used for a number of incubation time control 
experiments is a mixture of 139A and 79A and may lead to confusing incubation period results. 
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Figure 1.6: Pm-p polymorphisms 
Six alleles of Pm-p (a-f) have been described on the basis of Xba I, BstE II, Eco RI, TaqI 
and Sac I restriction fragment length polymorphisms a) (Carlson et aL, 1988). Xba I RFLPs were 
used to detect Pm-p a  and Pm-p b  alleles in early linkage experiments (Carlson et al., 1986) but only 
the short fragment of 3.5Kb is specific for the Pm-p a  allele because a number of mouse strains with 
both long and short Chandler scrapie incubation times share the larger 5.2 Kb Xba I fragment. The 
only RFLP which consistently differentiates mice with long and short Chandler and ME7 scrapie 
incubation times is a BstE II RFLP arising from an exon 3 dimorphism at codon 189. Indeed, the 
only allele conferring long incubation times with Chandler and ME7 scrapie is the Pm-p 
b  allele - 
mice with the other Pm-p alleles (a, c, d, e and]) have short Chandler incubation times (Table 1.4, 
below; Carlson et al., 1988) and all encode the PrP A allotype. Restriction enzyme abbreviations: 
Bst, Bst E II; E, Eco RI; S, Sac I; T, Taq I; X, XbaI. b). Mice with different incubation times encode 
distinct prion proteins (Westaway et al., 1987). Codon 108 L/F and 189T1V dimorphisms define two 
distinct allotypes PrP-A and PrP-B encoding different PrP molecules: PrP 108L_189T and PrP 
108F_189V. Despite the RFLPs described within the Pm-p locus (Carlson et al., 1988; Figure 1.6a, 
p32), the only consistent difference between mice with large differences in scrapie incubation times 
at the outset of this project were these codon 108 and 189 dimorphisms. During the course of this 
project two variant 3'UTR polymorphisms and some promoter differences have been described 
between Sinc s7 and p7 mice (Baybut and Manson, 1997) have been described. 
Table 1.4: Chandler scrapie incubation times in inbred mouse strains 










C57BL/6BJ a A 143 4 21 
NZW/LacJ a A 120 2 20 
lLn/J b B 322 15 11 
P/J b B 295' 
 9 21 
RIIIS/J 	c A 141 3 	4 
MAJMyJ 	d A 190 5 	6 
CAST/Ei 	e A 216 - 1 
MOLF/Ei 	f A 164 1 	7 
a, incubation time until death; b, incubation time until first diagnosis of scrapie 
SE, standard error of the mean; n, number of mice. 
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Section 1.3.4: Gene targeting 
These difficulties suggested that the issue of Sinc, Pm-i, Pm-p identity might 
only be resolved with gene targeting -a technology which can control for both the effect 
of other genes (by constructing co-isogenic lines) and PrP gene dosage effects. 
It was reasoned that dramatic alterations to the incubation time of mice in which 
the endogenous Pm-p a  allele, expressing the PrP A allotype, had been converted to the 
PrP B allotype would constitute a definitive test of the proposed congruence of Sinc, 
Pm-i and Pm-p. Non-Pm-p genes have been implicated as significant modulators of 
incubation times and neuropathology (Bruce and Dickinson, 1985; Carlson et al., 1988; 
Race et al., 1990; Carlson et al., 1994), therefore genetic variation was controlled by 
generating co-isogenic 129/01a mice differing only by targeted codon 108 and 189 
alterations (Moore et al., 1995). Gene targeting is discussed in detail in the next section. 
Section 1.4 Gene targeting 
Section 1.4.1: Introduction 
Gene targeting enables the generation of mice with defined genomic 
manipulations (reviewed by Moore and Melton, 1997). Much progress has been made 
within this field in recent years. Formerly it was possible only to delete genes, 
however a growing number of targeted alterations are now possible -although 
technically demanding. Such alterations include conditional gene deletion (Gu et al., 
1993), subtle alterations such a single base pair changes (Moore et al., 1995) and 
targeted chromosomal translocations (Smith et al., 1995). 
Embryonic stem (ES) cells are derived from the inner cell mass of 3.5 day 
blastocysts and give rise to the embryo proper (Balinski, 1975). ES cells are 
pluripotent and can proliferate in vitro in an undifferentiated state under the 
appropriate culture conditions (Martin, 1981; Evans and Kaufman, 1981). Early 
experiments demonstrated that ES cells could contribute to the germline tissue of 
chimaeras (Bradley et al., 1984) and that marker genes could be introduced into ES 
cells and transmitted to the mouse gerniline via chimeras (Robertson et al., 1986; 
Gossler et al., 1986). Genetic manipulation of ES cells in vitro by gene targeting 
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makes it possible to transmit a wide range of targeted alterations to the germline of 
mice (Figure 1.7, p37). 
Section 1.4.2: Early gene targeting 
The first application of gene targeting, as applied to mammalian chromosomal 
loci, utilised synthetic chromosomal markers providing selectable phenotypes in 
targeted clones (Lin et al., 1985; Thomas, Folger and Capecchi, 1986). The human 13-
globin locus was the first endogenous mammalian locus to be targeted (Smithies et al., 
1985). It was initially thought that only transcriptionally active genes might be 
available for homologous recombination -a phenomenon which would severely limit 
the general utility of gene targeting, especially as applied to ES cells. However, 
similar targeting frequencies were noted at the f3-globin locus in a cell type in which 
this gene was not expressed. 
When DNA is introduced into cells it has a number of fates including 
nucleolytic degradation, random integration and homologous recombination with 
chromosomal DNA (for a review see Bollag, Waldman and Liskay, 1989). The main 
constraint upon the success of gene targeting experiments in higher eukaryotes is the 
marked preference for random integration of targeting vectors rather than 
homologous recombination. The ratio of random integration to homologous 
recombination events in mouse ES cells has been estimated at 1000:1 (Thomas and 
Capecchi, 1987). To maximise the chances of identification and retrieval of targeted 
clones, gene targeting is performed with large numbers of cells and selection 
strategies which enrich for rare homologous recombination events. The main 
parameters governing targeting efficiency were determined by a series of experiments 
at the HPRT locus. This locus was well suited for gene targeting experiments as it is 
possible to select both for (with HAT: Szybalska and Szybalski, 1962) and against 
(with 6-thioguanine) HPRT function in vitro. Selection of cells for gain or loss of 
HPRT function is simplified because this gene is X-linked and is therefore hemizygous 
in male ES cells, thus only one allele need be inactivated to yield a selectable 
phenotype. 
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The influence of the length of vector homology has been investigated by a 
number of workers and the frequency of homologous recombination has been found 
to be proportional to the length of homology between the vector and target locus 
(Thomas and Capecchi, 1987; Hasty et al., 1991; Deng and Capecchi, 1992). Most 
vectors have between 5 and 10 kb of homology and bear a short and a long arm of 
homology. The short arm facilitates PCR detection of the targeting specific 
juxtaposition of vector sequence with the target locus (Doetschman, Maeda and 
Smithies, 1988). 
Vectors constructed with regions of homology from a source isogenic with the 
cell type being targeted provide higher gene targeting frequencies (teReile et al., 
1992). The importance of isogenic targeting vectors is now widely acknowledged, but 
a number of comparisons between the relative efficiencies of insertion and 
replacement vectors have been reported which do not control for this effect. However 
a direct comparison has been made at the c2 Na,K-ATPase locus by Askew et al., 
(1993) and suggests that at this locus insertion vectors have moderately higher 
targeting frequencies. Targeting vector design is discussed in detail in Hasty and 
Bradley (1993). 
Section 1.4.3: Gene targeting strategies and selection schemes 
The extension of gene targeting to non-selectable genes required the 
development of dominant selectable markers and efficient selection schemes. The 
most widely used selection scheme is the positive-negative strategy (Mansour, 
Thomas and Capecchi, 1988). Since both the transfection frequency and targeting 
frequency of ES cells are relatively is low, a positive selection scheme is required to 
select for cells which have integrated the targeting vector. The most common positive 
selectable marker in use is the bacterial neomycin phosphotransferase gene (neo) and 
is used in combination with G418. An HPRT minigene in combination with, HAT and 
HPRT deficient cells has also been used successfully (Reid et al., 1990; Selfridge et 
al., 1992; Stacey et al., 1994; Moore et al., 1995). Positive selection schemes select 
for stable neo transfectants and in practice this means both cells which have 
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Figure 1.7: Generation of mice from gene targeted embryonic stem cells 
Most mouse ES lines are derived from 129 substrains. ES cells can be 
genetically modified in vitro then introduced into blastocysts and, following embryo 
transfer and successful implantation, can generate germline chimeras. Coat and eye 
colour markers aid the identification of ES cell contribution to chimeras and to 
germline pups. 
Only 50% of germline pups carry targeted alleles because ES cells are usually 
heterozygous for targeted alterations. Germline transmission of 129/Ola HM-1-ES 
cell derived gametes is determined by the transmission of 129/Ola coat and eye colour 
markers (Selfridge et al., 1992): 129/Ola are homozygous for the white bellied agouti 
allele (Au) and the chinchilla allele (c' ) at the albino locus which results in a light 
brown coat colour. 129/Ola are also homozygous for the recessive allele, pink-eyed 
dilute (p)  and have pink eyes. 
When used in conjunction with recipient blastocysts which differ from 129/Ola 
at these loci, it is possible to determine the contribution of ES derived tissue in 
chimeras. For example, introduction of 129/Ola ES cells into BaIb C recipient 
blastocysts (Baib C mice have a white coat and pink eyes: c/c, PIP, A/A) results in 
white mice (blastocyst coat colour) and chimeric, 129/Ola derived tisue, shows up 
against this coat colour as light brown. Following test crosses between chimeras and 
inbred 129/Ola mice the transmission of ES gametes from germline chimeras is 
indicated by a chinchilla coat and pink eyes in progeny. Non germline pups have a 
grey coat and black eyes as they are F1(Balb C x 129/01a) i.e. they are cch/c,  p/P, 
AW/A.  
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undergone the desired gene targeting events and those which have undergone random 
integration events. As described previously, mammalian cells have a predilection for 
random integration and it is necessary to use a negative selection step to enrich for 
homologous recombinants. Selection against non-homologous recombinants with 
replacement vectors is facilitated by the introduction of negative selectable markers at 
the termini of regions of homology. Common negative selectable markers include the 
herpes simplex virus thymidine kinase gene (HSV-TK) and the diptheria toxin A 
fragment gene (DT-A). Sequence insertion vectors cannot utilise such selectable 
markers for simple knockouts because all of the vector integrates into the target locus 
(although they can be used for the run stage of hit and run). However, positive 
selection markers can be designed to enrich for targeting events by modifying the 
positive selection marker for expression which may be conditional upon introduction 
into a transcriptional unit e.g. by using a neo module which is promoterless, poly A-
less or contains a splice acceptor site such that neo is expressed as a fusion protein. 
The main differences between insertion and replacement vectors as used for gene 
knockouts are illustrated in Figure 1.8 (p40). 
Section 1.4.4: Generating ES cells with subtle alterations 
Section 1.4.4.1:Introduction 
A large number of genes have been inactivated by gene targeting - indeed 
more than 250 have been reported in the past 6 years. This has enabled the generation 
of a number of mouse models of human disease. However many disease-causing 
mutations do not arise from complete loss of function mutations but are caused 
instead by gain-of-function mutations resulting from subtle alterations such as point 
mutations, small deletions and repeat amplifications. Thus a major challenge is to 
develop methods to enable the introduction of such alterations. These procedures are 
technically very difficult and require prolonged in-vitro culture of ES cells -reducing 
their germ-line potential. There are two main approaches again utilising sequence 
insertion (Hasty et al., 1991; Figure 1.9, p42) and sequence replacement vectors 
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Figure 1.8: Insertion and replacement vectors for gene knockout 
Differences in the design of insertion and replacement vectors for the inactivation of a 
hypothetical gene by the introduction of neo into exon 3. Targeting vectors consist of 5' and 3' 
flanking sequence homologous with the target locus and a selectable marker gene (e.g. bacterial 
neomycin phosphotransferase). The neo marker and has the dual role of providing insertional 
mutagenesis of an essential exon within the target gene and functions as a positive selectable marker 
for stable transfectants. The main difference between a) insertion vectors and b) replacement 
vectors is the site of vector lineansation as this determines the final structure of the targeted allele. 
Insertion vectors a) are linearised within the region of flanking homology and undergo a 
single reciprocal recombination event with the target locus, stimulated by a double strand break or 
gap in the vector homology. The entire vector is integrated into the target locus resulting in 
duplication of sequence either side of the selectable marker. The degree of enrichment for 
homologous recombinants is low because there is only positive selection for stable transfectants - 
which are predominately random integrants1 . Negative selection modules such as HSV-TK are not 
possible as they will appear in the targeted locus. 
Replacement vectors b) integrate following a double reciprocal recombination event 
resulting in the complete replacement of a region of the target locus with vector sequence. This has a 
number of advantages, most notably that negative selection against non-homologous recombinants 
can be used to enrich for homologous recombinants. This is achieved by placing a negative-selectable 
marker outside the region of vector homology with the target gene. The rationale for this is that 
regions at the vector termini which are not homologous to the target gene are excluded from the final 
structure of the targeted locus. Thus negative selectable markers are expressed only transiently, if at 
all. Conversely, it is likely that a majority of random integrants will be stably transfected with the 
whole vector and express the negative selectable marker and will not survive counterselection. HSV-
TK in combination with the toxic viral thymidine kinase substrate gancyclovir is a popular negative 
selectable marker. The knockout designs shown here have a number of design flaws: i) in general a 
more secure null phenotype is observed when the promoter, first exon and first intron are disrupted 
or deleted, ii) the knockout allele in a) and b) could still generate a partially functional gene product 
by splicing around the neo module or by reading through neo to produce a fusion protein -perhaps 
with novel biological properties. 
IS  Good enrichment for homologous recombinants is possible by utilisation of a promoterless or polyA-less neo 
module but such methods are generally limited to genes expressed in ES cells. 
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Figure 1.9: Introducing subtle alterations with sequence insertion vectors 
The general method for the introduction of subtle alterations is illustrated by an 
early attempt to introduce a codon 101 proline to leucine alteration into Pm-p exon 3 
in HM-1 ES cells (David Melton, unpublished results). Targeting vector homologous 
sequence is indicated by heavy lines and filled boxes. The site of vector linearisation is 
indicated by an open arrow. This requires two steps and a positive-negative selection 
and is known as a "hit and run" strategy (Mansour et al., 1988). 
In the first step (the "hit"), an insertion vector is stably integrated resulting in a 
duplication of exon 3. Targeted ES cells are detected by a PCR screen of cells 
surviving HAT selection. In the second step (the "run") maintenance of the cells in 6-
thioguanine (a toxic HPRT substrate) provides selection against HPRT and enriches 
for ES cells which have lost the HIPRT minigene by resolution of the gene duplication 
-leaving a single copy gene which bears the desired mutation. In principle -50% of 
intrachromosomal recombinants will have retained the 101Leu mutation, however in 
practice all recombinant clones screened in several experiments had lost the 101Leu 
mutation. This has been attributed to the proximity of the site of linearisation with the 
101Leu mutation. Two linearisation sites were examined: Sma I (175bp from mutation) 
and Kpn I (21bp from the mutation). 
This and reports from other workers (Hasty and Bradley, 1993) suggests that 
the frequency with which the mutation is retained is strongly determined by the 
distance between the site of linearisation and the site of the mutation -mutations less 
than 1.5Kb from the site of linearisation are frequently lost. This constitutes a major 
limitation of sequence insertion vectors -although there have been a limited number of 
successes. The difficulties experienced with this system led to the adoption of a two 
step double replacement strategy (Moore et al., 1995). 
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Figure 1.10: Introduction of subtle alterations with double replacement gene 
targeting 
A two step double replacement strategy for the introduction of a subtle alteration into a 
hypothetical gene. This method was first suggested by Reid et al., (1990) and is described here using 
an HPRT minigene for positive selection in HPRT deficient cells in the first step and for negative 
selection in the second step. Positive-negative selection is required for the first step but negative 
selection alone is sufficient the enrich for targeting events during the second step because the HPRT 
minigene is integrated in a known position. 
Targeting vector sequence homology to the locus of interest is indicated by heavy lines 
(introns) and by filled boxes (exons). The site of vector linearisation is indicated by an open arrow. 
Dotted lines represent the limits of regions of homology and therefore delimit regions capable 
participating in homologous recombination events. The vector for the first step consists of a short 
region of 5' homology, an HPRT minigene driven by a P0K promoter for positive selection, 3' 
homology consisting of exons and introns down stream of exon 3 and a HSV thymidine kinase gene 
outside the 3' homology, for negative selection in the presence of gancyclovir. The vector for the 
second step consists of sufficient homologous sequence to reconstruct the disrupted step 1 allele and 
an engineered mutation (*). 
Step 1. The vector recombines with the target locus and effectively replaces exons 2,3 and a 
portion of intron 3 with a HPRT minigene. Targeted ES cells are HAT + ganc' and ES cell 
colonies surviving selection are screened for the presence of a targeting-specific PCR product with 
primers 1 and 2. These ES cells can be used for the construction of null mice or for an almost 
unlimited number of second steps. 
Step 2. The disrupted locus is reconstructed with sequences bearing an engineered mutation. 
Selection against the HPRT minigene with 6-thioguanine is sufficient to enrich for targeted ES cells. 
6-thioguanine resistant ES colonies are screened for the desired mutation by a combination of PCR 
with primers 3 and 4 and a restriction enzyme digest for a mutation-specific RFLP. PCR/RFLP 
positive colonies are also screened by Southern analysis for the desired targeted gene structure, 
desired RFLP and the absence of non-homologous recombination events. 
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(Figure 1.10, p44). Sequence insertion vectors have a number of disadvantages 
including i) lack of convenient negative selection methods, requiring the laborious 
screening of many ES colonies to find a targeted colony, i) the frequent loss of the 
engineered mutation following resolution of duplication and ii) the requirement for 
repetition of both gene targeting steps for every mutation. A double replacement 
strategy (first outlined by Reid et al., 1990) can largely overcome these problems. 
Section 1.4.4.2: Double replacement gene targeting 
The introduction of subtle alterations using replacement vectors requires two 
distinct replacement steps (Wu , Liu and Jaenisch, 1994; Moore et al., 1995) requiring 
two vectors. The first step results in the targeted introduction of a selectable marker 
into the desired locus -enabling a null allele to be generated if required (see Figure 
1.10, p44). A positive -negative selection strategy can be utilised for this step. The 
second step requires a replacement vector which consists of intact homologous 
sequence which bears the desired mutation. Selection is simplified by the use of 
negative selection against a marker introduced in the first step. The first step need 
only be performed once and an unlimited number of mutations can be introduced by 
performing multiple second steps with vectors bearing different mutations. This thesis 
describes the design and use of a double replacement strategy to introduce mutations 
into the PrP gene. During this work a number of reports have been published utilising 
a similar method (Wu, Liu and Jaenisch, 1994) at other loci. 
Section 1.4.5: Gene targeting in HM-1, an HPRT deficient mouse ES line 
The male embryonic stem cell line FM-1 is a HPRT (hypoxanthine-guanine 
phosphoribosyltransferase HPRT; IMP pyrophosphate phosphoribosyltransferase; 
EC.2.4.2.8) deficient 40XY ES cell line. HM-1 contributes to the mouse germline at 
high frequency (Magin et al., 1992). HM-1 cells have undergone a spontaneous 
deletion of approximately 10kb of sequence 5' of the HPRT locus which removes the 
promoter and exons 1 and 2 resulting in loss of HPRT expression from this allele 
(Thompson et al., 1989). HPRT is X-linked, therefore male ES cells are hemizygous 
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for this gene. Thus loss of function of one HPRT allele gives rise to HPRT null cells 
and a selectable phenotype. HPRT catalyses an early step of the purine salvage 
pathway in mammals. In humans mutations in HPRT leading to loss of HPRT function 
result in gouty arthritis or Lesch Nyhan disease (Lesch and Nyhan, 964) depending 
upon the levels of functional enzyme. However HPRT activity is non essential in 
rodent cell lines in vitro, provided that the main purine synthesis pathway is 
functional. This feature is very useful as it is possible to select both for and against 
HPRT activity in vitro with medium supplemented with HAT and 6-thioguanine 
respectively. HPRT deficient ES cells form the basis of an efficient selection system 
applicable to gene targeting in ES cells (Selfridge et al., 1992). HPRT minigenes can 
be incorporated into gene targeting vectors and can be used as positive-negative 
selectable markers in HPRT deficient cells. 
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Section 1.4.5: Project Aim 
Linkage and RFLP analysis (Carlson et al., 1986; Carlson et al., 1988; Carlson 
et al, 1993; Race et al., 1990; Hunter et al., 1987) indicates that the Pm-p locus is 
tightly linked to, and may be coincident with Sine and Pm-i. Further evidence for the 
congruency of S/nc/Pm-i and PrP was provided by the discovery that mice with 
different scrapie incubation times differ at dimorphic PrP codons 108 and 189 which 
give rise to two protein allotypes- PrP A and PrP B (Westaway et al., 1987). This 
argues that PrP dimorphic residues at codons 108 and 189 are responsible for control 
of scrapie incubation time currently attributed to the action of incubation time control 
loci Sine and Pm-i loci. Two approaches have been employed by other workers in 
order to resolve this issue (Westaway et al., 1991; Hunter et al., 1992), but neither 
have been able to formally demonstrate that Pmn-p, and its alleles, are responsible for 
the control of incubation time in the mouse. 
Gene targeting on an inbred background can overcome the limitations of 
previous approaches. This project will attempt to clarify the relationship between 
scrapie incubation time gene, Sine, Pm-i and the dimorphic PrP codons 108LIF and 
189T/V. The PrP codon region of 129/01a ES cells Pm-p a  allele will be converted by 
a two step double replacement gene targeting strategy from PrP 108L_189T to 
encode PrP 108F_189V (i.e. the PrP B allotype) normally expressed from the Pm-p b 
allele. The effect of gene variation in such mice will be controlled by transmitting the 
targeted PrP allele through the germline directly onto to 129/01a mice to generate a 
gene targeted line co-isogenic with wild-type 129/01a and differing only by the 
targeted alteration at PrP codons 108 and 189. 129/01a mice bearing the gene 
targeted PrP allele will be challenged with a variety of prion strains in order to 
determine the effect upon incubation time. This will test the hypothesis that the 
differences in incubation time attributed to Sine and Pm-i allelism arise from 
polymorphisms at PrP codon 108 and 189. As an extension to this main aim, the role 
of codons 108 and 189 will be explored individually by generating mice which differ 
from co-isogenic 129/01a wildtype mice by single PrP codon 108F and codon 189V 
alterations. 
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Chapter 2 
Mapping the 129/01a Pm-p locus 
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Section 2.1: Introduction 
The generation of mice with gene targeted PrP alterations required a detailed 
restriction map of the Pm-p locus and suitable cloned Pm-p DNA isogenic with HIM-
1, the ES line used for gene targeting. This chapter describes mapping of the Pm-p 
locus in HM-1 ES cells, the retrieval of a set of overlapping Pm-p genomic clones 
from an HM-1 genomic ? bacteriophage library and the subcloning of homologous 
DNA for targeting vectors. 
Section 2.2: 129/01a mice encode the Pm-pa allele and express the PrP A 
allotype 
Restriction mapping of Pm-p genes in more than 50 inbred mouse strains 
(Carlson et al., 1988) has established the presence of six distinct Pm-p alleles (Pm-p 
a_i) on the basis of restriction fragment length polymorphisms (Figure 1.6a, p32). At 
the outset of this project no restriction mapping data was available for the Pm-p locus 
in 129/01a, the mouse strain from which HM-1 ES cells are derived (Magin et al., 
1992). A restriction endonuclease map of the exon 3 region was generated (Figure 
2. 1, p51) using a 1.1Kb Smal/Eco RI probe (Probe D). This probe was derived from 
an NZW mouse Pm-p exon 3 genomic clone, pUC18N (Westaway et al., 1987). 
These mapping studies confirmed that 129/01a encoded the Pm-p a  allele. This was 
demonstrated by the presence of characteristic exon 3 restriction fragment length 
polymorphisms: a single 3.5Kb Xba I fragment and two BstEII bands of 5.2 and 
3.2Kb. The Xba I RFLP confirmed that 129/01a encodes the Pm-p a  allele as all other 
known Pm-p alleles (b-f) have a larger 5.2Kb exon 3 Xba I fragment (Figure 1.5a, 
p30). BstEII digests were consistent with both the presence of the Pm-p a  allele and 
the PrP allotype (PrP A: 108L_189T). The BstEII RFLP arises from a dimorphic PrP 
codon 189 residue which can encode threonine (T) or valine (V) as described in 
Figure 1.5b (p30). Mice expressing the PrP A allotype retain the exon 3 BstEII site 
but it is absent from mouse strains expressing the PrP B allotype. As described in 
Section 1.3 (p25), the Pm-p a  allele is linked to the Sinc s7 and Pm-i N  alleles (Hunter 
et al., 1993; Carlson et al., 1992). The mapping studies reported here which 
demonstrate that 129/01a encode the Pm-p allele, are consistent with the short MIE7 
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Figure 2.1: A map of the HM-1 Pm-p a  allele 
HM-1 genomic DNA was digested with the indicated restriction enzymes and 
hybridised to DNA probes derived from the Pm-p locus. All sizes in Kbp. 
Probe A: a 900bp Hinc II fragment derived from pTZE1BK; Probe B: a 1500bp Hinc 
II/Eco RI fragment derived from pTZE1BK; Probe C: a 1900bp BstEII/EcoRT 
fragment derived from a ?16-1 10Kb Not I clone in pBluescript (pPrP_NotlO); Probe 
D: a 11 00bp  Exon 3 Smal/EcoRl fragment (derived from pUC18N (Westaway et al., 
1987), a gift from Jean Manson, BBSRC/M1RC Neuropathogenesis Unit, Edinburgh); 
Probe E: a 700bp Barn HI/Eco RV fragment derived from the 3' end ofpl29PrP. 
PrP coding region Liii PrP UTR 
Enzyme abbreviations: B, Barn HI; E, Eco RI; H, Hind III; K, Kpn I; P, Pst I; X, Xba 
I; Bst, Bst Eli; Sal, Sal I; RV, Eco RV. 
Note 1: A number of cloned DNA fragments from this intron 2 region contained 
repetitive sequence and were not suitable as probes. Pm-p regions marked by an 
asterisk could not be mapped in genomic DNA because of a lack of suitable probes. 
However, it was possible to map intron 2 in Pm-p WASH II clones (see Figure 2.2, 
p55). 
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incubation times of 129/01a mice (160 days) and also demonstrates that 129/01a 
encode the S/nc s7 allele (Manson et al., 1994b). 
Section 2.3: Retrieval and mapping HM-1 Pm-pa  clones from a HM-1 
? DASH H genomic library. 
A ? DASH II bacteriophage HM-1 genomic library' was screened for 
sequences corresponding to the Pm-p locus. This library was constructed from a size 
selected (10-30Kb) Sau 3A partial digest of HM-1 genomic DNA and ligated to 
BamHI digested ? DASH II arms (Stratagene). The library was initially screened with 
a NZW Pm-p a  mouse exon 3 1.1Kb Sma L'Eco RI DNA fragment (probe D). 
Particular attention was given to recombinant X clones bearing an 8.5Kb Bam HI 
fragment because the genomic map indicated that this region contained the entire 
coding region and sufficient flanking homology for targeting vector construction 
(Figure 2. 1, p51). 
Primary screening identified 18 putative positive signals of which 10 remained 
positive to tertiary screening. Single, well isolated plaques were amplified and 
recombinant X DNA characterised by restriction endonuclease mapping and Southern 
analysis with probe D. Not I digestion  released a single band from each of the clones 
(except X16-1, see below) indicating that each clone was pure and enabling estimation 
of insert size (range 15-18. 5Kb). A Not I digest of clone ?,16-1  liberated two 
fragments of 10.5 and 5.2 Kb (Figure 2.2, p55) and subsequent analysis indicated that 
it contained a large proportion of Pm-p intron 2. Intron 2 is known to contain a Not I 
site in at least one other mouse strain encoding the Pm-p a  allele (Westaway et al., 
1994a). All 10 clones contained sequences hybridising to the probe D however four 
clones (X5-1, X6-2, X14-1 and A4/3.2) were found to share a common structure which 
did not fit that predicted from genomic mapping and all appear to have undergone a 
deletion event truncating the 2.1Kb Eco RI exon 3 fragment to 0.87Kb (data not 
1  a gift from Dr. Thomas Magin 
2  The ? DASH II vector contains Not I sites in its multiple cloning site. This enables Not I excision of the 
cloned fragment from the ? arms for subcloning or mapping. 
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shown). These clones were not further characterised. However, ? clones 16-1 and 17-
1 were mapped to high resolution by partial digestion and hybridisation to alkaline 
phosphatase conjugated T3 and T7 oligonucleotides in combination with a 
chemiluminescent substrate (Stratagene) (Figure 2.2, p55). 
Following the recovery of recombinant X clones containing exon 3 sequence, 
the library was re-screened for upstream sequence corresponding to the Pm-p 
promoter, exon 1 and exon 2. Screening was performed using a 900bp Hinc II probe 
(Probe A) derived from the liLn/J mouse strain Pm-p exon 1/intron 1 region 
(pTZE1BK: a gift from Dr. Herbert Baybutt, BBSRC/MIRC Neuropathogenesis Unit, 
Edinburgh). One clone, X12-1, was retrieved and mapped (Figure 2.2a, p55). 
Restriction analysis of Pm-p X. DASH II clones 12-1 and 16-1 indicated that they 
overlapped in intron 2. Both contain a number of shared restriction sites including the 
intron 2 Not I site (Figures 2.2a and b, p55). Clones 16-1 and 17-1 share a 
considerable degree of overlap in the exon 3 region, although X 17-1 is the only clone 
mapped to high resolution which bears the complete 8.5Kb Barn HI fragment (Figure 
2.2a, p55). The restriction maps of these clones were consistent with that observed in 
the genomic locus and indicated that they had not undergone any detectable deletions 
or rearrangements during cloning. Mapping data was used to construct a contiguous 
map of the X clones and is shown in Figure 2.2 d and e (p55). 
Section 2.4: Subcloning and mapping of a 8.5Kb BamHI Pm -p exon 3 fragment 
Three X clones (9-1, 14-2 and 17-1) proved to have the complete 8.5kb 
Bam}ll fragment spanning exon 3. This 8.5Kb Barn HI fragment was subcloned from 
?. clone 17-1 into pBluescript SKII+ in both orientations as pl29PrP (+1-) and 
mapped by single and double digestion with restriction endonucleases (Figure 2.3, p57 
and Figure 2.4, p59). All targeting vector DNA homologous to the 129/Ola Pm-p 
locus described in this thesis and in Moore et al., (1995), derives from this clone. 
The ORF of the exon 3 region was sequenced by the di-deoxy method using 
double stranded template from pl29PrP+ and a variety of exon 3 primers. This 
confirmed the genomic mapping studies which indicated that 129/Ola encoded the 
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Figure 2.2: Restriction analysis of HM-1 Pm -p 
° ADASH II clones 
Restriction analysis of Pm-p ?. DASH II clones retrieved from a Hlvl-1 ES cell 
genomic library. Panels a)., b). and c). show the extent of overlap of the three clones. 
Panels d). and e). show the contiguous map of these clones and their restriction 
fragment sizes. X clone 12-1 a).contains the promoter with exons 1 and 2 and a large 
portion of intron 2; X clone 16-1 b). contains part of intron 2 overlapping ?. 12-1 and 
exon 3; c). X 17-1 contains exon 3. The region indicated as a heavy line in c). and d). 
represent a 8.5Kb BamHI fragment containing HM-1 Pm-p 
a  exon 3 which was 
cloned into pBT to generate pl29PrP (Figures 2.3, p57 and Figure 2.4, p59). All sizes 
inKbp. 
PrP coding region 	:I: PrP UTR 
Enzyme abbreviations: B, Barn HI; E, Eco RI; H, Hind III; K, Kpn I; P, Pst I; X, Xba 
I; Sal, Sal I; RV, Eco RV. 
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Figure 2.3: Restriction analysis of p129PrP 
pl29PrP consists of a 129/01a mouse Pm-p a  exon 3 8.5Kb Barn HI fragment, 
derived from ? clone 17-1, cloned into the Barn HI site of pBluescript SKII+ 
(Stratagene). Single and double digests of pl29PrP+ separated on a 1%(w/v) agarose 
gel stained with ethidium bromide a). blotted and b). hybridised to the 1.1kb SrnaIIEco 
RI exon 3 probe (probe D). All targeting vector isogenic flanking DNA was derived 
from this 8.5Kb Barn HI clone. 
Enzyme abbreviations: B, Barn HI; E, Eco RI; H, Hind III; K, Kpn I; P, Pst I; X, Xba 
I; Bst, Bst Eli; Sal, Sal I; RV, Eco RV; S, Sma I. 
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Figure 2.4: A restriction map of p129PrF 
A restriction map of pl29PrP+ determined by single and double digests of 
plasmid DNA. The positions of the 1.1Kb Smal/Eco RI (probe D) and 700bp 
EcoRV/Barn HI (probe E) probes are indicated with filled rectangles. All sizes in Kbp; 
The region marked * contains unmapped Pst I fragments (-100-200bp). The position 
of the 5' Pst I site was confirmed by sequencing. 
[11111111 PrP coding region H2 PrP UTR 
Abbreviations: B, Barn HI; E, Eco RI; H, Hind III; K, Kpn I; P, Pst I; X, 
XbaI; S, Smal. 
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PrP A allotype (PrP 108L_1 89T). The 129/01a PrP ORF was identical to that of other 
inbred mouse strains known to encode the Pm-p a  allele such as NZW (Westaway et 
al., 1987; Genbank accession No. M18070) and RTvIIL (Locht et al., 1986; Genbank 
accession No. M13685). 
Section 25: Discussion 
Comparison of the HM-1 Pm-p gene structure with that of published Pm-p 
alleles (Carlson et al., 1988) indicates that 129/01a encodes the Pm-p a  allele. Studies 
presented here indicate that this allele spans approximately 23Kb (Figure 2. 1, p5  1), 
and although the positions of introns 1 and 2 have not been studied in detail, they 
appear to be 1.8Kb and 14Kb in length respectively. Mapping studies which show 
that 129/01a encode the Pm-p a  allele are consistent with a 160 day ME7 scrapie 
incubation time (Manson et al., 1994b) and also that 129/01a mice encode the Sinc s7 
allele. 
The significance of most of the RFLP's differentiating distinct alleles (Figure 
1.6 a, p32) is uncertain. However, an exon 3 BstEII RFLP arises from a dimorphism 
at codon 189 which can encode either threonine or valine (Westaway et al., 1987). 
Codon 108 is also dimorphic and can encode either leucine or phenylalanine. These 
dimorphisms are in phase and give rise to distinct PrP protein allotypes, PrP A and 
PrP B. PrP A encodes 108L 189T and PrP B encodes 108F 189 V. 
There have been a number of non-coding polymorphisms described in Pm-p. 
A large intron 2 insertion/deletion has been described (Westaway et al., 1994a). Initial 
investigations of cosmid clones derived from Pm-p a  and Pm-p b  mice indicated that 
this polymorphism might correspond to a gene or element controlling scrapie 
incubation time. However, this polymorphism does not consistently correlate with 
incubation time length. 
Polymorphisms have been described in the PrP 3' UTR where single 
nucleotide substitutions at nucleotides 444 (a to g) and 1010 (a to g) (H.N. Baybutt-
Genbank accession No. X83613) segregate with incubation time length. Recently 
Pm-p promoter polymorphisms have been described in mice with different Sine 
genotypes, suggesting a potential role in the control of incubation time. 
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Transgenic mice bearing 40Kb cosmid based Pm-p a  and Pm-p b  transgenes 
indicate that they are capable of position independent expression in the CNS 
(Westaway et al., 1991). However, a Pm-p a  cosmid-based transgene, in which intron 
1 had been deleted, did not express PrPmRNA in brain (Fischer et al., 1996). This 
suggests that this intron contains important expression control elements. Observations 
with large hamster PrP cosmid transgenes are consistent with this because attempts to 
use hamster PrP minigenes have failed to express detectable levels of hamster 
PrPmRNA in brain (Scott et al., 1989). Indeed, mouse Pm-p intron 1 contains a large 
number of consensus binding sites for transcription and other factors (Baybutt and 
Manson, 1997; Herbert Baybutt, personal communication). Recent evidence suggests 
that intron 2 does not appear to contain elements essential to widespread CNS 
expression, but that it may contain one or more elements directing expression to 
Purkinje neurons (Fischer et al., 1996). 
Section 2.6: Summary 
A genomic map of the 129/Ola mouse prion protein locus was generated, 
confirming it as the Pm-p a  allele. This map guided studies in which a complete set of 
X clones spanning the 129/Ola Pm-p a  allele were isolated. Restriction mapping of 
these clones confirmed that a set of overlapping clones has been retrieved and enabled 
the construction of a contiguous map of the whole gene. Comparison of the genomic 
restriction map with that of the contiguous map of the Pm-p . DASH II clones 
indicated that the X clones examined contained no cloning artefacts. A plasmid clone 
of the 8.5Kb BamEll fragment, pl29PrP, was obtained and mapped. This clone 
contains all the sequence homology necessary for the construction of isogenic 
targeting vectors. 
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Pm-p exon 3 inactivation in HM-1 ES cells 
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Section 3.1: Introduction 
A two step gene targeting strategy was used to introduce subtle alterations 
into the coding region of Pm-p exon 3 (Figure 3. 1, p66). This chapter describes the 
first step in this process in which the entire PrP protein coding region was replaced 
with a selectable marker resulting in an inactivated Pm-p allele. Pm-p a1  ES cells were 
used for a second round of gene targeting in which the PrP coding region was 
reconstructed with PrP sequence bearing engineered point mutations at codons 108 
and 189 (Chapter 5, p97). This method has been used to generate a number of ES 
lines bearing subtle alterations to the endogenous Pm-p gene (Moore et al., 1995: 
Appendix I). Pm-p a)-  ES cells were also used to construct PrP deficient mice (section 
3.6, p78). The analysis of Pm-p mice is described in the next chapter (Chapter 4, 
p84). 
Section 3.2: Construction of the Pm -p exon 3 inactivation vector 
A replacement type vector was used to inactivate Pm-p exon 3 (Figure 3. 1, 
p66). The generic design requirements for replacement vectors are described in Figure 
1.8 (p40). The vector used here was designed to introduce a selectable marker into 
exon 3. This provided a convenient allele structure for the second targeting step 
(Chapter 5, p97). To this end, the knockout vector was designed to replace a 2.1Kb 
Eco RI fragment spanning exon 3 with a 2.7Kb HPRT minigene. This generated an 
allele in which the complete PrP coding region was ablated. The vector consists of 
three main components: an HPRT minigene, isogenic sequence homologous to 
regions flanking 1 29/Ola Pm-p exon 3 and a HSV-TK selectable marker. 
The HPRT minigene used in this vector (PGKIDWM1) consists of exons 1-9 
and introns 7 and 8 from the mouse HPRT locus. The minigene was driven by a 
mouse Pgk-1 (phosphoglycerate kinase) promoter (Selfridge et al., 1992). Other 
minigenes are available which express much higher levels of HPRT however it has 
been demonstrated that high levels of HPRT expression are not necessary for efficient 
HAT selection in ES cells (Selfridge et al., 1992). The isogenic flanking DNA was 
derived from pl29PrP, a 8.5Kb genomic clone spanning the exon 3 region (Figures 
2.3, p57 and Figure 2.4, p59). A herpes simplex virus thymidine kinase gene (HSV- 
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TK) located at the terminus of the short arm of homology enabled negative selection 
against random integrants and therefore enrichment for homologous recombinants. 
This marker gene is driven by its own promoter and a mutant polyoma virus enhancer, 
PYF441 (Thomas and Capecchi, 1987). 
A three step cloning procedure was used to construct the Pm-p exon 3 
inactivation vector and is presented in Figure 3.2 (p68). The finished construct was 
designated vector C and a restriction map is shown in Figure 3.3 (p70). 
Section 3.3: Pm-p exon 3 inactivation in HM-1 ES cells 
Approximately 75x106 HM-1 ES cells at passage 14 were electroporated at 
800V, 3uF (GenePulser, BioRad) in 0.8m1 lx HBS (21mM HEPES, 5mM D-glucose, 
8mM Na2 HPO4, 5mM KC1, 140mM NaCl) with linearised vector C in 2 independent 
experiments (Table 3. 1, pTl). Cells were plated in ES medium supplemented with LIF 
and antibiotics. Approximately 24 hours following electroporation, HAT selection for 
HPRT activity was added by replacing medium with HAT supplemented medium 
(Szybalska and Szybalski, 1962). Four days later negative selection against HSV-TK 
activity was initiated by replacing the medium with medium supplemented with 
gancyclovir (GCV) and HAT. 
Section 3.4: PCR screening for gene targeted Pm-p ES cell clones 
PCR screening for homologous recombinants is provided for by the detection 
of the targeting specific juxtaposition of HPRT minigene sequence with a region of 
the Pm-p locus outside the targeting vector (Figure 3.4, p72). ES colonies were 
picked 15-21 days after electroporation and screened by PCR with primer pair GI 176 
and 262W. Targeted colonies were identified by the presence of a targeting specific 
band of 2.28Kb (Figure 3.4, p72). Gene targeted ES clones were identified at high 
frequency from two independent experiments (Table 3. 1, p77). To confirm the 
authenticity of these PCR products, PCR product was blotted and hybridised to [7-
32P]ATP 5' labelled 
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Fig 3.1: A two step double replacement strategy for the introduction of subtle 
alterations into Pm -p exon 3. 
Alterations to Pm-p exon 3 were introduced in two distinct steps. In the first 
step the Pm-p exon 3 protein coding region was ablated by targeted replacement with 
an HPRT minigene. In the second step (described in chapter 5) Pm-p exon 3 was 
reconstructed by replacing the HPRT minigene with exon 3 sequence bearing protein 
coding alterations at codons 108 and 189. A number of distinct second steps are 
possible. Three are illustrated in which PrP codon 10817 1 89V and single codon 108F 
and 189V alterations are introduced. 
For the first step, positive selection for HPRT activity is achieved with HAT 
supplemented medium. Enrichment, or negative selection against random integrants, 
is provided by supplementing the ES medium with gancyclovir (G-CV). 
In the second step, the HPRT minigene is replaced by intact exon 3. 
Selection against HPRT function with the toxic purine analogue 6-thioguanine is 
sufficient to enrich for targeting events. 
Abbreviations: HAT, hypoxanthine aminopterin and thymidine; HPRT, hypoxanthine 
phosphoribosyl transferase ; HSV-TK, herpes simplex virus thymidine kinase gene 
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Fig 3.2: Pm-p exon 3 knockout vector construction 
The Pm-p exon 3 knockout vector was constructed as described below and 
the final vector (vector C) consists of a mouse HPRT minigene flanked with 1.85 Kb 
5' and 3.7Kb 3' Pm-p homologous sequence. A 2.0 Kb herpes simplex virus 
thymidine kinase module was placed upstream of the 5' flanking homology. 
Step 1): 1.85Kb of 5' flanking sequence corresponding to a PstI/EcoRI 
fragment from p129PrP+ and 3.7Kb 3' flanking sequence corresponding to the 
EcoRI/EcoRV fragment of pl29PrP+ were ligated into PstI/EcoRV cut pBluescript 
SKII+. The resulting construct was designated Vector A. 
Step 2): Vector A was linearised with EcoRI and ligated with a 2.7 kb 
EcoRT PGKIDWM1 fragment bearing the HPRT minigene. 
Step 3): Vector B was linearised by Bam Fill/Not I double digestion and 
ligated to a 2kb Barn HI/NotI fragment bearing the HSV-TK gene from pBT/PSP-
TK(Xba#1)(this vector was modified by Dr N.Redhead, ICMB, University of 
Edinburgh). The finished construct was designated vector C and a restriction map is 
shown in Figure 3.3 (p70). The vector has a unique Cla I restriction site at its 3' end 
for vector linearisation. This site is shown in bold. 
Key restriction sites are shown: B, Barn HI; E, Eco RI; P, Pst I; RV, Eco RV; 
N, Not I. 
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Figure 3.3: Restriction map of the FrP knockout vector 
Restriction map of Pm-p exon 3 knockout vector C. A number of sites have 
been omitted for clarity. 
Restriction enzyme abbreviations: B, Barn HI; B, Eco RI; H, Hind III; K, Kpn I; P; 
Pst I. All sizes in Kb. 
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Figure 3.5: Pm -p inactivation 
Map of the wild-type Pm-p a  allele and the inactivated Pm-p - allele. The 
targeted insertion of the HPRT minigene into exon 3 results in the introduction of an 
Xho I site into the Pm-p locus. This is demonstrated by the presence of a 5.2Kb band 
following Barn HIIXho I double digestion and hybridisation to a 700bp Eco RV/Barn 
HI probe (Probe E). The extent of vector homology is indicated by broken lines. All 
sizes in Kb. 
Restriction enzymes: B, Barn HI; E, Eco RI; H, Hind III; P, Pst I. 
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Figure 3.6: Southern analysis of Pm -p knockout ES clones 
Southern blot of ES clones bearing an inactivated Pm-p allele. Barn HI/Xho I 
double digestion of ES genomic DNA hybridised to a 700bp Eco RV/Barn 111 probe 
(Probe E). The wildtype Pm-p allele does not contain an Xho I site and results in a 
8.5Kb fragment whilst the targeted allele contains an HPRT minigene bearing an Xho 
I site -resulting in a band of 5.2 Kb. Clone 27*  is mixed clone in which only a 
proportion bear the Pm-p allele. This is a distinct clone from A27 in lane 2. 
75 	 Chapter 3: Pm-p inactivation in HM-1 ES cells 
JIM-1 27 34 6 	22 23 	27 30 	34a 35 






- SIXIIic band. 
Table 3.1: Targeting frequencies and germline transmission data for 
exon 3 knockout ES clones 
	
Exp't Date 	Linearisation 	Targeting 	Targeted 	Germiine Transmission 
No. 	 Site 	 Frequency' 	ES Line 
1 	Oct. 	Cia I 	21/72 	HM-1/i27 	Yes" 
1993 	 HM-1/34 Yes' 
2 	Nov. 	Cia 	 6/48 	HtvI-1/i\6 	Yes 
1995 	 HM-1/22 Yes 
HM-1/i23 	Not tested 
HM-1/i30 Not tested 
HM-1/A34 	Not tested 
HM-1/A35 Not tested 
Targeting frequency =No.Targeted coloniesfNo.HAT+GANC resistant colonies. 
This clone was used in a second step by Dr Nicola Redhead and generated mice with a PrP 
codon 101Leu alteration linked to Gerstmann Straussier Scheinker syndrome (Moore et al., 
1995) 
C, 	This clone was used in a second step and generated mice with a PrP codon 108F and 
189V alterations (Moore et al., 1995). This is described in chapter 5. 
primer G1177, a 20-mer which hybridises to sequence within the 5' arm of targeting 
vector homology. PCR products were also screened by hybridisation to a HPRT 
eDNA 1.1Kb probe. All PCR products giving rise to the predicted 2.28Kb band 
hybridised to both GI 177 and HPRT cDNA; This confirmed the authenticity of the 
2.28Kb products (data not shown). These studies were performed in collaboration 
with Dr Nicola Redhead, ICM1B. 
Section 3.5: Southern analysis of PCR positive ES colonies 
PCR positive clones were investigated by Southern analysis for the presence 
of targeting-specific changes to Pm-p restriction fragments (Figure 3.5, p74; Figure 
3.6, p76). These clones were also investigated for evidence of additional random 
integration events. The knockout vector replaced a 2.15Kb EcoRl exon 3 fragment 
with a 2.7Kb HPRT minigene containing an Xho I site. The targeted introduction of 
the HPRT minigene into Pm-p exon 3 was detected by the introduction of this novel 
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Xho I site into the predicted position. The wildtype Pm-p exon 3 lies within a 8.5Kb 
Barn HI fragment and targeting-specific changes to restriction patterns around this 
fragment were detected in Barn Fll/Xho I double digested ES genomic DNA. This 
digest produces an 8.5 Kb band from the wild-type Pm-p allele but is truncated to 5.2 
Kb by the introduction of the HPRT minigene into the predicted position within exon 
3 when hybridised to probe E (Figure 3.6, p76). A single Barn HI digest also produces 
a 9.1-9.2 Kb band when hybridised to probe E and arises from the replacement of the 
2,15Kb Eco RI band with the HPRT minigene, which is approximately 700bp larger 
(see Figure 3a, lane 2 in Moore et al., 1995 in Appendix I). 
Barn HTIXho I digests were also hybridised to a 1.1Kb HPRT cDNA 
fragment. This demonstrated, as before, the presence of the HPRT sequence within 
the predicted position in the 8.5Kb Barn HI fragment spanning exon 3. This probe 
hybridises to the knockout vector, and the absence of additional banding with this 
probe, indicated that all of the Pm-p a  ES lines tested had not undergone any 
detectable random integration events. This is consistent with observations of a number 
of gene targeting experiments in which additional random integrants are uncommon in 
ES clones which have undergone a gene targeting event. 
Section 3.6: Testing the germline potential of Pm-p a1  ES clones and the 
generation of PrP deficient mice 
The main objective of this research project was the generation of ES cells and 
mice with gene targeted alterations to PrP codons 108 and 189. This involves a two 
step double replacement gene targeting method (Figure 3. 1, p66) which requires the 
prolonged in vitro maintenance of ES cells, which is known to reduce their ability to 
contribute to the germline. The suitability of Pm-p a/-  ES clones for further gene 
targeting work was assessed by their ability to contribute to the germline. 
A number of ES clones with a low frequency of spontaneous 6-thiogunaine 
resistance were selected for blastocyst injection. Low levels of 6-TG resistance are 
required for the second gene targeting step. In the second step, a high level of 6-TG 
resistance would make it very difficult to identify gene targeted colonies amongst the 
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vast excess of non-targeted ES cells (Stacey et al., 1994).1  A number of chimeras 
were generated and were tested for their ability to contribute to the germline. 
Germline transmission was obtained from chimeras derived from different ES clones 
(Table 3. 1, p77) and were mated with 129/01a and Baib C stock to generate to Pm-p 
mouse lines. The 129/01a line was maintained as a pure bred 129/01a stock without 
any outbreeding onto other mouse genetic backgrounds. An outbred stock was also 
generated by crossing germline chimeras with Balb C and then maintaining this stock 
by random breeding of Pm-p -/- ' mice. Mice bearing the Pm-p - allele were analysed 
for PrP expression and this is discussed in the following chapter (Chapter 4, p84). 
Section 3.7: Discussion 
Four laboratories have independently performed PrP knockouts (Bueler et al., 
1992; Manson et al., 1994; Sakaguchi et al., 1995; Moore et al., 1995). The gene 
targeting frequencies described here, in which HPRT deficient ES cells are used in 
conjunction with an HPRT minigene, compare favourably with those of other groups 
(Table 3.2, p82). The final structure of each of the targeted alleles is shown in Figure 
3.7 (p81).. Bueler et al. (1992) used a vector flanked by 3.0 Kb of 5' homology and 
760bp Kb of 3' homology. Positive selection for cells stably transfected by the 
targeting vector was provided by a Neo module driven by a HSV-TK promoter. The 
low gene targeting frequencies observed in this experiment (1/5,000) are presumably a 
result of both the short region of 3' homology and the lack of a means of 
counterselection against random integrants. This PrP allele has undergone the 
replacement of codons 4 to 188 with a Neo module. Northern analysis indicates that a 
substantial quantity of a fusion transcript bearing neo and the remaining 3' PrP 
In the first step a Pm-p allele is inactivated by the introduction of an HPRT minigene. This endows 
HPRT deficient HM-1 ES cells with a HPRT +ve  phenotype and resistance to HAT selection. In the 
second step HPRT is replaced with an intact PrP coding region bearing codon 108 and 189 
alterations (Chapter 5). This second step utilises loss of HPRT function, and therefore 6-thioguanine 
(6-TG) resistance, to enrich for ES cells bearing PrP alterations. However this selection method also 
permits the survival of all ES cell types which are HPRT -ye  Non-targeted HPRT -ye  cells are 
undesirable and may be present in a targeted ES clone as a minor contaminant. These include the 
original HPRT deficient HM-1 parental clone and Pm-p ES clones in which the HPRT minigene 
has been silenced or deleted. This is discussed by Stacey et al., (1994). 
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Figure 3.7: A Comparison of Pm -p null allele structures 
Alignment of all extant Pm-p null alleles showing the extent of flanking 
homology, the position and type of selectable markers used and the extent of targeted 
deletions. All alleles are aligned by a common exon 3 Eco RI site (broken line). 
The alleles generated by Moore et at., (1995) and Sakaguchi et al., (1995) 
result in the complete removal of the PrP protein coding region by the replacement 
with a selectable marker. This also results in loss of approximately 1Kb of intron 2 
sequence. Knockouts generated by Bueler et at., (1992) and Manson et al., (1994a) 
result in no demonstrable PrP' expression but do not completely delete the PrP ORF. 
Bueler et al., (1992) deleted a portion of the protein coding region between codons 3 
and codons 188 and introduced a series of stop codons between the Neo module and 
the remaining 67 PrP C-terminal codons. The null generated by Manson et al., (1994) 
results in the insertion of a MT-Neo module into exon 3 at codon 95, between the 4th 
and 5th N -terminal octapeptide repeat. All sizes in Kb. 
Abbreviations: B, Barn RI; E, Eco RI; H, Hind III; K, Kpn I; P, Pst I; RV, Eco RV; 
X, Xba I; HPRT, hypoxanthine phosphoribosyltransferase minigene; MT, 
metallothionein promoter; Neo, neomycin phosphotransferase; ORF, PrP open 
reading frame; PGK, phosphoglycerate kinase promoter; TK, thyrnidine kinase 
promoter. 
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Table 3.2: PrP knockouts 
Reference Positive selectable marker! 
drug selection 
Counter selectable 
marker/ drug selection 
Targeting 
frequency' 
Bueler et al., 1992 TK-Neo/ G418 Not used 1/5000 
Manson et al., 1994a MT-Neo/ G418 HSV-TK/ GCV 1/800 
Moore et al., 1995 PGK-HPRT/ HAT HSV-TK/ GCV 1/6, 1/4 b 
Sakaguchi et al., PGK-Neo/ G418 HSV-TK/ GCV 1/321 
1995 
gene targeting frequency is defined as the number of targeted colonies divided by the number 
of drug resistant colonies surviving selection screened. 
data from two independent experiments 
GCV, gancyclovir 
HAT, hypoxanthine, aminopterin, thymidine 
HSV, Herpes simplex virus 
HSV-TK, Herpes simplex virus thymidine kinase gene driven by its own promoter 
HPRT, hypoxanthine-phosphoribosyltransferase minigene (Selfridge et al, 1992) 
MT, metallothionein promoter; 
Neo, neomycinphosphotransferase 
PGK, mouse phosphoglycerate kinase promoter; 
TK, HSV-thymidine kinase 
sequence is expressed from this allele (Weissmann et al., 1993). 
Manson et al. (1994a) used a replacement-type vector bearing 1.2Kb of 5' 
homology, 2.4 kb of 3' homology and a MT-Neo module. The higher gene targeting 
frequency obtained with this vector is probably due to the use of a HSV-TK module 
in combination with gancyclovir for counterselection. This allele retains the whole PrP 
coding sequence but the ORF is interrupted by a MT-Neo module inserted into a Kpn 
I site in exon 3, corresponding to codon 952  Thus PrP sequences upstream and 
downstream of the Kpn I site are present in the final allele structure. It is therefore 
formally possible that this allele can still produce low levels of mRNA, either as a 
fusion transcript with Neo or by splicing around the neo module. However, SDS-
PAGE indicates that this allele expresses undetectable levels of PrP -an observation 
which is consistent with the scrapie resistance of mice generated from ES cells bearing 
this mutation (Manson et al., 1994b). 
2  PrP codon 95 lies between the 4th  and 5th  N-terminal repeat. 
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Sakaguchi et al., (1995) used a large targeting vector with 2.0 Kb of 5 
homology and 15kB of 3' homology in conjunction PGKINeo positive selection and 
counterselection with HSV-TK and gancyclovir. The final allele structure is very 
similar to that described in this thesis (Moore et al., 1995) and both generate a secure 
PrP null allele because the entire PrP protein coding region is replaced with a 
selectable marker. 
Extensive homology to the target locus is known to provide higher gene 
targeting frequencies (Thomas and Capecchi, 1987; Hasty et al., 1991; Deng and 
Capecchi, 1992), however this cannot be the sole explanation for the high gene 
targeting frequencies observed in this thesis. The vector described in this chapter uses 
considerably shorter flanking homology than that used by Sakaguchi et al., (1995). 
This suggests that the higher gene targeting frequencies for the knockout described in 
this chapter (Moore et al., 1995) arise from the high efficiency of the HPRT/HAT 
selection system. This system has been used to inactivate a wide range of genes with 
similar or even higher gene targeting frequencies and include mouse ct-lactablbumin 
(Stacey et al., 1994), cytokeratin-10 (Porter et al, 1996), ERCCI (Kan-Tai Hsia and 
David Melton, unpublished data) and DNA ligase I (Bentley et al., 1996). 
Section 3.8: Summary 
A number of ES clones have been generated in which one allele of PrP has 
been inactivated by the targeted introduction of an HPRT minigene. This allele 
generates a secure PrP null because all of the PrP protein coding region and part of 
the 3 'UTR has been removed. Clones with low levels of 6-thioguanine resistance were 
tested for their ability to colonise the mouse germline. A number of clones generated 
germline chimeras. This demonstrated the generation of a number of Pm-p a!-  ES 
clones suitable for the second step of gene targeting. Germline transmission of the 
Pm-p null allele enabled the generation of two lines of Pm-p ' mice. The analysis of 
these mice is described in the following chapter. The second gene targeting step is 
described in chapter 5. 
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Section 4.1: Introduction 
PrP deficient mice were generated as a by-product of the two step double 
replacement method as described in Chapter 3. No overt biological differences were 
observed between Pm-p ' , Pm-p 31-  and wild-type mice during the routine 
procedures involved in breeding the PrP null line, consistent with published reports of 
independently produced Pm-p ' lines (Bueler et al., 1992; Manson et al., 1994a). 
Following the report by Sakaguchi et al., (1996) of an adult onset cerebellar 
phenotype at 70 weeks, a number of 129/01a and outbred Pm-p mice were aged to 
determine whether they developed this phenotype. A similar phenotype was observed 
and is described in Section 4.3 (p88). 
Section 4.2: PrP expression in Pm -p and Pm -p mice 
The levels of PrP mRNA and PrP' in whole adult brain were compared in 
129/01a Pm-p ala  Pm-p a!-  and Pm-p ' mice (Figure 4. 1, p87). This revealed that PrP 
mRNA expression was reduced by -P50% in Pm-p brain relative to wild-type 
129/01a Pm-p ala  mice and that PrP mRNA was absent from Pm-p mouse brain 
(Figure 4. 1, panel a, p87). Western analysis of crude brain homogenates also indicated 
a -50% drop in PrP' expression in Pm-p ' brain and the absence of detectable levels 
of PrP' in homozygous nulls (Figure 4. 1, panel b, p87). The drop in PrP expression at 
the level of RNA and protein are consistent with previous reports in independently 
produced PrP null mouse lines (Bueler et al., 1992; Manson et al., 1994a; Sakaguchi 
et al., 1995). The scrapie susceptibility of these Pm-p " mice is currently being tested. 
The Pm-p " line generated during the course of this project are referred to as ICMB 
Pm-p 
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Figure 4.1: Brain PrP expression in ICMB Pm -p and Pm -p ' mice 
Whole brain PrP expression was examined at the level of RNA (panel a) and 
protein (panel b) in adult male mice. 
Panel a). Brain PrP mRNA expression was reduced to 50% of wild-type 
levels in Pm-p a1  mice expressing a single functional Pm-p 
a  allele and is absent in 
Pm-p ' mice homozygous for the Pm-p - allele. Northern analysis of whole brain 
total RNA (bug) from wildtype Pm-p '/' (lane 1), Pm-p 
a!-  (lane 2) and Pm-p ' (lane 
3) mice. RNA was hybridised to Probe D (mouse PrP exon 3 1.1 Kb SmalfEco RI 
exon 3 ds. DNA fragment). 
Panel b). PrP' expression in Pm-p '/- brain is reduced to --50% wild-type levels 
and is absent from Pm-p mice. Immunoblot analysis of crude brain homogenate 
containing 20ug of total brain protein derived from adult Pm-p 
ala  (lane 1), Pm-p aJ-
(lane 2) and Pm-p ' (lane 3) mice. PrP was detected using PrP polyclonal antiserum 
1 A8 (Farquar et al., 1994b) at a dilution of 1:1000 and mouse antirabbit alkaline 
phosphatase conjugated IgG (Promega) at a dilution of 1:7500. Alkaline phosphatase 
activity was visualised with the colorimetric substrate NBT/BCIP (Promega). 
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Section 4.3: A neurological phenotype in 129/01a PrP deficient mice 
Section 4.3.1: Introduction 
Sakaguchi et al., (1996) have reported a fully penetrant cerebellar ataxia in 
F2[129/Sv x C57BL/6J] Pm-p mice with onset at approximately 70 weeks (-490 
days). Rotorod tests' performed along with age-matched controls indicated a loss of 
co-ordination beginning at 49 weeks which progressed to a severe ataxia between 80 
and 90 weeks. Gross examination of brains from 90 week old Prn-p mice revealed 
that the cerebellum was atrophied and weighed significantly less than that of Pm-p 
ala 
and Pm-p a!-  littermates. Histological examination of Pm-p 	cerebella revealed a 
marked loss of Purkinje neurons from many, but not all areas of the cerebellum. A 
thinning of the cerebellar molecular layer was also apparent in 87 week old mice. 
The absence of a similar phenotype in other lines of PrP knockout mice of a 
similar age and of comparable genetic background (personal communication cited in 
Sakaguchi et al., 1996; Jean Manson, personal communication) suggested that this 
phenotype might be artefactual rather than the specific effect of PrP deficiency. 
Comparison of the structure of all independently generated Pm-p knockout 
alleles (Figure 3.7, p81) revealed that the PrP null allele described in this thesis 
(Moore et al., 1995) had a number of similarities to that generated by Sakaguchi et 
al., (1995). They are as follows: i) both alleles delete the entire PrP protein coding 
region, ii) both alleles delete a 1Kb portion of intron 2 upstream of the protein coding 
exon and iii) both use the strong PGK promoter to drive expression of the selectable 
marker. These similarities in knockout allele structure are not shared by the knockouts 
generated by Bueler et al., (1992) and Manson et al., (1994) which do not develop an 
ataxic phenotype. 
This suggested that the presence or absence of a similar phenotype in the mice 
generated during the course of this thesis might provide an insight into this issue. A 
phenotype with some similarities to that reported by Sakaguchi et al., (1996) was 
observed and the remainder of this chapter is devoted to this issue. 
A test of cerebellum and spinal cord function 
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Section 4.3.2: Preliminary observations of a phenotype in ICMB 129/01a 
PrP deficient mice 
Groups of male and female inbred ICMB 129101a Pm-p " mice were 
maintained in excess of 1 year. Thus far, all 129/01a Pm-p mice older than 14 
months develop a phenotype similar in many respects to that reported by Sakaguchi et 
al., (1996). The phenotype was first manifest in a single male and began as a mild gait 
abnormality and a ruffling of the coat between the shoulder blades at 423 days. Poor 
coat condition is normally considered a reliable sign of illness in laboratory mice. 
Many common illnesses of laboratory mice result in rapid deterioration, however this 
single Pm-p 	mouse was unusual in that its general health did not appear to 
deteriorate markedly. This mouse was observed frequently and a number of 
preliminary observations were made: the hind quarters of the mouse became thin and 
tended to swing laterally when the animal walked -reminiscent of the "mincing gait" 
reported by Sakaguchi et al., (1996). The mouse lost 10% of its body weight over a 
period of three weeks but stabilised thereafter. The gait abnormality progressed 
slowly over 10 weeks and at 70 weeks the mouse had obvious tremor of the whole 
body but also of the forelimbs, especially the right foreleg -which it avoided placing 
weight on when walking. The animal then started to develop signs of respiratory 
distress and was sacrificed at 496 days. Following initial observations in this mouse, 
the remaining Pm-p mice were observed closely for further abnormalities. These 
preliminary observations proved to be typical of the phenotype observed in other 
ICMB 129/01a Pm-p mice aged more than 14 months. Using the above clinical 
signs as indicators of the phenotype, the mean age of onset was estimated at 442 
days2 or 63 weeks. 
The coat ruffling, proved to be an early indicator of a spinal curvature because 
many mice eventually developed a kyphosis in the thoracic region between vertebrae 
T2 and T4 and between T6 and T13 (data not shown). The gait abnormality was 
progressive and in some mice a marked atrophy of the pelvic girdle musculature was 
also apparent. The extent to which loss of postural muscle tone contributes to both 
2  Mean age of onset 442 days, SE=5, SD=22 days, n=22 
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the kyphosis and the gait abnormality is uncertain. The brains of affected animals were 
examined for signs of neuropathology. 
Section 4.3.3: Neuropathology in ataxic Pm-p " mice 
Examination of H&E stained sections from three ICMB 129/01a Pm-p " 
ataxic mice revealed no obvious morphological abnormalities, however moderate 
symmetrical vacuolation was apparent in many white matter areas throughout the 
brain, being most severe in the cerebellar white matter. A reduction in the number of 
Purkinje neurons was apparent in many cerebellar lobules, with a large proportion of 
the remaining Purkinje neurons appearing pyknotic or eosinophilic. A comparison was 
made with available material3 from age matched 129101a wildtype mice and an 
independently generated line of 129/01a Pm-p mice (Manson et al., 1994a)4 which 
do not develop a late onset neurological phenotype (Jean Manson, personal 
communication). This revealed a comparable degree of vacuolation in both 129/01a 
wild-type and NPU Pm-p ' mice', indicating that the vacuolar change apparent in 
400-500 day old ICMB Pm-p ' mice is age related and does not arise as a result of 
the PrP knockout. 
Purkinje neurons in the 4th  and 10th  cerebellar lobules were counted  in 
129/01a wild-type, NPU Pm-p and ICMB Pm-p brains (Table 4. 1, p91). The 
extent of Purkinje cell loss in lobule 4 is illustrated in Figure 4.2 (p92). Counting 
studies revealed that NPU Pm-p mice (n=2) and wild-type 129/01a mice (n=2) had 
similar Purkinje cell counts in lobule 4 -consistent with the absence of a late onset 
ataxia in this line of Pm-p mice. NPU Pm-p ' mice appeared to have slightly fewer 
Purkinje cells than wild-type mice in lobule 10. The significance of this observation is 
Space limitations in the animal facility in which the 129/01a Pm-p mice were housed precluded 
the maintenance of age matched Pm-p a/a  Pm-p a1  and Pm-p -/- ' mice. 
Age matched wild-type 129/01a and Pm-p 	mice were kindly provided by Jean Manson, 
BBSRC/MRC Neuropathogenesis Unit, Edinburgh. These are referred to as NPU Pm-p mice. 
All mice had moderate but extensive vacuolar change in the corpus callosum which extended to the 
lateral ventricles and ventrally to the stria terminalis, cerebral peduncles and pyramidal tract/optic 
tract. Moderate vacuolation was also observed in the dorsal medulla and thalamus. 
These lobules were counted because they are well defined and consistently appear on standard 
lesion profile sections of the cerebellum. 
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Figure 4.2: Purkinje neuron loss in ICMB Pm -p ' mice 
Purkinje neuron frequency in cerebellar lobule 4 in aged wild-type 129/01a, NPU 
Pm-p (Manson et al., 1994) and ICMB Prn-p mice. 
Panel a). illustrates the area of lobule 4 used for cell counting in all mice 
(magnification x2). Purkinje cells were counted along the interface between the 
granular and molecular layers between points 1, 2 and 3 (indicated). Note: white 
matter vacuolation is apparent in the region below "1". This is typical of the extent of 
vacuolar change in all aged mice examined so far. 
Panels b). -d). area around "2" in panel a). in the relevant mouse line (magnification 
AO). 
Panel b). 129/01a wild-type cerebellum showing a complete layer of Purkinje neurons, 
many of which appear eosinophilic. 
Panel c). Normal levels of Purkinje neurons in NPU Pm-p mice (Manson et at., 
1994). The close similarity in number of Purkinje neurons in wild-type and NPU Pm-
p ' mice is consistent with the absence of an ataxia in this line. 
Panel d). ICMB Pm-p (Moore et al., 1995) cerebellum with reduced numbers of 
Purkinje neurons. The arrow indicates one of the few remaining Purkinje neurons. 
Table 4.1: Cerebellar Purkinje neurons are 
reduced in ataxic Pm -p " mice (preliminary data) 
Mouse lincf 	Mouse age 	Purkinje cells 	Purkinje cells 
(days) 	lobule 4t 	lobule lOt 
Wild-type 550 128 54 
550 136 70 
NPU Pm-p 551 128 33 
550 144 39 
ICMBPrn-p 517 43 12 
517 56 29 
496 63 20 
¶ All mice used for this study were male. 
This is the average of counts performed on duplicate sections from each mouse. 
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uncertain given the small numbers of animals examined -the small size of this lobule 
may also predispose it to sampling variation. 
Counting studies based upon a small sample of ICMB Pm-p mice (n=3) 
indicated that these mice had considerably less Purkinje neurons than wild-type 
129/01a and NPU Pm-p mice in both lobules 4 and 10. 
Section 4.4: Discussion 
An adult onset phenotype characterised by kyphosis and ataxia is evident in 
ICMB Pm-p mice with a mean onset age of 442 days (+5 SE, n=22). The 
phenotype is somewhat milder than reported by Sakaguchi et al., (1996) and this is 
probably because the studies reported here are in mice which are 64-70 weeks old 
whilst Sakaguchi et al., (1996) reported the phenotype in mice older than 80 weeks. 
Examination of the brains of 129/01a wild-type, Pm-p and Pm-p mice 
revealed a degree of age related vacuolation which was not related to PrP deficiency. 
However, preliminary Purkinje cell counting studies indicate that Pm-p mice have a 
marked reduction in Purkinje cells in two cerebellar lobules -consistent with ataxia in 
these mice. Future studies with larger numbers of mice are required. The observation 
of normal levels of Purkinje neurons in lobule 4 in NPU Pm-p mice is consistent 
with the absence of an adult onset ataxia in these mice. Further studies will examine 
the slightly reduced numbers of Purkinje cells in lobule 10 of NPU Pm-p mice. The 
studies reported here, whilst preliminary in nature, are consistent with those of 
Sakaguchi et al., (1996) and indicate that the ataxic phenotype arises from the loss of 
cerebellar Purkinje neurons. 
The counting studies reported here also indicated that a large proportion of 
Purkinje cells in all aged mouse lines were eosinophilic or pyknotic. This indicates that 
there is an age-related degeneration of this cell type in 129/01a mice. Future studies 
will examine the number of Purkinje neurons in these mouse lines at various ages to 
develop a clearer picture of the age related loss of this cell type and to establish 
whether ICMB Pm-p mice have normal levels of Purkinje neurons earlier in life. 
Studies with older ICMB Pm-p mice may reveal an even more marked loss of 
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Purkinje neurons. The marked thinning of the molecular layer reported by Sakaguchi 
et al., (1996) is not apparent in the ICMB Pm-p ' mice studied so far but may arise in 
older mice. 
The adult onset neurological phenotype in ICMIB 129/01a Pm-p mice had a 
mean age of onset of 442 days or -P63 weeks. This is about 7 weeks earlier than 
reported by Sakaguchi et al., (1996). Potential explanations for this difference may 
include the benefit of foreknowledge of a possible phenotype, the use of different 
phenotype scoring criteria and the effects of genetic background. Sakaguchi et al., 
(1996) used a different 129 ES cell substrain (129/Sv) and crossed their chimeras with 
C57BL/6J. Their phenotype was subsequently reported in segregating F2[12915v x 
C57BL/6J] crosses. The importance of genetic background as a major modifier of 
gene knockout phenotypes is well established (for reviews see Gerlai, 1996; Lathe, 
1996). 
Section 4.4.1: What causes the Pm -p " phenotype? 
Sakaguchi et al., (1996) concluded that the ataxic phenotype was the result of 
the loss of PrP' function, however the absence of this phenotype in two other 
independent PrP null lines obliges consideration of alternative explanations. These 
include: i) an additional mutation in the ES clones used to construct the ataxic Prn-p 
mice, ii) a naturally occurring mutation within the mouse stocks used for the 
generation of the ataxic nulls, iii) differences in 129 ES cell sub-strain and iv) 
differences in structure of the PrP null allele. These will be discussed in turn: 
The possibility that an additional mutation may have been introduced into the 
ES cells generated by Sakaguchi et al., (1995, 1996) seems remote given the 
independent appearance of a similar phenotype in the mice described in this thesis. 
Similarly, the possibility that the mouse stocks used by Sakaguchi et al., (1996) to 
generate their Pm-p -1- ' line may have carried a recessive mutation such as pcd or 
wobbler seems unlikely given that i) most naturally occurring mutations affecting the 
cerebellum present with ataxia much earlier in life and ii) the independent appearance 
of the ataxic phenotype in a separate line of PrP deficient mice co-isogenic with wild-
type 129/01a mice. 
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Most ES lines are derived from 129 substrains and all groups reporting PrP 
knockouts have used 129-based ES lines. There is considerable genetic variation 
between 129 substrains (Simpson et al., 1997) and this is a potential explanation for 
the presence of a cerebellar phenotype in only 2 of 4 Pm-p mouse lines. However, 
two observations suggest that this is not relevant: i) the knockout reported in this 
thesis and that reported by Manson et al., (1994a) have utilised related ES lines7 with 
a common 129/01a origin but only one mouse line develops the ataxia and ii) the 
knockout line reported in this thesis and that of Sakaguchi et al., (1995,1996) both 
develop ataxia but were generated using distinct ES lines which were derived from 
different 129 substrains (HM-1: 129/01a and Ji: 129/Sv respectively). 
The PrP null allele constructed during this thesis (Moore et al., 1995) and that 
of Sakaguchi et al., (1995, 1996) are similar in several respects: i) both alleles delete 
the entire PrP protein coding region, ii) both alleles delete a 1Kb portion of intron 2 
upstream of the protein coding exon and iii) both alleles use a strong PGK promoter 
to drive expression of the selectable marker. This argues that the presence or absence 
of the ataxic phenotype is associated with these features because PrP null mice which 
do not display the phenotype have quite different allele structures (Figure 3.7, p81). 
Manson et al., (1994a) have inserted an MT-Neo module into the Kpn I site of exon 
3, retaining all of exon 3 sequence and generating a null allele with a frame shift. 
Bueler et al., (1992) replaced a large portion (but not all) of the PrP ORF with a TK-
Neo module. Both knockouts result in loss of PrP' expression and both lines are 
scrapie resistant (Bueler et al., 1993; Prusiner et al., 1993; Manson et al., 1994b). It is 
possible that the knockout alleles generated by Bueler et al. (1992) and Manson et al., 
(1994a) generate a fusion transcript reading through the neo gene into the remainder 
of the PrP coding region and 3'UTR which retains some residual function. Indeed the 
presence of such a transcript in Pm-p brain has been reported in the line generated 
by Bueler et al. (Weissmann et al., 1993). It is possible that the exon 3 region contains 
Manson et al., (1994a) used E14 and Moore et al., (1995) used HM-1. HM-1 was derived from 
E14TG2a which was in turn derived from E14. The E14 ES line was derived from 129/01a 
blastocysts. 129/01a (full name 129/01a Hsd) is maintained by Harlan UK and was established from 
129IReJ stock animals from the Jackson Laboratory in 1978 (Simpson et al., 1997). 
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some sequence with a regulatory function in Purkinje neurons and that Sakaguchi et 
al., (1995, 1996) and Moore et al., (1995), in deleting the whole coding region, have 
removed this sequence. In both ataxic lines 1Kb of intron 2 sequence 5' to exon 3 has 
also been removed and it is conceivable that this may inactivate an unknown 
transcriptional unit or control element in this region. 
In addition to the structural differences between independent knockout lines 
there are differences in the selectable modules retained in the targeted allele. 
Sakaguchi et al., (1995) and Moore et al., (1995) replaced the whole coding region 
and part of intron 2 with PGKINeo and PGK/HPRT respectively whilst the knockouts 
generated by Manson et al., (1994a) and Bueler et al., (1992) were performed by 
inserting MT/Neo and TKINeo modules respectively. Both the HSV-thymidine kinase 
(TK) and metallothionein (MT) promoters are relatively weak whilst the mouse 
phosphoglycerate kinase promoter is comparatively strong (PGK). It is possible that 
the insertion of a PGK promoter into the Pm-p locus can exert some cis acting 
influence on the expression of genes/elements within the Pm-p locus. It is also 
possible that such an effect is exerted upon neighbouring genes outside the Pm-p 
locus. There are precedents for dysregulation of neighbouring genes by PGK/neo 
constructs. For example a PGK/Neo module has been shown to reduce the expression 
of a number of genes within the granzyme cluster and can act over distances of over 
100Kb (Pham et al., 1996). 
Further experiments may reveal whether the phenotype is the result of the loss 
of PrP' function. To this end, a PrP transgene is currently being bred onto a Prn-p 
background (Prof Stanley Prusiner, personal communication). 
Section 4.5: Summary 
The original report of cerebellar dysfunction in Pm-p mice (Sakaguchi et al., 
1996) was difficult to reconcile with the other lines generated independently in which 
it did not develop. The observations reported here independently verify the ataxic 
phenotype. Further studies will be required to establish whether the ataxia in Pm-p 
mice arises as a result of PrP' deficiency or some other cause. 
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Generation of embryonic stem cells with PrP 
codon 108 and 189 alterations 
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Section 5.1: Introduction 
In the first gene targeting step, described in chapter 3, Pm-p exon 3 was 
inactivated by the targeted introduction of an HIPRT minigene. This converts HPRT 
deficient HM-1 cells to an HPRT +ve  phenotype. This chapter describes the second 
step in which the HPRT minigene in such cells was replaced with engineered exon 3 
sequence (Figure 3.1, p66). Targeted ES cells revert back to an HPRTVe  phenotype 
enabling enrichment by selecting against HPRT+\e  ES cells with 6-thioguanine, a toxic 
HPRT substrate. 
Section 5.2: Second step vector construction 
Section 5.2.1: Mutagenesis cassette construction 
A mutagenesis cassette was generated by cloning exon 3 sequence containing 
part of the PrP A ORF into M13mp18. The cloning strategy was adapted to maintain 
the smallest portion of the PrP coding region in M13mp18 to minimise problems 
associated with the stability of larger inserts in M13 vectors and to reduce the 
potential for the introduction of undesired mutations. 
A 934bp Kpn 1-Ecoki fragment was isolated from pl29PrP and cloned into 
M13mp18. This generated the M13 clone m129K/E' containing wildtype exon 3 
ORF sequence corresponding to the PrP A allotype (PrP 108L 189T). m129KJE' 
ssDNA derived from the antisense strand enabled the use of sense mutagenesis 
oligonucleotides (Figure 5. 1, plo1). 
Prior to in vitro mutagenesis by the Kunkel method, double stranded 
m129KfE' RF II DNA was passaged through diii irng mutant E.coli strain 0236. 
This generated m129KfE't ssDNA containing dUTP. The incorporation of dUTP 
provides biological selection against the parental strand of the heteroduplex following 
in vitro mutagenesis and transformation into a dul ung wild type E.coli strain (Kunkel 
et al., 1987). This method enables the isolation of mutants at high frequency and is 
described more detail in Section 9.13. 10 (p212). 
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Section 5.2.2: Introduction of the PrP codon 189V mutation 
m129K/E' dUTP ssDNA was isolated and 200ng was annealed with 3 pmol 
of phosphorylated HPLC purified mismatch oligo G6020 (5' 
gcagcacacggtcgtcaccaccaccaaggg 3'). This oligonucleotide introduces a ACC-GTC 
mutation resulting in the substitution of a PrP codon 189 threonine for a valine. The 
mutant oligonucleotide/daughter strand was extended using T7 DNA polymerase. An 
aliquot of the reaction product was used to transform dut ung wildtype DH5aF' 
competent cells. Ten well separated M13 plaques were picked, amplified in 1.5m1 
liquid cultures and RF II d.s. DNA was screened for the introduction of the codon 
189V mutation. The ACC-GTC mutation alters two nucleotides within the exon 3 Bst 
Eli recognition sequence G'GTNACC resulting in loss of this restriction site. Putative 
mutants, in which the BstEII was lost, were obtained at high frequency (6/10) and 
confirmed by di-deoxy sequencing (data not shown) using the human PrP primer 
508X (a gift from Dr. Otto Windi, BBSRC Centre for Genome Research, Edinburgh). 
This primer corresponds to a region 200nt upstream of the mouse codon 189 position. 
All m129KIE189 ' clones were sequenced between -40nt and +105nt from the codon 
189 position and all were found to have sequence indistinguishable from wildtype 
mouse, other than the desired mutations. A 934bp Kpn-Eco RI fragment from a clone 
containing the codon 189V mutation was isolated and used to construct the plasmid 
targeting vector p189V (Figure 5.3, p105). To generate a double mutant 
p108F189V targeting vector, a m129PrPK/E 189V  mutant was used for a further 
round of mutagenesis to introduce the PrP codon 108F alteration. 
Section 5.2.3: Introduction of the PrP codon 108F mutation 
A CTC-TTC mutation was introduced into the codon 108 position of 
m129K/E189 '. Mutagenesis was performed as described above for the codon 189V 
mutation but with mutagenesis oligonucleotide G6877 (5' ccaaaaaccaactcaagcatgtggc 
3'). This mutation does not generate a known RFLP1 but mutants were detected by 
'The codon 108 mutation results in the loss of a Mnl I site but this enzyme is no longer commercially available. 
99 	 Chapter 5: Generation of embryonic stem cells 
with PrP codon 108 and 189 alterations 
Figure 5.1: m129PrPK/E Wt  mutagenesis cassette 
The M13-based mutagenesis cassette ml29PrP 
KE•  This cassette contains a 
934bp KpnILEco RI PrP exon 3 fragment and generates ssDNA corresponding to the 
antisense strand of PrP enabling the use of sense mutagenesis primers. 
Restriction enzymes: B, Barn FIT; E, Eco RI; H, Hind III; K, Kpn I; P, Pst I; X, Xba I. 
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Figure 5.2: In vitro mutagenesis -screening for the 108F mutation 
Single stranded DNA was sequenced for the 108F mutation with the M13 
forward primer. Sample loadings as illustrated. The wildtype control was 
m129K/E Wt  Two of four clones screened were 108F mutants (1 and 4). Sequence 
surrounding codon 108 is shown for orientation. 
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Figure 5.3: Construction of targeting vectors p189V and p108F_189V 
Targeting vector pl08F-189V was constructed in a single cloning step by 
ligating a 934bp Kpn/Eco RI fragment from the double mutant m129K/E 
108F_189V  with 
a 6.7Kb Barn HI /Eco RI Vector A fragment and a 3.35Kb Barn Fll/Kpn I pl29PrP+ 
fragment. Vector p189V was constructed in a similar manner using a 934bp codon 
189V mutant fragment from m129K/E'89". 
Abbreviations: B, Barn HI; E, Eco RI; K, Kpn I; RV, Eco RV. 
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Figure 5.4: Construction of targeting vector pl08F. 
Vector p108F was constructed in a single cloning step as follows: a 3.4 Kb band 
containing the PrP 108F mutation was isolated from vector plO8F_189V by double 
digestion with Barn HI and Asp 7001 (an isoschizorner of Xmn I). A 704bp band 
containing the wildtype codon 189T was isolated from pl29S/E' by Eco RI/Asp 
7001 double digestion. A 6.7kb Barn HI/ Eco RI fragment was isolated from Vector 
A. These fragments were ligated and of 7 bacterial colonies screened, 5 contained the 
desired recombinant, one clone was further investigated by restriction analysis and 
had the predicted structure. A restriction map of this vector is shown in Appendix II. 
Abbreviations: B, Barn HI; E, Eco RI; RV, Eco RV. 
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Figure 5.5: Restriction map of targeting vector p108F_189V 
A restriction map of the completed PrP exon 3 targeting vector p108F_189V. 
This vector was linearised at a unique 3' Cia I site prior to eiectroporation. 
Abbreviations: B, Barn HI; E, Eco RI; H, Hind III; K, Kpn I; P, Pst I; S. Sma I; X, 
XbaI. 
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dideoxy sequencing of ssDNA from small scale cultures (Figure 5.2, p103). Codon 
1 08F1 89V double mutants were detected at high frequency: two of four plaques (1 
and 4) picked at random contained the desired 108F mutation. 
Section 5.2.4: Targeting vector construction 
Vector p108F 189V was constructed in a single cloning step as shown in 
Figure 5.3 (p105) using a 934bp KpnlI! Eco RI fragment from ml29KIE8F189V.  The 
restriction map of this targeting vector is shown in Figure 5.5 (pl09).  The 
construction of vector p108F is shown in Figure 5.4 (pl07)  and its restriction map is 
in Appendix II. The complete PrP coding region of the three targeting vectors was 
sequenced and confirmed the presence of the codon 108 and 189 alterations and the 
absence of other mutations, deletions or cloning artefacts. 
Section 5.3: Introducing PrP codon 108 and 189 alterations into ES cells 
Section 5.3.1: Introduction 
As described in the chapter 3, the targeted introduction of the exon 3 
inactivation vector results in the replacement of a 2.1 Kb Eco RI Pm-p exon 3 
fragment with a 2.7 kb HPRT minigene. This endows the HPRT deficient male H1v1-1 
ES cell line with an HPRT+Ve  phenotype and sensitivity to 6-thioguanine. Thus in the 
second step it is sufficient to enrich for targeting events by selecting for ES cells 
which have lost HPRT function. Only Pm-p a!-  ES lines with a low frequency of 
spontaneous 6-thioguanine resistance were used for second targeting steps. 
Section 5.3.2: ES cell culture 
The same protocol was used for all second step targeting experiments: 3x107 
Prn-p' ES cells at passage 22-26 were electroporated with 200ug of Cia I linearised 
second step targeting vector in 800ul of HEPES-phosphate buffered saline, pH 7.05 
at 850V, 3u Fd (BioRad Gene Pulser) in sterile BioRad electroporation cuvettes (path 
length 0.4cm). The cells were then incubated at room temperature for 10 minutes 
before plating out onto ES medium without selection at a density of 3-4x106 
cells/75cm2 flask into 6-10 independent pools. Cells were maintained for 5-7 days 
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without selection (to enable decay of HPRT in targeted cells) then plated out onto 
90mm dishes at a density of 1-2x106 cells/dish in ES medium supplemented with 
5ug/ml 6-thioguanine. Drug resistant ES colonies were picked 10-14 days later and 
half of each colony was screened for the targeted alteration. The remainder of each 
colony was grown in 24 well dishes in ES medium in the absence of selection. PCR 
positive colonies were expanded and aliquots were frozen for blastocyst injection, if 
required. Genomic DNA was prepared from each PCR positive ES clone and 
investigated by Southern analysis for the appropriate Pm-p gene structure. 
Section 5.3.3: Detection of PrP codon 108F and 189V alterations 
The exon 3 region of ES colonies surviving 6-thioguanine selection was 
amplified by PCR and the reaction product screened for the presence of codon 108 
and 189 alterations. The codon 108F alteration was detected by allele specific 
oligonucleotide hybridisation and the codon 189V alteration was detected by the loss 
of a Bst Eli site. 
Heat-inactivated proteinase K-treated ES lysates were amplified with PrP 
exon 3 primers 348M and 411Y generating a 1,327bp product from both wildtype and 
targeted PrP alleles (Figure 5.6, p1  13). The codon 189V alteration was detected by 
the loss of a Bst Eli site within the exon 3 PCR product (Figure 5.6, panel a, p113). 
PCR products from targeted 189V alleles remain undigested as the 189V alteration 
alters two nucleotides within the sequence G'GTNC, ablating the BstEII 
recognition site. The codon 108F alteration is a single nucleotide change (CTC to 
ITC) and does not give rise to an RFLP with any commercially available restriction 
enzyme. Therefore PrP exon 3 PCR products were screened for the 108F alteration 
using allele specific oligonucleotide hybridisation (ASO) with [7-32P]ATP labelled 
108F mutant 19-mer Hi 160 (5'-gccacatgcttgaagttgg-3': Westaway et al., 1987). This 
is illustrated in Figure 5.6 (p113). 
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Figure 5.6: Detection of ES cells with 108F_189V alterations 
Four ES clones with targeted codon 10817_189V alterations are shown: 
clonesl4, 18, 44 and 45. Following PCR amplification of exon 3, a 1,327bp PCR 
product is generated. Reaction products were first screened for the codon 189V 
alteration (Panel a) by digestion with BstEII (20U/tube) at 60°C for 2 hours. 
Digested PCR products were electrophoresed on a 1.5% agarose gel. PCR products 
from wildtype alleles have a centrally placed BstEII site and generate 2 bands of 697 
and 630bp. PCR products derived from targeted 189V ES colonies do not digest with 
Bst Eli. All clones are heterozygous and have one wildtype and one targeted allele. 
The codon 108F alteration was detected following the transfer of the Bst Eli 
digested PCR product onto nylon membrane. Membranes were hybridised to y-ATP32 
5' labelled 108F primer at 37°C and washed at low stringency at room temperature 
(20°C). The membrane was exposed to provide a control for loading variation 
between PCR samples (Panel b). This illustrates that the 108F oligonucleotide 
hybridises to 2 bands at low stringency: the larger 1,327bp band is derived from a 
targeted 189V allele which has lost its Bst Eli site and the lower band represents the 
hybridisation of the 108F mutant oligo to wildtype PCR product under conditions of 
low stringency. 108F mutant ES clones 14, 18, 44 and 45 were detected by their high 
signal intensities, relative to controls, following a wash at raised stringency (62°C) 
(Panel c). In experiments involving the targeting vector plO8F_189V where both 
mutations were expected on the same allele, 1,327bp exon 3 PCR products which 
resisted BstEIi digestion and generated a 108F specific signal enabled the physical 
linkage of codon 108F and 189V alterations on the same allele. 
Serial dilutions of positive and negative controls were included in all 
experiments. Positive controls were generated separately to avoid cross-
contamination and consisted of PCR product generated from VMIDk (PrP B: 
1 08F1 89V) mouse genomic DNA. Negative control PCR product was generated 
from HM-1 (PrP A: 108L 189T) genomic DNA template. The detection of single 
108F and 189V alterations is described in Moore et al., (1995), Appendix I. 
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Section 5.3.4: Southern analysis of PCR positive ES clones 
As described previously, 6-thioguanine resistant ES colonies electroporated 
with the plO8F 189V targeting vector were screened for the 108F and 189V 
alterations by hybridisation to a [y-32P]ATP labelled codon 108F oligonucleotide and 
BstEII digestion respectively. Similar targeting frequencies were observed in two 
independent experiments using different Pm-p - first step clones (4/60 with HM-
1/A34 and 4/72 with HM-1/A27). A total of eight PCR/ASO positive clones were 
found to be gene targeted by Southern analysis. 
Putative targeted clones were investigated for i) the loss of the HPRT 
minigene, ii) reconstruction of the targeted Pm-p allele and iii) the absence of 
additional non-homologous recombinants. 
The second step replaces the HPRT minigene with Pm-p exon 3 sequence 
bearing codon 108F and 189V alterations. Therefore ES genomic DNA was 
investigated for the loss of the HPRT minigene by Barn Fll/Xho I double digestion 
(Figure 5.7, panel a, p116). In one experiment, hybridisation to the 3' probe (probe E) 
indicated that four of seven 6-thioguanine resistant clones had lost the 5.2 Kb band. 
These clones had a single 8.5Kb band, characteristic of an intact Pm-p exon 3. 
However, this banding pattern is not diagnostic of the gene targeted introduction of 
PrP codon 1 08F1 89V alterations as this could also occur as a consequence of gene 
conversion. 
Further investigation by BstEII digestion and hybridisation to an exon 3 
coding probe demonstrated that clones 14, 18, 44 and 45 had one allele with the 
targeted codon 189 T to V alteration and one wildtype allele. This is illustrated in 
Figure 5.7, panel b (p116). The wildtype allele digests into two fragments of 5.2Kb 
and 3.2Kb whilst the targeted allele yields a single fragment of 8.4 Kb with the exon 3 
coding probe (probe D). Clones 31, 37 and 46 do not have a codon 189T to V 
alteration and have retained the HPRT minigene. This is consistent with the retention 
of the 5.2 Barn Fll/Xho I band as indicated in Figure 5.7 panel a (p116). No additional 
bands were observed in any of the gene targeted clones indicating that there were 
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Fig 5.7: Southern analysis of ES clones bearing codon 108F_189V alterations 
Panel a). Autoradiograph of Barn HhJXho I double digests of candidate 
targeted clones 14, 18, 31, 37, 44, 45 and 46 hybridised to the 700bp Barn HI/Eco 
RV 3' probe (probe E). Barn Fll!Xho I digests of HM-1 and HM-1/A34 are included 
as negative and positive controls respectively. Panel b). Autoradiograph of BstEII 
digested genomic DNA from the clones shown in panel a hybridised to a 1.1Kb Sma 
IIEco RI probe (Probe D) with HM-i and HM-1/A34 DNA controls. 
Panel a) indicates that the gene structure of clones 14, 18, 44 and 45 has been 
converted from that of the first step HM-1/34 line to that of the HIVI-i parental line. 
This is demonstrated by the loss of the 5.2 Kb Barn HLIXhoI band characteristic of the 
first step Pm-p '/- 1  clone structure. Panel b) indicates that in clones 14, 18, 44 and 45 
the exon 3 Bst Eli site has been lost. This is consistent with the introduction of a PrP 
codon 189V alteration into one allele and is indicated by the generation of a novel 8.4 
Kb BstEII fragment from the 3.2 and 5.2 Kb fragments. This panel, together with 
those in Figure 5.8 (p1  18), indicates that there are no additional random integrants in 
any of the clones shown. 
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Fig 5.8: Further analysis of ES clones bearing PrP codon 108F_189V alterations 
Autoradiographs of ES clones with codon I 08F_1 89V alterations, depicted in 
Figure 5.6. Panel a). Barn HI digests of clones 14, 18, 44 and 45 hybridised to the 
1.1Kb Sma JJEco RI coding region probe. HM-1 and HM-1/A34 DNA are controls. 
Panel b) Kpn I digests of the same clones shown in panel a). Both panels indicate that 
the gene structure of clones 14, 18, 44 and 45 has been converted from that of the 
I-IM-11A34 line back to that of the HM-1 parental line -consistent with gene targeting. 
A more detailed analysis of the Pm-p structure of clone 45 is provided in Chapter 6 
(p125). 
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no additional non-homologous recombination events. 
Further analysis of clones 14, 18, 44 and 45 by hybridisation of probe D to 
Barn HI and Kpn I digests confirmed that the restriction pattern around Pm-p in these 
clones was consistent with a wild-type Pm-p allele (Figure 5.8, p1  18). Furthermore, 
the use of probe D in these studies did not reveal any evidence of random integrants in 
these clones. 
Single PrP codon 108F and 189V alterations were introduced into ES cells 
using the above procedure, however none of these ES clones generated germline 
chimeras. Therefore data relating to these experiments is not presented. 
Section 5.4: Discussion 
Section 5.4.1: A two step double replacement gene targeting method 
The work presented here and in chapter 3 illustrates that a double replacement 
gene targeting method can be used to introduce subtle alterations into ES cells. This 
enables the production of multiple lines of ES cells, and ultimately mice, with defined 
PrP gene alterations (Moore et al., 1995). The method has a number of advantages 
over alternative methods such as "hit and run". One important advantage is that no 
selectable markers are left in the targeted locus after the second step -it is possible 
that markers might influence the expression of targeted locus in an unpredictable 
manner. Recently, evidence has emerged from experiments directed at the granzyme 
gene cluster which show that the PGK!Neo selectable marker can dysregulate genes 
neighbouring targeted loci up to 100Kb distant (Pham et al., 1996). Given the 
widespread use of this marker cassette it is possible that this phenomenon might be 
shared by a number of gene targeted ES lines in which this marker is retained. It is 
possible that a number of mouse phenotypes which have been attributed to the 
specific effects of targeted gene deletions or to subtle gene alterations, might instead 
arise from the effects of the selectable markers. The potential for confusion is likely to 
be exacerbated by the common arrangement of mammalian genes into gene families in 
which gene isoforms with similar or complementary functions are arranged into 
clusters. This has been observed in a number of gene knockouts (Olson et al., 1996). 
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It is possible that the adult onset neurological phenotype observed in two 
independently generated lines of PrP nulls (Sakaguchi et al., 1995,1996 and chapter 4 
of this thesis) is due to the effect of the selectable marker on neighbouring genes. 
These observations suggest that the two-step gene targeting strategy 
employed here is appropriate to a wide range of applications. This is because, 
following the second step, the gene targeted allele contains no foreign sequence and 
differs from the wild-type allele only with respect to the engineered subtle alterations. 
The evidence for the deleterious effects of selectable markers suggests (Pham et al., 
1996; Olson et al., 1996) that future gene knockout vectors should be designed with 
LoxP (or FRT/FLP recombinase) recognition sites flanking selectable markers to 
enable their removal from the targeted locus. 
A number of parameters are thought to influence the efficiency with which 
gene targeted clones are retrieved with this two step gene targeting system. The 
selection system used for the second step enriches on the basis of HIPRT function i.e 
cells expressing HPRT are killed. However this selects for at least three classes of 
cell: i) HPRT deficient HM-1 cells carried over from the first targeting step as a minor 
contaminant, ii) cells which have spontaneously lost HPRT function and iii) 
homologous recombinants. The problems associated with HM-1 carryover can be 
overcome by generating a number of independent step 1 clones and performing 
second steps in ES lines with low levels of spontaneous 6-thioguanine resistance 
(Stacey et al., 1994). Cells which have lost HPRT function can arise for a number of 
reasons including minigene deletion, gene conversion and methylation of the minigene 
promoter. The role of methylation in silencing of the HPRT minigene has been 
explored in step 1 Ligase 1 heterozygous knockout lines which were found to be 
difficult to retarget. It appears that methylation of the minigene at high frequency 
results in a high rate of 6-thioguanine resistance which precludes the efficient retrieval 
of targeted clones in the second targeting step. The Pgk-1 promoter used to drive this 
minigene is methylated, suggesting that an alternative promoter (HPRT), which is not 
methylated to the same extent, is more appropriate for use at this locus (D. Melton, 
unpublished results). 
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Section 5.4.2: Recent gene targeting developments 
A number of new reagents have enabled technical improvements to gene 
targeting strategies. These include the use of viral internal ribosome entry site (IRES) 
and site-specific recombinases such as the yeast 2u circle FLP recombinase and 
bacteriophage P1 Cre recombinase. The IRES enables the translation of two distinct 
mRNA species from the same bicistronic transcript. This enables positive-negative 
selection to act upon the products of a single transcript produced from a single 
NeoIHSV-thymidine kinase selectable marker under the control of a shared promoter 
and poly A addition site. This enables strong and predictable expression of both 
markers and can be further improved by utilising promoter or polyA trap strategies. 
Cre recombinase can mediate recombination between a pair of LoxP sites in 
vitro or in vivo (Abremski, Hoess and Sternberg, 1983; Gu et al., 1993) resulting in 
deletion of all intervening sequence. This enzyme can also mediate the insertion of 
sequence bearing a single LoxP site into chromosomal loci marked with a LoxP site 
(Sauer and Henderson, 1990). Cre-LoxP can be used in mammalian cells to excise 
LoxP flanked DNA and has been used for a number of gene targeting strategies 
including conditional gene deletion (Gu, Zou and Rajewsky, 1993) and targeted 
chromosomal translocations (Smith et al., 1995). 
The Cre-LoxP system can also be adapted to remove selectable markers from 
targeted loci enabling the introduction of subtle alterations into genes in a single step 
(Taki, Meiering and Rajewsky, 1993; Gu, Zou and Rajewsky, 1993). 
One group has recently reported the targeted replacement of the entire mouse 
PrP coding region with the human homologue (Kitamoto et al., 1996). Lox P flanked 
selectable markers were removed efficiently by transient expression of Cre 
recombinase in fertilised eggs from germline mice (Araki et al., 1995). However this 
targeted allele retained a single Lox P site in the PrP 3 'UTR. No expression of human 
PrP was noted from mice made with these cells -perhaps because the human PrP 
coding region contained a codon 145 stop mutation 
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Figure 5.9: A highly efficient single step PrP gene targeting method 
This method is analogous to the first step of the two step method and takes advantage 
of the high gene targeting frequencies commonly achieved for first steps using the HM-
I/HPRT system. The vector is similar to a PrP knockout vector but differs in several critical 
respects: i) it contains a mutant PrP coding region, ii) the HPRT minigene does not inactivate 
PrP but inserts downstream of PrP exon 3 and iii) the PGKIHPRT minigene is flanked by Lox 
P sites, enabling deletion in vitro or in vivo by Cre recombinase. 
Selection for the gene targeting step is provided using positive-negative selection with 
HAT and gancyclovir as described in chapter 3 for the PrP knockout. Low passage number 
targeted ES cells can be injected at this stage to make chimeras, however the evidence for the 
deleterious effects of the PGKIHPRT minigene in mid-adult Pm-p knockout mice (Chapter 4) 
indicates that the selectable marker is best removed. This can be done by mating young adult 
germline mice bearing this allele with a strain of mouse which expresses Crc recombinase in 
gametes, such as the deleter mouse strain produced in the Rajewsky lab (Scwenk, Baron and 
Rajewsky, 1996). Unfortunately these mice are of mixed genetic background and the targeted 
line would lose its co-isogenic status. 
However these cells can be subjected to Crc recombinase-mediated deletion of the 
HPRT minigene in vitro and ES cells in which the minigene has been deleted can be used for 
blastocyst injection, at lower passage than is common in ES clones made using the two step 
method. 
One limitation of this method is that a single LoxP site is retained downstream of PrP 
exon 3. Suitable controls for this site can be provided by making a line of mice in which the 
mutation has not been introduced but which have the other features of this allele -these ES 
cells arise as a by-product of the gene targeting process. One line should suffice as a control 
for any number of PrP mutations introduced using this method. This method is intended to be 
complimentary to the double replacement method. 
A preliminary experiment to introduce the PrP 108F alteration in ES cells was very 
encouraging: 59/96 of the HAT/gancyclovir resistant ES colonies were targeted and 40% of 
them had introduced the 108F alteration. This is one of the highest targeting frequencies 
gained to date for a subtle alteration in mammalian cells. 
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(Kitamoto, Jizuka and Tateishi, 1993). Stop codons have been reported to 
dramatically reduce mRNA levels in a number of human genes associated with disease 
such as CFTR (Hamosh et al., 1991), -gIobin (Baserga et al., 1988) and 
triosephosphate isomerase (Beigrader et al., 1993). A similar phenomenon was 
observed in a transgenic line expressing human PrP with a stop codon at codon 143 
(Fischer et al., 1996). A number of lines of these mice expressed very low levels of 
PrP mRNA and no detectable PrP 
A broadly similar method was adapted for use with the HPRT/HM-1 system 
during the course of this thesis and has been used to introduce single PrP codon 108F 
and 189V alterations into HM-1 ES cells. This single step method appears to be 
highly efficient and is described in Figure 5.8. It is hoped that these cells will enable 
the generation of mice with single PrP codon 108F and 189V alterations. Scrapie 
challenge of such mice may reveal the relative contribution of each of these 
dimorphisms to the control of scrapie incubation time. 
Section 5.5: Summary 
Eight clones bearing targeted PrP 10817_189V alterations were generated 
using a two step double replacement gene targeting method. The gene targeted Pm-p 
allele has been named, Pm-p a[108F_189V]  to distinguish it from both wildtype Pm-p 
a 
and Pm-p b  alleles. The germline transmission of this allele and analysis of its CNS 
expression in adult mice is described in more detail in the next chapter. A number of 
clones bearing single PrP alterations to codons 108 and 189 were generated but did 
not transmit to the germline. A modified method has been developed and used 
successfully to introduce single codon 108F and 189V alterations into ES cells in a 
single targeting step and blastocyst injections using low passage ES cells are currently 
underway. 
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PrP Codon 108 and 189 alterations 
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Section 6.1:Introduction 
This chapter describes the germline transmission of the Pm-p a[108F_189V]  allele, 
analysis of the allele structure and the analysis of PrP expression from this allele at the 
level of mRNA and protein in adult mouse brain. 
Section 6.2: Germline transmission of the Pm-p 4[10'F—"9'1  allele 
A number of targeted ES clones bearing the Pm-p 
a[108F_189V]  allele were used 
for blastocyst injection. Targeted ES clone HM-1/A34/BB#45 generated 1 male and 3 
female chimeras. One female chimera (No. 19) was mated with an inbred male 129/Ola 
and transmitted the gene targeted allele through the germline' to a single male 
129/Ola founder. This founder was co-isogenic with 129/01a. 
The HTvI-1 ES line is HPRT deficient and was derived from E14TG2a2 
(Hooper et al., 1987). E14TG2a and HM-1 share a large HPRT 5' deletion which has 
deleted the promoter and upstream exons resulting in a non functional allele (Simon 
Thompson, PhD thesis; Thompson et al., 1989). HPRT is X-linked, therefore male 
HIM-i ES cells are HPRT deficient. Although HPRT deficiency in humans causes 
Lesch-Nyhans disease (Lesch and Nyhan, 1964), HPRT deficiency in mice has few 
deleterious effects. A number of workers have generated HPRT deficient mice in an 
attempt to develop an animal model of Lesch-Nyhan disease, however HPRT 
deficiency causes no overt phenotype in mice unless they are more than 2 years old 
Gem-dine transmission from female chimeras has been observed on a number of occasions in this 
laboratory (David Melton, personal communication) and by others (Kuehn et al., 1987). Although 
the HM-1 ES line is male and XY ES cells bias towards the production of male chimeras, female 
chimeras are not uncommon and can contribute to the germline. XY ES cells do not normally 
undergo oogenesis in chimeras but often convert the sex of a female recipient blastocyst to a male 
phenotype enabling spermatogenesis and germline transmission. Sex conversion is not always 
complete -sometimes resulting in an infertile hermaphrodite. However, germline transmission from a 
male ES line in a female chimera is presumably due to the loss or silencing of all or part of the Y 
chromosome such that the ES cell-derived germ cells and oocytes are effectively XO (Papaioannou 
and Johnson, 1993). 
2  E14TG2a was isolated from the E14 ES line as a 6-thioguamne resistant clone (Handyside et al., 
1989). 
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(Williamson, Hooper and Melton, 1992) or if they are treated with APRT inhibitors 
(Wu and Melton, 1993). 
Given the uncertain effect of HPRT deficiency in mice challenged with scrapie 
it was considered prudent to ensure that any gene targeted lines derived from HM-1 
ES cells did not carry the HPRT mutant allele. 
The Pm-p a[108F_189V]  heterozygous male founder carried the mutant HPRT 
allele. All Pm-p a[108F_189V]  positive progeny derived from crosses between the founder 
and 129/Ola inbred stock were screened for the mutant HPRT allele. Tail genomic 
DNA from 50 Pm-p a[108F_189V]  heterozygous pups was screened by BamHI digestion 
and Southern analysis by hybridisation to a HPRT probe (Konecki et al., 1982)(data 
not shown). Only mice bearing a wildtype HPRT allele were retained for further 
breeding. This ensured the elimination of the mutant HPRT allele from this mouse 
line. 
To generate sufficient numbers of 129/Ola mice for 301V challenge, HPRT 
wildtype, Pm-p a[108F189V]  heterozygous mice were crossed, progeny were PrP 
genotyped by a combination of PCR and BstEII digestion for the 189V alteration and 
allele specific oligonucleotide hybridisation for the 108F alteration. Groups of 129/Ola 
wildtype mice and mice heterozygous and homozygous for the Pm-p a[108F_189V]  allele 
were transferred into quarantine at the BBSRC/MIRC Neuropathogenesis Unit, 
Edinburgh. The first cohort were challenged with 301V and a second set of mice were 
challenged with ME73. 
Section 6.3: Analysis of Pm -p a[108F_189V]  allele structure. 
The structure of the wildtype Pm-p a  and Pm-p a[108F_189V]  alleles were 
compared by restriction mapping using a variety of Pm-p probes (Figures 6. 1, p130, 
Figure 6.2, p1133). The HM-1 Pm-p a  allele was compared with that of the germline 
Pm-p a[108F_189V]  heterozygous ES clone (HM-i/A34/#BB45), the Pm-p a[108F_189V] 
heterozygous founder (BB1000) and a mouse homozygous for the Pm-p a[1OSF_189V] 
allele (BB1507). VM/Dk DNA was also included and enabled a comparison of the 
The MIE7 challenge experiment is still underway so the data is not yet available. 
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structures of the Pm-p a  and Pm-p a[108F_189V]  alleles with that of the Pm-p b  allele and 
is discussed in Section 6.3.1. 
Hybridisation with the intron 1/exon 2 probe (probe B) indicates that a large 
10.9Kb Barn HI fragment containing the promoter, exon 1, introni, exon 2 and part 
of intron 2 is shared in all 129/01a lines (Figure 6.1, panel a, p130). An intron 2 probe 
(probe C) indicates that all 129/01a samples share a common 6.7Kb Barn HI fragment 
(Figure 6. 1, panel b, p1  30) and hybridisation to an exon 3 probe (probe D) indicates 
that all lines, including VMIDk, share a common 8.5Kb Barn HI fragment (Figure 6. 1, 
panel c, p130). 
Hybridisation to BstEII digested DNA with an exon 3 probe (probe D) 
confirmed the presence of 2 BstEII bands of 5.2 and 3.2 Kb in HM-1 and in all lines 
encoding the wild-type Pm-p a  allele (Figure 6.1, panel d, p130). In lines 
heterozygous for the Pm-p a[108F_189v]  allele, these wild-type bands are present in 
addition to an 8.4 Kb band. The 8.4 Kb band is the sum of the 5.2 and 3.2 Kb wild-
type bands and arises from the PrP 189V alteration which ablates a BstEII site within 
exon 3. A single band of 8.4 Kb is present in DNA homozygous for the gene targeted 
allele. 
Hybridisation of the exon 3 probe (probe D) to a Kpn I digest (Figure 6. 1, 
panel d) (p130) indicates that all lines share a common 6.5Kb exon 3 fragment. 
Hybridisation of BstEII and Kpn I digests with probe E (Figure 6.1, panel E, p130) 
extended the analysis downstream of exon 3. This revealed no differences between the 
129/01a DNA samples and indicated that they shared a 11 Kb BstEII and a 6.5 Kb 
Kpn I fragment. 
These mapping studies demonstrate that the Pm-p 3 [108F-189V] allele has the 
structure of a Pm-p a  allele which has been modified by the removal of a single exon 3 
Bst Eli site4. This is based on mapping studies covering in excess of 30 Kb, including 
1Kb upstream of the promoter and more than 11Kb downstream of exon 3. The 
absence of additional banding or of altered banding patterns indicates that there are no 
The codon 108F alteration does not result in the gain or loss of a restriction site. 
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Fig 6.1: Structure of the targeted pi',i...p 
a[108F_189V]  allele 
Southern analysis of genomic DNA from ES cells and mouse tail samples 
using a variety of restriction digests and Pm-p probes B-E. 
Panels a)-c). depict Barn HI digests. 
Panels d) & e) depict BstEII and Kpn I digests. 
Panel a). Barn HE digests hybridised to an intron 1/exon 2 probe (probe B) 
Panel b). Barn HI digests hybridised to an intron 2 probe (probe C) 
Panel c). Barn HI digests hybridised to an exon 3 probe (probe D) 
Panel d). Bst Eli and Kpn I digest hybridised to an exon 3 probe (probe D) 
Panel e). Bst Eli and Kpn I digests hybridised to a probe downstream of exon 
3 (probe E) 
The same loading order was used in all panels: 
"HM-1": 129/01a FM-1 ES cells, encoding 2 wildtype Pm-p 
a  alleles 
"ES#45": 129/01a ES clone HM-1/A34/BB#45, Pm-p 
a[108F_189V]  heterozygous 
"A/gtB": 129/01a Pm-p a[108F_189V] heterozygous founder (BB 1000)' 
"gtB/gtB": 129/01a Pm-p a[108Fi89v]homozygote 
"VM/Dk": VMLDk Pm-p b  hornozygote 
The Gavin Hastings Memorial Mouse or "wee Gay" 
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detectable deletions, insertions or other rearrangements in the gene targeted allele. 
These studies are consistent with the hybridisation studies shown in chapter 5 which 
indicated that there were no additional non-homologous recombination events in the 
ES line HM-1/A34/BB#45. 
Section 6.3.1: Comparison of Pm-p ' and Pm-p b  alleles 
Comparison indicated that the 129/01a Pm-p a  and VMIDk Pm-p b  alleles had 
a similar general gene structure, although a number of differences were apparent 
(Figures 6. 1, p130 and Figure 6.2, p133). Hybridisation of an exon 3 probe (probe D) 
to BstEII digests revealed a 14 Kb band in VMiDk and 2 bands in 129/01a Pm-p a 
(Figure 6.1, panel d). The VMIDk 14Kb BstEII fragment arises from digestion at a 
site downstream of exon 3 and an upstream site close to exon 2 (Figure 6.2, p133) 
whilst the 129/01a Pm-p a  allele has a BstEII site within exon 3, a site 1.9Kb 
upstream of the 8.5Kb Barn HI fragment and a third site 3.2 Kb downstream of exon 
3. Hybridisation to a probe 3' of exon 3 (probe E) reveals a BstEII RFLP. Here 
129/01a have a band of 11Kb whilst VM/Dk have a much shorter band of 2.2 Kb 
(Figure 6.2, panel e). 
A number of differences between 129/01a Pm-p a  and VMIDk Pm-p b  are 
apparent in intron 2 (Figure 6.1, panels a and b, p130). Hybridisation to probe B 
indicates that VMIDk has a slightly larger Barn HI fragment (Figure 6.1, panel a, 
p130). This difference probably arises from a polymorphic site within intron 2 rather 
than at the promoter. This is because other mapping studies performed on a genomic 
clone containing the Pm-p b  promoter 6  from the ILn/J strain indicates that the Barn 
111 site immediately upstream of the 129/01a and ILn/J promoters are shared. It is 
likely that this is also the case with \TMIDk as it also encodes the Pm-p b  allele. That 
this RFLP arises from a site within intron 2 is consistent with differences in Barn HI 
6 pTZE lB/K, a gift from Jean Manson, BBSRC/NPU Neuropathogenesis Unit, Edinburgh. 
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Fig 6.2: A map of Pm-p U, 	 b  and the targeted Pm -p a[108F_189Y]  allele 
A restriction map depicting the structure of the gene targeted Pm-p 
a[108F_189V] 
allele, the parental 129/01a Pm-p a  allele and the VMIDk Pm-p 
b  allele. This map is 
derived from Southern analysis data shown in Figure 6.1. The main non-coding 
differences between Pm-p a  and Pm -p b  are RFLPs within the introns and a difference 
in the size of intron 2. The intron 2 size difference arises from a —P6.7Kb 
insertion/deletion polymorphism (Westaway et al., 1994a). 
The promoter is indicated by an arrow and the approximate position of the 
intron 2 insertion/deletion polymorphism is indicated by the triangle. The endpoints of 
this polymorphism are unmapped. Probes are indicated by filled boxes over the Pm-p 
region of origin. 
All sizes in Kb. Enzyme abbreviations: B, Barn RI; Bst, Bst Eli; E, Eco RI; H, 
Hind III; K, Kpn I; N, Not I; RV, Eco RV; X, Xba I. (B), a Barn HI site detected by 
mapping 2DASHII Pm-p clones but which is not detectable in genomic disgests with 
available probes. 
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banding apparent with an intron 2 probe (Figure 6. 1, panel b, p130). Barn HI RFLPs7 
have been described in a number of mouse strains (Westaway et al., 1994a). 
Section 6.4: Expression from the targeted Pm-p aLio8F_189v1  allele. 
The PrP allotype expressed from the gene targeted Pm-p a[108F_189V]  allele is 
referred to here as PrP gtB. This distinguishes it from PrP A and PrP B allotypes 
which are the products of wildtype Pm-p a  and Pm-p b  alleles respectively. Mice 
heterozygous and homozygous for the targeted Pm-p a[108F_189V]  allele are referred to 
as PrP A/gtB and PrP gtB/gtB. Although PrP gtB and PrP B have identical predicted 
amino acid sequences, this nomenclature acknowledges that they are expressed from 
different Pm-p alleles. 
Expression of PrP mRNA from the targeted Pm-p a[108Fj89v]  allele was initially 
investigated in ES cells by RT-PCR. Discrimination between PrP A and PrP gtB 
transcripts was possible by BstEII digestion and codon 108F allele specific 
oligonucleotide hybridisation. This confirmed expression of PrP gtB transcripts of the 
predicted size from the targeted allele (data not shown). Following germline 
transmission of this allele, brain RNA was investigated for PrP transcripts (Figure 6.3, 
panels a and b, p136). This confirmed expression from the Pm-p allO8F_189V1  allele and 
enabled a comparison with expression levels in mice encoding wild-type Pm-p a  and 
Pm-p b  alleles. Wildtype PrP AlA mice had a PrP mRNA size of 2.1Kb. The size and 
abundance of this transcript was shared with PrP AIgtB and PrP gtB/gtB mice. 
Comparison of the above lines with VMiDk, which express the PrP B allotype from 
the wildtype Pm-p b  allele, revealed no apparent differences in PrP mRNA abundance 
or size. Evidence that Pm-p a  and VMIDk Pm-p b  mice have similar levels of brain 
PrPmRNA is consistent with previous studies in Pm-p a  and Pm-p b  mice (Westaway 
et al., 1987; Manson, McBride and Hope, 1992). Figure 6.3 (panel a, p136) also 
indicates that PrP gtB/- mice encoding only one functional Pm-p a[108F_189V]  allele have 
--50% reduced levels of PrP mRNA. 
This polymorphic region was present on one of the ?,DASH II clones retrieved from the HM-1 
library. It was cloned into pBluescript as a 10Kb Not I fragment, however no further studies have 
been performed with this clone (pNotlO). 
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Figure 6.3: PrP expression in adult brain 
Panels a). and b). Northern analysis of male adult mouse brain total RNA 
Panel c). SDS-PAGE analysis of PrP' in uninoculated mouse brain. 
Panel a) bug of total RNA from whole mouse brain hybridised to PrP coding 
probe D. Panel b). mouse cc-actin reprobe of the same membrane shown in a). 
Panel c). 12% SDS-PAGE (Laemmli, 1970) of brain homogenates 
immunoblotted with rabbit anti-mouse PrP antiserum 1A8 at a dilution of 1:1000. All 
samples contained SOug of total brain protein. Prestained molecular weight markers, 
New England Biolabs. All sizes in KDa. 
Mouse line abbreviations: 
PrP A/A: wild-type 129/01a Pm-p a 
PrP A/gtB: 129/01aPrn-p ala[1OSF_189V] 
PrP gtB/gtB: 129/01a Pm-p a[108}L189V]/a[108F_189V] 
VMIDk PrP B/B: VMJDkPrnpb 
PrP gtB/-: 129/01a Pm-p a[108F_189V]/- 
PrP -I-: 129/01a Pm-p 
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Figure 6.4: Comparison of brain PrP expression levels by densitometry 
Comparison of PrP' expression levels in wild-type brain and in mouse lines encoding 
the Pm-p a[108F_189V]  allele. Duplicate serial dilutions of crude brain homogenate 
representing 50ug, 25ug and 12.5ug of total protein samples from 2 age matched 
adult males were separated by 12%SDS-PAGE (Laemmli, 1970). PrP was visualised 
by immunoblotting with PrP antiserum 1A8 at a dilution of 1:1000. Bound antibody 
was detected with an alkaline phosphatase conjugated secondary antibody at a 
dilution of 1:10,000 (Vistra ECF kit, Amersham) in combination with a fluorescent 
alkaline phosphatase substrate. The PrP signal was quantitated with a Molecular 
Dynamics STORM fluorescent imaging system interfaced to a Mackintosh PowerPC. 
Following background subtraction and correction for the null signal, mean signals 
standard error) were plotted against total protein load (ug). 
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The level of PrPC  in uninoculated mice was investigated by western blotting 
(Burnette, 1981). This confirmed that the targeted Pm-p a[108F_189V]  allele was 
expressed at the level of protein in adult brain and enabled a comparison of PrP' brain 
expression levels in wildtype 129/01a PrP A/A, PrP A/gtB, PrP gtB/gtB mice and 
VMIDk PrP B/B mice. PrP immunoblot analysis of 50ug of total protein from crude 
brain homogenates (Figure 6.3, panel c, p136) indicated that PrP' brain expression 
levels in these lines were indistinguishable. Figure 6.3 (panel c, p136) also illustrates 
that the SDS-PAGE banding patterns appear unaltered in mice expressing PrP gtB 
from the Pm-p a[108F_189V}  allele. 
Further studies were performed on whole brain PrP expression by measuring 
the PrP signal with fluorescence densitometry. PrP immunoblots were performed as 
before but with serial dilutions of crude brain homogenate containing SOug, 25ug and 
12.5ug of total brain protein. Figure 6.4 (p138) illustrates that this approach revealed 
no significant differences in the levels of ppC  expression between 129/01a PrP A/A, 
PrP A/gtB and PrP gtB/gtB mice. No significant difference (95% level, Students t-
test) was noted between the above lines and PrP B/B VMIDk mice encoding a 
wildtype Pm-p b  allele. A small difference was noted in the SOug signal between the 
PrP A/A and the other lines expressing from two alleles, however this was not 
significantly different from the others at the 95% level (Students t-test). Conversely, 
comparison of the PrP gtB/- signal with that of the other lines detected a significant 
difference (95% level, Students t-test) -indicating that with this method a 40-50% 
reduction in expression can be detected. 
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Section 6.5: Discussion 
Section 6.5.1: pp a[108F_189V]  allele structure 
The gene targeted Pm-p a[108F_189V]  allele structure was compared with that of 
the parental Pm-p a  allele. These studies confirmed that the gene targeted allele had 
the predicted structure and that there were no apparent deletions or other 
rearrangements. A number of lines of evidence suggest that deletions within the Pm-p 
locus may have a significant effect upon the expression of PrP. This is illustrated by a 
series of transgenic lines produced by Fischer et al (1996) in which the PrP transgene 
was based upon a cDNA construct. Brain PrP expression at the level of mRNA and 
protein was undetectable in 8 independent lines of Pm-p /pPrPcDNA transgenic 
mice. These lines carried a Cos 6. 1/ILnIJ4 mouse Pm-p b  transgene modified by the 
removal of intron 1 and intron 2 but retaining an intact Pm-p promoter, exon 1 and 2, 
fused to exon 3. The absence of PrP expression in a number of independent lines 
suggests that there are essential expression control sequences in the introns of Pm-p 
Indeed, a number of Pmn-.p elements necessary for the expression of a reporter 
construct in mouse neuroblastoma cells have recently been described in the promoter 
region and intron 1 (Baybutt and Manson, 1997). 
Deletions of the Pm-p locus can have more subtle effects upon PrP' 
expression. For example, two independent lines generated by Fischer et al., (1996), 
hgPrnpal9 and hgPrnpa 20, in which intron 2 (and some sequence downstream of 
exon 3) had been removed, exhibited normal PrP expression levels throughout brain 
but PrP was absent from cerebellar Purkinje neurons -a cell type which normally 
expresses high levels of PrP'. The loss of PrPmRNA and PrPC  expression in these 
lines presumably arises from the removal of 12Kb of intron 2 sequence (or 15Kb of 
sequence downstream of exon 3). This suggests that these regions contain one or 
more control elements necessary to direct PrP expression to cerebellar Purkinje 
neurons8. 
8  This is interesting given the widespread death of cerebellar Purkinje neurons in 2 independent lines 
of Pm-p null mice. It may also be added that the absence of a similar phenotype in aged hgPrna 19 
and hgPrna 20 mice suggests that the cerebellar phenotype is not the result of loss of PrP function. 
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Section 6.5.2: Comparison of the Pm-p a  and Pm-p b  alleles 
It is known that Pm-p a  and Pm-p b  alleles differ with respect to the PrP 
allotype expressed (Westaway et aL, 1987), however little is known of other 
differences between these alleles. The Pm-p b  allele (as derived from ILn/J inbred 
mice) has been used as the basis of many PrP transgenes (Westaway et al., 1991; 
Prusiner et al., 1990; Scott et al., 1993) including mice which develop a late onset 
neuromyopathy (Westaway et al., 1994b). There is little published mapping data for 
the Pm-p b  allele in VM/Dk mice, therefore a knowledge of the features 
differentiating this allele from other mouse Pm-p alleles, particularly the Pm-p a  allele, 
is desirable. The mapping studies performed here with VM/Dk confirm that this allele 
shares a short intron 2 sequence with other Pm-p b  mouse lines (Westaway et al., 
1994a). Carlson et al., (1993) has proposed that the Pm-p b  allele present in P/J, ILnIJ 
and VM/Dk were derived from a common ancestor. The structure of the VM/Dk Pm-
p allele is very similar to that described in other Pm-p b  alleles, including the intron 2 
polymorphism (Carlson et al., 1986, 1988; Westaway et al., 1994a) and is consistent 
with a common origin for the Pm-p b  allele. 
The 129/01a PrP co-isogenic mice described here differ only by 2 PrP amino 
acids and share a common Pm-p structure. This controls for the unknown effects of 
non-coding polymorphisms within 129/01a co-isogenic mice. 
Section 6.5.3: PrP codon 108 and 189 alterations do not alter PrP expression 
levels 
The issue of PrP' expression levels is important in experiments concerning 
incubation time because raised PrP' expression levels have previously been shown to 
shorten incubation times in transgenic mice (Prusiner et al., 1990; Westaway et al., 
1991; Carlson et al., 1994; Telling et al., 1996; Fischer et al., 1996) and reduced PrP' 
levels are known to extend incubation times in gene targeted mice bearing only a 
single functional PrP allele (Prusiner et al., 1993; Bueler et al., 1993; Manson et al., 
1994b; Sakaguchi et at., 1995). 
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Comparison of 129/01a PrP A/A PrP mRNA levels with that of the other lines 
encoding the gene targeted Pm-p a[108F_189V]  allele indicates that they are 
indistinguishable. The indistinguishable levels of PrP' in 129/01a wildtype and VMIDk 
mouse brain are consistent with extant reports of indistinguishable brain PrPc levels in 
NZW (Pm-p a  PrP A/A), ILn/J (Pm-p b,  PrP B/B) (Westaway et al., 1987) and 
congenic \IM-Sinc s7 (Pm-p a  PrP A/A) and Sinc p7 (Pm-p b,  PrP B/B) mice 
(Manson, McBride and Hope, 1992). 129/01a PrP gtB/- mice encoding a single 
functional Pm-p a[108F_189V]  allele exhibit a 50% reduction in PrP mRNA levels. This 
is consistent with several independent reports of mice which express only one 
functional Pm-p allele (Bueler et al., 1992; Manson et al., 1994a; Sakaguchi et al., 
1995). The observation of -50% reduced levels of PrPC  in mice with only one allele 
argues against a translational control mechanism for the control of PrP levels in brain. 
Section 6.6: Summary 
The targeted Pm-p a[108F_189V]  allele was transmitted though the germline and used to 
generate sufficient numbers of mice for 301V and ME7 challenge. Northern and 
western analysis of adult brain indicated that this allele was expressed in brain and that 
its expression level was indistinguishable from wildtype 129/01a and \'MJDk mice. 
The data presented here indicates that 129/01a mice, which normally express the PrP 
A allotype from the Pm-p a  allele, express the PrP B allotype from a gene targeted 
Pm-p a[108F_189V]  allele at levels indistinguishable from non-targeted co-isogenic 
littermates and VltvfIDk mice. This argues that alterations to incubation times and 
neuropathology in challenged mice are a consequence of the engineered codon 108 
and 189 alterations and do not arise as a result of major changes to PrP B expression 
levels. 
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Chapter 7 
301V challenge of mice with gene targeted 
PrP codon 108 and 189 alterations 
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Section 7.1: Introduction 
The postulated congruence of Sinc/Prn-i and Pm-p argues that incubation times 
in mice are controlled by PrP dimorphisms at codons 108 and 189'. This proposal was 
tested by 301V challenge of mice in which the endogenous Pm-p a  allele, encoding the 
PrP A allotype (108L_189T) was converted by gene targeting to encode the PrP B 
allotype (1 08F_1 89V). 
The pattern of allelic interaction known to occur between 301V and Sinc alleles is 
such that VMIDk Sinc p7p7  mice have short incubation times of 115-119 days and 
C57BL/6J Sinc s7s7  mice have longer incubation times of 260 days. 301V challenge of 
wild-type 129/01a mice gives incubation times of -227 days, indicating that 129/01a 
encodes the Sinc s7 allele  (Jean Manson, unpublished data). 
It was reasoned that if codons 108 and 189 were the molecular determinants of 
incubation time, conversion of the PrP allotype from PrP A to PrP gtB should also have a 
corresponding effect on the apparent Sinc genotype. Thus the 301V incubation time was 
predicted to shorten from that of wild-type 129/01a Sinc s7 mouse strain to a 116 day 
incubation time characteristic of VIMJDk -a wildtype mouse strain encoding the Sinc p7 
allele and the Pm-p b  allele. A dramatic shortening of the 301V incubation time in 
129/01a PrP gtB/gtB mice would constitute good evidence that PrP codon 108 and 189 
dimorphisms control incubation time and would support the proposal that Sinc, Pm-i and 
Pm-p are congruent. 
Section 7.2: 301V origin and properties 
Mice bearing gene targeted PrP alterations were challenged with 301V because 
this strain has a rapid incubation time in VMIDk Sinc p7p7  mice and relatively short 
incubation times in other genotypes -leading to an experiment of shorter duration than 
with other agent strains. 301V is a mouse passaged BSE strain derived from a terminal 
Friesian Holstein cow with pathologically confirmed BSE (Bruce et al., 1994). Primary 
This is because these are the only known features that consistently segregate with scrapie 
incubation time length (Westaway etal., 1987; Carlson et al., 1986, 1988; Westaway et al., 1994a). 
2  ME7 challenges of this mouse strain also indicate that it encodes the Sinc s7 allele (Manson et al., 
1994b). 
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transmission from a number ofBSE isolates has clearly demonstrated a major role for the 
Sinc gene in the control of incubation time. Subpassage from a single VMJDk mouse 
with an incubation time of 433 days into VMIDk mice resulted in very short incubation 
times of 116 (+1-3 SE) days -one of the shortest recorded incubation times in mice 
expressing normal levels of PrP. Subsequent mouse-mouse passages in \TMIDk  have 
indicated that 301V is stable and it is used here at its 5th passage. 
Section 7.3: 301V challenge protocol 
HPRT wildtype co-isogenic 129/01a mice heterozygous for the gene targeted 
Pm-p a[108F_189V  allele (i.e. PrP A/gtB mice) were mated to generate mice of three 
genotypes: Pm-p 	(PrP AlA), Pm-p ala[1OSF_189V]  (PrP A/gtB) and Pm-p 
a[108F_189V]/[108FJS9V} (PrP gtBlgtB) mice. The progeny from this cross were genotyped for 
PrP codon 108 and 189 alterations before 301V challenge. Groups of 16 mice from each 
of the three genotypes were challenged by inoculation with 20ul of a 10.2  dilution of 
301V terminal VMIDk brain homogenate by the intracranial route under halothane 
anaesthesia. The experiment was performed blind in that the genotype of the 129/01a 
mice was unknown to personnel scoring for scrapie signs and at the end of the 
experiment the code was broken by matching ear notch number with PrP genotype. 
Postmortem tail samples were PrP genotyped and all corresponded with those obtained 
before challenge. Control challenges were also set up with V.N'JfDk, C57BL and 
F1[C57xVM] mice using the same inoculum under identical conditions. 
Section 7.4: 301V incubation times 
301V challenge of mice encoding the gene targeted Pm-p a[108F_189V]  allele 
demonstrated a critical role for PrP codon 108 and 189 alterations in the control of 
incubation time (Table 7.1, p146  and Figure 7.1 p148). Control challenges with VMIDk 
mice had short incubation times of 119 days (+2 SE, n=12) whilst C57BLI6J and 
F1[C57xVM/Dk] mice had longer incubation times of 299 days (+4 SE, n10) and 268 
days (+3 SE, n=10) respectively. These incubation times confirm that the inoculum used 
for the challenge of gene targeted mice was stable and had properties characteristic of 
301V. 
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Wildtype 129/01a PrP A/A mice had mean incubation times of 244 days (±2.0 
SE, n=16). This is close to the 227 day (±3 SE) incubation time previously obtained with 
301V challenge of this mouse strain (Jean Manson, unpublished observations) -the small 
difference in incubation times may be attributable to inter-experimental variation or, less 
likely, to genetic drift between NPU and ICMB 129/01a stocks. 301V challenge of 
129/01a PrP gtB/gtB mice homozygous for the Pm-p 
a[108F_189V]  allele demonstrated that 
alterations to codons 108 and 189 have a dramatic effect upon incubation time. These 
mice had a mean incubation time of 132.6 days (±1SE, n=16), more than 100 days 
shorter than wildtype 129/01a PrP A/A mice. This difference is highly significant 
(p<0.0001, Mann Whitney test) and supports the proposal that PrP codon 108 and 189 
dimorphisms (i.e. PrP allotypes A and B) control 301V incubation time. 
Table 7.1: 301V i.c. challenge of 129/01a mice with gene targeted PrP codon 108 
and 189 alterations 
Mouse Pm-p allele PrP Sinc 	Mean SE a SD 
Strain allotype genotype Incubation (days) (days) 
time (days) 
129/01ad Pm-p a/a A/A s7s7 	244 2.0 8 16 
129/01a Pm-p a/a[108F_189V]  A/gtB - 	259 2.2 8.5 15 
129/01a Pm-p a[108F_189V]/ gtB/gtB - 	132.6 0.2 0.7 13 
a[108F189V] 
C57 	Pm-p a/a 	 A/A 
Fl[C57xVM] Pm-p a/b 	 AM 
vM f Pm-p b/b 	 BIB 
standard error of the mean 
standard deviation 
number of mice 
129/OlaHsd, supplied by Harlan UK. 
C57BL 
VM/Dk 
s7s7 299 4 12.6 10 
s7p7 268 3 9.5 10 
p7p7 119.4 2.1 7.3 12 
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Figure 7.1: 301V Incubation times are dramatically altered by PrP codon 108 
and 189 alterations 
Histogram showing the 301V incubation times of 129/01a PrP A/A, A/gtB and 
gtB/gtB mice. Incubation times of C57BL/6J (PrP A/A), VMIDk (PrP B/B) and 
F1[C57 x VM] (PrP A/B) controls are also shown. 
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The close similarity between the 301V incubation times of 129/01a PrP gtB/gtB mice 
and that of VMJDk PrP B/B mice also supports this proposal (Table 7. 1, p146). This is 
the strongest evidence to date that SincIPrn-i and Pm-p are congruent. 
The mean incubation time of 129/01a PrP A/gtB mice was 259 (±2 SE, n16) 
days. This is close to incubation times observed in the 301V challenge of FIl[C57xVM] 
mice of 268 (±3 SE, n=10) days. Previous 301V challenges of C57BL (Pm-p ) VM/Dk 
(Pm-p b)  and F1[C57xVM] (Pm-p ) mice have shown that Fl Pm-p a/b 
mice have incubation times approximately 20-30 days shorter than C57 Pm-p a  mice 
(Bruce et al., 1994). This indicated that the Pm-p a  allele, or rather the PrP A allotype, is 
dominant in conferring long incubation times with 301V. It was reasoned that 301V 
challenge of 129/01a PrP A/A and PrP A/gtB mice would show a similar incubation time 
ranking. However, 129/01a PrP A/gtB mice had 301V incubation times approximately 
15 days longer than that of PrP A/A 129/01a mice. This difference is statistically 
significant (p=0.001, Mann-Whitney test) and is slightly different from the relationship 
noted with 301V challenge of control F1[C57xVMIDk] PrP AIB mice which had 
incubation times 31 days shorter than PrP A/A C57BL mice (Table 7. 1, p146  and Figure 
7.1, p148). 
Section 7.5: Brain PrPSC  levels in 301V challenged mice 
Sedimentable PrP (or PrPSC  33-35) was isolated from 301V infected brains, 
immunoblotted and investigated for proteinase K resistance. Loss of solubility and partial 
resistance to proteinase K are operational definitions of PrPS  (Meyer et al., 1986). 
Figure 7.2 (p151) illustrates that sedimentable PrP was evident in all three 129/01a 
genotypes. In the upper panel PrP' from uninfected mice is included for reference3 . 
Proteinase K resistant PrP (or core PrP 27-30) was apparent in all brains investigated. 
Proteinase K removes of a --67 amino acid N-terminal portion of PrPSC  33-35 (Hope et 
al., 1986; Somerville, Ritchie and Gibson, 1989) resulting in a downward band-shift (+ 
lanes). Broadly speaking, the amount of sedimentable PrP in these genotypes was similar, 
PrP', as it is soluble, remains in the supernatant following ultracentrifugation and little or no PrP' 
is isolated with this method. Therefore PrP from uninfected mice is derived from crude brain 
homogenates. 
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Figure 7.2: PrP&  in 301V terminal brain 
PrP immunoblots of three 301V terminal brains from each 129/01a PrP genotype. PrP 
was detected with PrP antiserum 1A8, alkaline phosphatase conjugated IgG and 
visualised with BCIPTNBT. PK + samples were treated with 50ugIm1 proteinase K for 
1 hour at 37°C. 
Upper panel: PrPC(C)  from uninoculated brain, sedimentable PrP (PK-) and 
proteinase K resistant PrP (PK+) from 129/01a PrP A/A, A/gtB and gtBlgtB 301V 
terminal brains (mice 30, 26 and 9). Uninoculated 129/01a Pm-p ' mouse brain is 
also shown (-I-). 
Lower panel (left): sedimentable PrP (PK-) and proteinase K resistant PrP (PK+) 
from 129/01a PrP A/A, A/gtB and gtB/gtB 301V terminal brains (mice 3, 17 and 13). 
Lower panel (right): sedimentable PrP (PK-) and proteinase K resistant PrP (PK+) 
from 129/01a PrP A/A, A/gtB and gtBlgtB 301V terminal brains (mice 18, 27 and 
10). 
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although a number of differences were noted. Figure 7.2 (p  151, upper panel) indicates 
that although PrP AlA and gtB/gtB mice have similar levels of sedimentable PrP (PK - 
lanes), PrP gtB/gtB mice have higher levels of PrP (PK + lane). This relationship is 
also apparent in the other panels within this figure (Figure 7.2, upper and lower panels, 
p151). That 129/01a PrP gtB/gtB have similar or higher levels of PrPS  than 129/01a PrP 
A/A mice, despite a >110 day shorter incubation time, indicates that the kinetics of PrPS 
accumulation are faster in this genotype. 
PrP AIgtB mice had less sedimentable PrP and proteinase K resistant PrP than 
the other 129/01a genotypes and is consistent with the longer incubation times and the 
reduced neuropathology apparent in some brains areas (see next section). 
SDS-PAGE banding patterns sometimes vary between agent strains (Kascsak, 
Rubenstein and Carp, 1991; Collinge et al., 1996). The minor extent to which the PrP A 
and gtB allotype influences the PrP SDS-PAGE banding patterns in 301V terminal 
brains is apparent in Figure 7.2 (p15  1).  It appears that, although the absolute amounts of 
PrP in each PK- and PK+ lane was subject to some variation, the PrP banding pattern 
and the ratios of the bands appeared to be relatively invariant -at least in the small 
numbers of samples analysed here. This indicates that with 301V the engineered PrP 
codon 108 and 189 dimorphisms have little apparent effect upon the 301V PrPSC  banding 
patterns at this level of analysis. 
Section 7.6: The influence of PrP codon 108F_189V alterations on 301V 
neuropathology 
Section 7.6.1: Introduction 
The severity, type and distribution of neuropathology is known to be influenced 
by the strain of agent, inoculation route, host S/nc genotype and the effects of 
unidentified genes (Fraser and Dickinson, 1967, 1968; Fraser, 1976; Bruce et al., 1989, 
199; Hecker et al., 1992; Carlson et al., 1994). However, previous attempts to examine 
the role of PrP A and B allotypes in the control of neuropathology have been unable to 
exclude the effects of other genes. Genetic variation has been partially excluded in 
studies with congenic VMIDk and VMIDkSincs7  lines (Bruce et al., 1991) and 
C57BL/6J Pm-p congenic lines (Carlson et al., 1994). However congenic lines differ not 
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only with respect to their Sinc or Pm-p alleles, but also with respect to genes closely 
linked to Sinc or Pm-p. For example, Carlson has attributed variant 87V scrapie 
neuropathology in B6.I-1 mice to the effects of a Pm-p linked gene between Spr8 and 
Pax-1 (Carlson et at., 1994). 
The 129/01a PrP co-isogenic mice generated during the course of this project 
enable, for the first time, the investigation of the role of PrP A and B allotype whilst 
controlling for the effects of other genes. The effects of non-coding Pm-p 
polymorphisms (Westaway et al., 1994a; Baybutt and Manson, 1997) are unknown, 
however 129/01a PrP co-isogenic mice share a common Pm-p a  allele which differs only 
by two amino acids in exon 3. Neuropathological studies performed on 301V terminal 
brains from these mice revealed that alterations to codons 108 and 189 modified the 
extent, distribution and kinetics of neuropathological change in a number of brain areas. 
Section 7.6.2: PrP allotype and vacuolar change 
Vacuolar change in 301V terminal brain was assessed in 12 standard brain areas 
by lesion profiling (Fraser and Dickinson, 1967, 1968). This revealed that PrP codon 
108 and 189 alterations were associated with a number of alterations to the lesion profile 
of 129/01a mice (Figure 7.3, panel a, p155). Differences between the various 129/01a 
genotypes were observed in grey matter areas 1 (dorsal medulla), 4 (hypothalamus), 8 
(medial cerebral cortex), 9 (medial cerebral cortex at the level of the septum) and to a 
lesser extent in white matter area 2*  (mesencephalic tegmentum). 
In all of these areas, except area 4 (hypothalamus), 129/01a PrP gtB/gtB mice 
had more severe vacuolar change than the other 129/01a genotypes. The extent of 
vacuolar change apparent in the dorsal medulla (area 1) is illustrated in Figure 7.4 
(panels a-c, p158). Although the cochlear nucleus is not scored as part of the lesion 
profile system, it is apparent here that 129/01a PrP gtB/gtB mice have more severe 
vacuolar change than PrP A/A mice (Figure 7.4, panels d-f, p158). 
This gene influences neuropathology in the thalamus, habenula and raphe nucleus. 





Figure 7.3: 301V lesion profiles 
Comparison of 301V lesion profiles in 129/01a PrP A/A, PrP A/gtB, PrP 
gtB/gtB and VM!Dk mice. Lesion profiles have been superimposed to aid 
comparison. Panel a). 129/01a PrP A/A, A/gtB and gtB/gtB lines. Panel b). 
Comparison of 129/01a PrP gtB/gtB and VM/Dk PrP BIB. 
Lesion profiles were constructed by scoring H&E stained 6uM sections for 
vacuolar degeneration on a scale of 0 to 5 in nine standard grey matter areas and 0 to 
3 in three white matter areas as described (Fraser and Dickinson, 1967, 1968). Error 
bars represent the standard deviation, 10-12 mice were used for each lesion profile. 
Grey matter areas: 1, dorsal medulla; 2, cerebellar cortex; 3, superior 
colliculus; 4, hypothalamus; 5, medial thalamus; 6, hippocampus; 7 septum; 8, medial 
cerebral cortex at the level of the thalamus; 9, medial cerebral cortex at the level of 
the septum. 
White matter areas (*): 1, cerebellar white matter; 2, mesencephalic 
tegmentum; 3, pyramidal tract. 
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These observations are particularly significant given the short incubation times of 
129/01a PrP gtB/gtB mice and indicates that the PrP gtB allotype can determine more 
severe vacuolar change in a number of brain areas. It is also apparent that PrP gtB/gtB 
mice have similar terminal scores to PrP A/A and A/gtB mice despite their short 
incubation times -this may indicate that the kinetics of vacuolar change are faster in PrP 
gtB/gtB hosts. 
Comparison of 129/01a PrP gtB/gtB and VMIDk (PrP B/B) lesion profiles 
(Figure 7.3, panel b, p155) reveals some areas of shared vacuolar change. Similar scores 
are apparent in grey matter areas 1, 2, 4, 5, 8 and 9 and in white matter areas 1*  and 3* 
These similarities suggest that the PrP gtB and PrP B protein direct vacuolar change to 
common sites in these mice. In a number of areas 129/01a PrP gtB/gtB mice have more 
severe vacuolar change. It is unlikely that this represents a difference in the properties of 
the gene targeted Pm-p a[108F_189V]  allele and the wildtype Pm-p b  allele because 
examination of Figure 7.3 (panel a, p155) reveals that all 129/01a genotypes have more 
severe vacuolar change in these areas -this argues that the differences apparent between 
129/01a gtB/gtB and VMIDk represent the effects on non-Pm-p genes. 
The terminal lesion profiles of all three 129/01a genotypes are similar in a 
number of areas but in areas where differences are apparent (areas 1, 8, 9, 2*)  it is 
notable that PrP A/A and PrP A/gtB 129/01a lines have very similar lesion scores. This 
relationship is consistent with the similar incubation times of PrP A/A and PrP A/gtB 
mice. 
The extent of vacuolar change in the hypothalamus (area 4) is conspicuous in 
that it is the only area where PrP A/A mice have a higher lesion score than PrP gtB/gtB 
mice (Figure 7.3, panel a, p155). The fact that PrP A/gtB mice have lower scores here 
despite incubation times which are longer than PrP A/A mice suggests that greater 
vacuolar change in the PrP A/A hypothalamus is not merely a non-specific consequence 
of long incubation times but reflects a difference between the PrP A and PrP gtB 
allotypes in their ability to promote vacuolar change in the hypothalamus. This area is 
also unusual in that it is the only area in which 129/01a PrP A/gtB mice have lower 
scores than PrP A/A mice -elsewhere they are closely similar. A similar phenomenon is 
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Figure 7.4: Vacuolar change in the dorsal medulla and cochlear nucleus 
H&E stained coronal sections of terminal 301V brain. PrP gtB/gtB mice had more 
severe vacuolar change than the other 129/01a genotypes in a number of brain areas 
including the dorsal medulla (panels a-c, scoring area 1) and the cochlear nucleus 
(panels d-f). 
Panels a) PrP A/A b). PrP A/gtB, c)PrP gtB/gtB. Magnification x 40. 
Panels d) PrP A/A e). PrP A/gtB, f)PrP gtB/gtB. Magnification x 10. 
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Figure 7.5: Vacuolar change in the hypothalamus 
H&E stained coronal sections of terminal 301V brain. PrP A/A mice had more severe 
vacuolar change than the other 129/01a PrP genotypes in the hypothalamus (scoring 
area 4). 
Panel a) PrP A/A b). PrP AlgtB, c)PrP gtB/gtB. Magnification x 40. 
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also observed in an independent set of 301V challenges in Sinc congenic mice (Dr. 
Moira Bruce, unpublished data). This suggests that this phenomenon is a reproducible 
effect which is determined by PrP allotype. This provides further evidence that the gene 
targeted Pm-p a[108F_189V]  allele can reproduce neuropathological features of wildtype 
Pm-p b  allele. 
Section 7.6.3: Neuronal loss and PrP accumulation 
301V challenged 129/01a PrP co-isogenic mice revealed significant differences in 
the extent of PrP neuronal loss in the hippocampal region (Figure 7.6, p163). PrP A/A 
mice had severe neuronal loss in the hippocampus, indeed some PrP A/A mice had very 
little remaining hippocampal structure. Widespread pyramidal cell death was apparent in 
the CAI, CA2 and CM regions. Extensive neuronal loss is also evident in the granular 
layer of the dentate gyms. PrP gtB/gtB mice also exhibited severe pyramidal cell loss but 
had a largely intact dentate gyms and, in general, the hippocampal architecture was 
better preserved than in PrP A/A mice. The PrP A/gtB hippocampus had little evidence 
of cell loss. The extent of hippocampal cell loss in PrP A/A and PrP A/gtB mice was 
reminiscent of the reduced hypothalamic vacuolar change in PrP A/gtB mice. 
PrP deposition was examined by immunohistochemistry in 301V terminal brains. 
PrP deposition was most prominent in the hippocampus and the thalamus (Figure 7.7, 
p165 and Figure 7.8, p167). Although these studies were based on a small number of 
mice from each genotype (n=4), and some variation was evident between mice of the 
same PrP genotype, they indicate a role for PrP allotype in the control of PrP deposition. 
All 129/01a PrP genotypes had widespread cytoplasmic PrP accumulation in the 
hippocampus which gave this area a mottled appearance. In all genotypes PrP plaques, 
when present, were limited to the subcallosal region, specifically the junction between 
the oriens layer and the alveus. 
In addition to a widespread cytoplasmic staining pattern, PrP A/A mice had 
significant extracellular PrP deposition and numerous prominent regularly spaced PrP 
plaques in the alveus (Figure 7.7, panel a, p165). The extent of neuronal loss apparent in 
the PrP A/A hippocampus corresponded well with the extent of PrP deposition. 
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Figure 7.6: Neuronal loss in the hippocampus 
H&E stained coronal sections of the hippocampus cut at the level of the 
thalamus. Magnification x 10. Panels a). PrP A/A b). PrP A/gtB, c)PrP gtB/gtB. 
Panel a). Extensive neuronal loss throughout the PrP A/A hippocampus, particularly 
in pyramidal neurons of the CAI, CA2 and CA3 regions. Cell loss was also evident in 
the granular layer of the dentate gyms. Panel b). Little neuronal loss was apparent in 
the PrP A/gtB hippocampus. Panel c) Extensive loss of pyramidal cells in the CAI, 
CA2 and CA3 regions of the hippocampus in PrP gtB/gtB mice, but not to the extent 
that was evident in PrP A/A mice. PrP gtB/gtB mice have little cell loss in the dentate 
gyms. 
Brains were fixed in formal saline and 6tM hippocampal sections cut at the level of 
the thalamus. 
The main features of the mouse hippocampus are shown below: 
Pyramidal layer 
Dentate gyms 
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Figure 7.7: PrP deposition in the hippocampus 
PrP staining in the hippocampus of 301V terminal 129/01a PrP co-isogenic brain. The 
subcallosal region is shown in which a PrP allotype-dependent PrP staining pattern 
was evident. Panels a). PrP A/A b). PrP AlgtB, c). PrP gtB/gtB. 
Brains were treated with 98% formic acid, PLP fixed and 6p.M coronal sections cut at 
the level of the thalamus. PrP was detected primary using antiserum 1A8 with the 
peroxidase-antiperoxidase method and sections were lightly counterstained with 
haemotoxylin. PrP staining was performed by Patricia McBride. Magnification x40. 
Panel a). PrP A/A mice have considerable extracellular PrP staining with frequent 
large PrP plaques. 
Panel b). PrP A/gtB mice have the longest incubation time but less PrP deposition 
than PrP A/A mice. A largely intact layer of CAT pyramidal neurons is evident in the 
bottom of this panel. 
Panel c). Irregular, small PrP plaques were present in the PrP gtB/gtB hippocampus. 























Figure 7.8: PrP deposition in the thalamus 
PrP staining in terminal 301V brain. PrP allotype was associated with differences in 
PrP staining in the thalamus, particularly in the dorsal lateral geniculate nucleus. 
Panels a). PrP A/A b). PrP A/gtB, c). PrP gtBlgtB. Magnification xlO. 
Brains were treated with 98% formic acid, PLP fixed and 6p.M coronal sections were 
stained for PrP using 1A8 a polyclonal PrP antiserum and developed with the 
peroxidase-antiperoxidase method. Sections were lightly counterstained with 
haemotoxylin. PrP staining was performed by Patricia McBride. 
Panel a). Large amounts of PrP staining was evident in the dorsal lateral geniculate 
nucleus in PrP A/A brain. 
Panel b). PrP A/gtB mice also had PrP deposition in this region but to a lesser extent. 
Panel c). PrP gtB/gtB mice had little PrP deposition in this area. 
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Irregularly spaced PrP plaques were also present to a lesser degree in the PrP A/gtB 
subcallosal region (Figure 7.7, panel b, p165). Given the longer incubation periods of 
PrP A/gtB mice this indicates that the severe PrP deposition evident in the PrP A/A 
subcallosal region is not simply due to a long incubation period but is a property of the 
PrP A allotype. PrP gtB/gtB mice had occasional small plaques in the alveus but they 
were smaller and less frequent than in the other genotypes (Figure 7.7, panel c, p165). 
In the dorsal and ventrolateral thalamic nuclei, both focal and diffuse PrP 
deposits were evident in all genotypes although it was apparent that PrP A/A and A/gtB 
mice had more PrP deposition here than PrP gtB/gtB mice. This was particularly marked 
in the dorsal lateral geniculate nucleus where PrP A/A mice, and to a lesser extent PrP 
A/gtB mice, had moderate or large accumulations of PrP, whilst PrP gtB/gtB mice had 
much less evidence of accumulation here (Figure 7.8, p167). 
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Section 7.7: Discussion 
Section 7.7.1: Sinc/Prn-i and Pm-p are congruent 
129/01a PrP gtBlgtB mice homozygous for the targeted Pm-p a[108F_189V]  allele 
had incubation times of 133 days -more than 110 days shorter than wild-type 129/01a PrP 
A/A mice encoding the wild-type Pm-p a  Pm-i N  and S/nc s7 alleles. The dramatically 
shortened incubation times of 129/01a PrP gtB/gtB mice were very similar to the 119 day 
incubation times of Vrvl/Dk PrP B/B mice encoding the Pm-p b  Pm-i' and the S/nc p7 
alleles. This data shows that PrP codon 108 and 189 alterations can convert incubation 
times from that characteristic of mice encoding Pm-p a  Pm-i N  and S/nc s7 alleles to 
those characteristic of mice encoding Pm-p b  Pm-i ' and Sinc p7 alleles. This 
demonstrates that PrP codon 108 and 189 dimorphisms are the major molecular 
determinants of 301V incubation time in the mouse. This is the best evidence yet that 
S/nc/Pm-i and Pm-p are congruent and confirms long standing observations that a single 
gene exerts a major control over incubation times for a number of mouse adapted scrapie, 
CJD and BSE isolates (Dickinson, Meikle and Fraser, 1968; Carlson et al., 1986, 1988, 
1993; Kingsbury et al., 1983; Bruce et al., 1994). 
Although the role of PrP codons 108 and 189 are demonstrated here with a single 
mouse adapted BSE strain (Bruce et al., 1994) it is expected that mice bearing the gene 
targeted Pm-p aF108F_189V1  allele will respond to challenge with other strains in a manner 
characteristic of the wild-type Pm-p b  allele. Preliminary observations from ME7 
challenge experiments indicate that this is the case. 
Transgenic studies have established that increased PrP expression levels accelerate 
incubation period (Westaway et al., 1991; Prusiner et al., 1990; Telling et al., 1996; 
Fischer et al., 1996). The PrP immunoblotting studies described in chapter 6 (Figures 6.3 
p1.36 and Figure 6.4, p138) indicate that gene targeting has not altered the PrP 
expression levels of mice bearing the gene targeted allele with respect to wild-type 
129/01a and VMIDk mice. This argues that the dramatic shortening of incubation time is 
not attributable to raised PrP expression levels in mice expressing the Pm-p a[108F_189V] 
allele but is due to the specific effect of the engineered codon 108F and 189V alterations. 
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The 301V incubation times of 129/01a PrP gtB/gtB and \TMIDk  (PrP B/B) mice 
are very similar and indicate that the gene targeted Pm-p a[108F_189V]  allele is capable of 
specifying the short 301V incubation times normally associated with the Pm-p b  allele. 
The 133 day incubation time of 129/01a PrP gtB/gtB mice is 14 days longer than is 
observed in 301V challenges of VMIDk, which are 119 (±2 SE days, n12) days (Table 
7.1, p146). Potential explanations for this slight incubation time difference include the 
effect of non-PrP genes, the effects of non-coding Pm-p polymorphisms and slight 
differences in the pattern or level of PrP expression between the wild-type Pm-p b  allele 
and the gene targeted Pm-p a[108F_189v]  allele. 
A 14 day difference between 129/01a PrP gtB/gtB and VM!Dk mice is well within 
the range of incubation times observed in mice encoding the same Pm-p allele. For 
example, the 301V incubation times of wild-type 129/01a and C57BL PrP A/A inbred 
mouse strains, which both encode the Pm-p a allele, differ by -5 5 days (Table 7. 1, p1  46). 
A number of non-coding Pm-p polymorphisms which differentiate the Pm-p a  and Prnpb 
alleles have been described -although the significance of these polymorphisms is 
uncertain. The dramatic alteration in incubation times reported here in 129/01a mice 
encoding a common Pm-p a allele, which differs by only two amino acid alterations, 
indicates that Pm-p coding polymorphisms have the major role in the control of 
incubation time. However, it is possible that non-coding Pm-p polymorphisms are 
responsible for the small difference between the incubation times of 129/01a homozygous 
Pm-p a[108F_189V] and VMJDk Pm-p b  mice. 
As described above, PrP expression levels have a major influence upon 
incubation times (Prusiner et al., 1990; Telling et al., 1996; Fischer et al., 1996). A role 
for large differences in PrP' expression is doubtful given the similar levels of brain PrP' 
expression observed in 129/01a PrP co-isogenic lines and VMIDk mice. However, at the 
level of analysis afforded by PrP immunoblotting it is not possible to exclude that the 
gene targeted Pm-p a[108FJ89V]  allele expresses PrP at slightly lower levels than the 
wildtype Pm-p a  and/or Pm-p b  alleles. Even if more detailed analysis can show that the 
Pm-p a[108F_189V]  allele expresses PrP at levels lower than wild-type Pm-p alleles, the 
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main finding of this project (that codons 108 and 189 modulate incubation time) will 
remain secure. This is because reduced PrP gtB expression levels from the Pm-p 
a[108F_189V] allele would almost certainly act to prolong incubation times in 129/01a PrP 
gtB/gtB mice. If this were the case, the dramatic shortening of 301V incubation times 
described here in 129/01a PrP gtB/gtB mice would constitute an underestimate of the 
biological effects of PrP codon 108 and 189 dimorphism. This would strengthen the case 
that they control incubation time in mice encoding wildtype Pm-p b  alleles. When 
available, a mouse PrP ELISA will be used to compare the whole brain PrP expression 
levels in mice expressing PrP A from the Pm-p a  allele, PrP B from the Pm-p b  allele and 
129/01a mice expressing PrP gtB from the gene targeted Pm-p a[108F_189V]  allele. 
Although previous studies indicate that the levels of PrP expression in Pm-p a 
and Pm-p b  mice are indistinguishable (Westaway et al., 1987; Manson, McBride and 
Hope, 1992), it is formally possible that they do differ. A subtle difference in PrP A and 
PrP B expression levels from these alleles would lead to incubation times which were 
dependent not only on the differential actions of PrP A and B allotypes but also on 
expression level effects. A similar argument could be deployed with respect to PrP 
expression pattern. Such effects could not be fully reproduced in gene targeted mice 
differing only with respect to PrP codon 108 and 189 dimorphisms. 
It is also possible that the Pm-p a[108F_189V]  allele differs from the wildtype VMIDk 
Pm-p b  allele in a region outwith the PrP ORF leading to minor expression levels 
differences in vivo. In support of this notion are observations of non-coding 
polymorphisms within Pm-p. The Pm-p intron 2 structure of 129/01a and VMIDk differ 
with respect to a cryptic 6.7Kb insertion/deletion (Westaway et al., 1994a) and two PrP 
3'UTR polymorphisms have been reported at nt 444 and nt 1010 which differ between 
Pm-p a  and Pm-p b  mice [H.Baybut and J.Hope, Genbank Accession numbers X83612 
and X83613]. However, little is known of the effect that these polymorphisms may have 
upon PrP expression and further analysis will be required to exclude this as a source of 
slight differences in PrP expression level or expression pattern between mice encoding 
Pm-p ' and Pm-p b 
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301V challenge of C57BL (Pm-p a)  and F1[C57xVM] (Pm-p ) mice reveal 
that Fl Pm-p 	mice have incubation times approximately 31 days shorter than C57 
mice (Table 7. 1, p146). This indicates that the Pm-p a  allele, or rather the PrP A allotype, 
is dominant in conferring long incubation times with 301V. It was therefore expected that 
301V challenges in 129/01a PrP A/A and PrP AIgtB mice would reproduce this 
incubation time ranking. Indeed, 129/01a PrP A/gtB mice had incubation times close to 
that observed in F1[C57xVM] (Table 7. 1, p146) and F1[VM-Sinc 7 x VM] mice (Table 
7.2, p172, below; Moira Bruce, unpublished data), but they were 15 days longer than 
129/01a PrP A/A mice. 
Table 7.2: 301V i.c. challenge of Sine congenic mice' 
Mouse Strain/Cross PrP genotype PrP Sine Mean SE b 
allotype genotype Incubation (days) 
time a  (days) 
\TM.Sinc 7 c 	 Pm-p ala A/A s7s7 248.8 5.8 
F! [VM-Sinc 7 x VM/Dk] d 	Pm-p a/b A/B s7p7 226.9 2.1 
VMIDk 	 Prn-p 	B/B 	p7p7 	117.5 	1.4 
a This is unpublished data kindly  provided by Dr Moira Bruce, MRC/BBSRC 
Neuropathogensis Unit, Edinburgh; b, standard error of the mean; c, also known as SV; d also 
known as S VV. 
There are a number of potential explanations for this, including the possibility that 
the Pm-p aF108F_189V1  allele expresses at slightly lower levels than the Pm-p b  allele. 
Although the expression studies reported here indicate that this is unlikely, it is not 
inconceivable. If this were the case, it could provide an explanation for the slightly longer 
incubation times of both 129/01a PrP gtB/gtB and 129/01a PrP AIgtB mice. It is more 
likely that genetic differences between 129/01a and VMIDk are responsible for this slight 
deviation from the predicted incubation time ranking of Pm-p a  and Pm-p ala[108FJ89V] 
	
mice. Indeed, control challenges with Pm-p 	(PrP AIB) mice were performed on 
F1[C57xVM] mice and it is possible that genes linked to Pm-p b  could modify the 
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incubation time in Fl mice. If this were the case, 129/01a PrP co-isogenic mice which 
share a common genetic background would not be able to reproduce this effect. 
It is also formally possible that 129/01a co-isogenic PrP A/A and PrP A/gtB mice 
reveal, for the first time, a small degree of overdominance which is not evident in 
challenges with other mouse strains. In support of this is the observation that 
overdominance was a consistent feature in primary transmissions of BSE to C57BL, 
VMIDk and F1[C57xVM] mice and that 301C, a C57BL passaged mouse adapted BSE 
strain, exhibits overdominance (Table 7.3, p174; Bruce et al., 1994). The reduced 
pathology evident in PrP A/gtB mice would support this. 
Section 7.7.2: PrP codon 108 and 189 dimorphisms control some aspects of 301V 
neuropathology 
129/01a PrP gtB/gtB mice had a number of differences in neuropathology that 
correlated well with their shorter incubation times. The PrP gtB allotype was responsible 
for raised levels of PrPSC,  directed more severe vacuolar change to a number of areas and 
in many scoring areas appeared to promote more rapid vacuolar change. 
Compared to PrP A/A mice, PrP A/gtB mice had a large number of similarities in 
lesion profile. However, reduced levels of PrPS  in whole brain and reduced levels of 
neuropathology in a number of areas were consistent with the slightly longer incubation 
times of PrP A/gtB mice. Examples of reduced pathology included considerably reduced 
cell loss in the hippocampus, less vacuolar change in the hypothalamus and reduced PrP 
deposition in both the thalamus and the hippocampus. 
Although PrP A/A mice had more extensive PrP deposition in the thalamus and 
hippocampus this was not reflected by higher levels of PrPsc on PrP immunoblots from 
terminal brains. Indeed, PrP immunoblotting indicated that PrP gtB/gtB had higher 
levels of PrP. This discrepancy may be because impressive regional differences in the 
extent and degree of PrP deposition are lost when whole brains are homogenised and 
examined by SDS-PAGE. It is also possible that PrP gtB/gtB brain contains a 
considerable amount of diffuse PrP which is difficult to quantify by 
immunohistochemistry. 
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The incubation time rankings of 129/01a PrP A/A and 129/01a PrP A/gtB mice 
are similar -indicating that the PrP A allotype is dominant. It was notable that in almost 
all lesion profile scoring areas, PrP A/A and PrP A/gtB mice had similar scores, 
suggesting that the PrP A allotype is also dominant in its ability to promote vacuolar 
change in multiple scoring areas. The hypothalamus was conspicuous in that it was the 
only area in which PrP A/gtB lesion scores were lower than in 129/01a PrP A/A mice . 
This may reflect a difference between PrP A and PrP gtB allotypes in their ability to 
target vacuolar change to this area. The relative sparing of the PrP A/gtB hypothalamus 
suggests that the PrP gtB allotype can have a "protective" effect. A similar effect was 
evident in the relative neuronal preservation of the PrP A/gtB hippocampus (Figure 7.6, 
p163) and in the reduced PrP deposition in the hippocampus (Figure 7.7, p165) and 
thalamus (Figure 7.8, p167). The reduced pathology in these areas of 129/01a PrP A/gtB 
brain may explain their prolonged or "overdominant" incubation times with respect to 
129/01a PrP A/A mice. 
It is currently uncertain whether the ranking of the PrP A/A and PrP A/gtB 
incubation times in 129/01a PrP co-isogenic mice really reflects overdominance because 
129/01a PrP A/gtB mice have incubation times which are only 15 days longer than 
129/01a PrP A/A mice. As Table 7.3 (below) illustrates, in other challenges where 
overdominance has been established, F1[C57xVM] PrP A/B mice have incubation times 
which are at least 60 days longer than parental C57BL PrP A/A and VM!Dk PrP B/B 
incubation times. 
Table 7.3: Overdominance in various mouse TSE strains 
Incubation time (days) 
Strain PrP A/A 	PrP A/B PrP B/B Reference 
301C 207 	565 363 Bruce et al., 1994 
22A 474 	567 199 Bruce et al., 1991 
139A 166 	270 208 Bruce et al., 1991 
PrP A/A= C57BL; PrP A!B=F'1[C57xVM]; PrP BIB= VMJDk. Note: all i.c challenges. 
The reduced vacuolar change observed in the 129/01a PrP A/gtB hypothalamus is also apparent in 
the lesion profiles of 30 1V challenged Sinc congenic mice (Dr. Moira Bruce, unpublished data). 
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It has been suggested that overdominance, co-dominance and complete dominance arise 
from various degrees of blocking effect between the heterologous host PrP allotype and 
the more productive interactions occurring between isologous host and inoculum donor 
PrP molecules. Carlson has suggested that overdominance arises from reduced levels of 
the PrP allotype isologous to the inoculum donor PrP sequence (Carlson et al., 1994). 
Currently it is unclear which, if any, of these explanations is correct. There is some 
evidence that a total blocking interaction does not occur in 301V: this is because 129/Ola 
PrP Al- mice have 301V incubation times of —320 days (Jean Manson, unpublished 
data). Although it is difficult to compare incubation times from different experiments, the 
244 day incubation time of 129/Ola PrP A/gtB mice reported in this thesis suggests that 
the gtB allotype is contributing to the shorter incubation period in PrP A!gtB mice 
(compared to Al- mice). This indicates that the PrP gtB allotype is functional in the 
presence of the PrP A allotype -arguing against a total blocking effect. This is consistent 
with Carlson's proposal that overdominance, when it is observed, arises from reduced 
levels of the allotype isologous to the prion inoculum. However, if this is the case it is 
unclear why different degrees of overdominance are apparent with different strains of 
agent (Table 7.3, p174). One potential explanation arises from the observation that 
distinct strains respond differently to reduced levels of PrP isologous to that of the 
inoculum donor. For example, ME7 incubation times6 in 129/01a PrP A/A mice are 160 
days and are prolonged to 284 days in PrP Al- mice (Manson et al., 1994) but RMIL 
incubation times are prolonged from 143 days (±4 SE) in PrP A/A mice to 426 days (± 
18 SE) in the corresponding strain of PrP Al- mice (Prusiner et al., 1993; Carlson et al., 
1994). Although these incubation times are taken from different experiments they 
indicate an role for agent strain in the response to reduced levels of PrP. Thus the 
different degrees of overdominance, and perhaps other dominance phenomena, may 
reflect strain-determined responses to reduced levels of the PrP allotype isologous to the 
donor inoculum. 
6  ME7 and RML passaged in PrP A/A hosts. 
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Section 7.8: Summary 
The dramatically shortened incubation times in 129/01a Pm-p a[108F_189V] 
homozygotes demonstrate that PrP codon 108 and 189 dimorphisms control incubation 
time with 301V and argues strongly that Sinc/Prn-i and Pm-p are congruent. 
PrP codon 108F and/or 189V alterations resulted in changes to the 
neuropathology of PrP gtB/gtB and PrP AIgtB mice. 129/01a PrP gtB/gtB mice had a 
number of features which corresponded well with their short incubation times: they had 
more PrPS,  greater lesion scores in a number of areas whilst the extent of vacuolation in 
other areas indicated that the rate of vacuolation was increased in PrP gtB/gtB mice. 
Compared to PrP A/A mice, PrP AIgtB mice exhibited significantly less vacuolar 
change in the hypothalamus, less neuronal death in the hypothalamus and reduced PrP 
deposition in the thalamus and subcallosal region of the hippocampus. These observations 
were consistent with the longer incubation times of PrP AIgtB mice compared to PrP 
A/A mice. 
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Chapter 8 
Summary 
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Section 8.1: Murine scrapie incubation time genetics 
Classical genetic studies performed by Alan Dickinson and colleagues nearly 
thirty years ago established that experimental scrapie incubation time in mice was under 
the control of a single gene, Sinc encoding two alleles, s7 and p7 (Dickinson, Meikie and 
Fraser, 1968). Similarly, large differences in Chandler scrapie incubation time between 
NZW/LacJ and ILn/J inbred mouse strains enabled the identification of Pm-i, a gene 
encoding 2 alleles, N and I (Carlson et al., 1986, Carlson et al., 1988). 
Important clues to the identity of both Pm-i and Sinc followed the discovery of 
linkage of both genes to the mouse prion protein gene, Prn-p, using Xba I RFLP analysis 
(Carlson et al., 1986; Hunter et al., 1987). A potential molecular basis for Sinc and Pm-i 
allelism was inferred following the discovery that mouse strains with large differences in 
incubation time encode different prion protein allotypes, PrP A and PrP B. PrP allotypes 
arise from codon 108L/F and 189T/V dimorphisms such that PrP A encodes 108L_189T 
and PrP B encodes 108F_189V (Westaway et al., 1987). Sinc/Prn-i and Pm-p are 
closely linked (Carlson et al., 1986, 1988; Carlson et al., 1993), but the unambiguous 
delineation of the relationship between these genes is lacking and four independent test 
crosses have yielded small numbers of progeny with discordant PrP genotype and scrapie 
incubation times (Carlson et al., 1986, 1988; Race et al., 1990). The lethal nature of 
these experiments has frustrated attempts to determine whether discordant mice 
represent meiotic recombination events between Pm-p and a linked, but distinct, 
incubation time control locus, or whether the discordant incubation times are due to the 
reproducible co-segregation of other genes which, in combination, have a large effect 
upon incubation time. 
A convincing demonstration of recombination between S/nc/Pm-i and Pm-p 
would be highly significant and could indicate that incubation times for murine scrapie, 
and perhaps other prion diseases, are controlled by a tightly linked but distinct locus from 
that encoding the prion protein. To date, all attempts have failed to formally demonstrate 
that Pm-p allelism is the major determinant of murine scrapie incubation time. One such 
approach utilised congenic VMJDk (Sinc 77) and VM/DkSincs787  mouse lines which 
encode distinct Sinc alleles, Pm-p alleles, PrP allotypes and have dramatically different 
scrapie incubation times yet share a common VMIDk background (Hunter et al., 1987; 
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Bruce et al., 1991; Hunter et al., 1992). However, such lines could not provide formal 
proof of congruence between S/nc/Pm-i and Pm-p because they also differ with respect 
to 	10cM of chromosomal DNA flanking Pm-p which could contain a number of other 
genes responsible for incubation time control (Hunter et al., 1992). In an attempt to 
overcome these problems, transgenic mice were generated encoding the PrP B allotype 
expressed from a Pm-p b  cosmid transgene but PrP overexpression prevented a formal 
demonstration that codons 108 and 189 controlled incubation times in these mice 
(Westaway et al., 1991; Carlson et al., 1994). 
Section 8.2: Gene targeting 
Section 8.2.1: Introduction 
The difficulties associated with previous attempts to investigate the relationship 
between Sinc, Pm-i, Pm-p suggested that the issue might only be resolved with gene 
targeting. It was reasoned that dramatic alterations to the incubation time of mice in 
which the endogenous PrP A allotype had been converted to the PrP B allotype would 
constitute a definitive test of the congruence of S/nc, Pm-i and Pm-p. It has also been 
shown that non-Pm-p genes can have a significant effect upon scrapie incubation times 
and neuropathology (Bruce and Dickinson, 1985; Carlson et al., 1988; Race et al., 1990; 
Bruce et al., 1991; Carlson et al., 1994) and it was also reasoned that this source of 
variation might also be controlled by generating co-isogenic 129/01a mice differing only 
by targeted codon 108 and 189 alterations (Moore et al., 1995). As an extension to this 
main aim, it was intended that the role of codons 108 and 189 be explored individually by 
generating mice which differ from co-isogenic 129/01a wildtype mice by single PrP 
codon 108F and codon 189V alterations. 
A two step double replacement gene targeting strategy (Moore et al., 1995) was 
used to alter Pm-p a  exon 3 in HM-1 (Magin et al., 1992), a 129/01a ES cell line 
(Simpson et al., 1997). To facilitate gene targeting, a genomic map of the 129/01a prion 
protein locus was generated using HM-1 ES cells. This confirmed that 129/01a had 
RFLPs characteristic of the Pm-p a  allele. The genomic map of Pm-p a  also guided 
studies in which a contiguous set of X DASH II clones spanning the 129/01a Pm-p 
a 
allele were isolated from an HM-1 genomic library. A plasmid clone of the 8.5Kb BamI-il 
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fragment, pl29PrP, was retrieved and mapped. Mapping studies of pl29PrP revealed 
that this clone contained all the sequence homology necessary for the construction of 
isogenic targeting vectors. DNA sequencing of the exon 3 region in pl29PrP confirmed 
that 129/01a mice expressed the PrP A allotype (Westaway et al., 1987; Carlson et al, 
1988). These studies were consistent with previous MIE7 and 301V challenges in wild-
type 129/01a mice which demonstrated that this mouse strain was Sinc 77 (Manson et al., 
1994b; Jean Manson, unpublished data). 
Section 8.2.2: Step 1 -PrP inactivation 
In the first gene targeting step a number of ES clones were generated in which 
one allele of PrP was inactivated by the targeted introduction of an HPRT minigene. 
Clones with low levels of 6-thioguanine resistance were tested for their ability to colonise 
the mouse germline. A number of clones generated germline chimeras, demonstrating 
their suitability for the second gene targeting step. 
Gem-dine transmission of the Pm-p null allele enabled the generation of Pm-p ' 
mice. Ageing of Pm-p mice in excess of 14 months revealed an adult onset ataxia with 
onset 442 days (+5 SE, n=22), similar to that previously described by Sakaguchi et al., 
(1996). The phenotype was somewhat milder and this could be because these mice were 
younger than those described by Sakaguchi et al., (1996). Preliminary counting 
experiments of Purkinje cells in two cerebellar lobules indicated that the PrP nulls made 
during the course of this thesis had reduced numbers of this cell type. The independent 
observation of an adult-onset ataxia in these mice verifies the observations of Sakaguchi 
et al., (1996). Whilst it appears reasonable to conclude that the ataxia arises from the loss 
of Purkinje cells, it is not apparent why this cell type dies in Pm-p 	mice. Further 
studies will investigate this issue. 
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Section 8.2.3:Step 2 -generation of mice with PrP codon 108 and 189 alterations 
Gene targeting was used to specifically alter PrP codons 108L_189T to 
108F189V, to generate a modified Pm-p a  allele expressing the PrP B allotype1. The 
targeted Pm-p a[108F_189V]  allele differed from the endogenous 129/01a Pm-p a  allele only 
by engineered alterations to codon 108 (CTC-ITC) and codon 189 (ACC-IC) 
resulting in L-F and T-V substitutions respectively. The structure of the targeted Pm-p 
a[108F_189V] allele was investigated by Southern analysis using a variety of Pm-p probes 
and confirmed that the targeted Pm-p a[108F_189V]  allele had the predicted structure and 
had undergone no detectable deletions, insertions or other rearrangements during the 
gene targeting process. 
ES cell clones bearing the Pm-p a[108F_189V}  allele were used to construct chimeras. 
A germline chimera was mated with inbred 129/01a mice to generate progeny 
heterozygous for the Pm-p a[108F_189V]  allele. All Pm-p a[108F_189V]  alleles were maintained 
on a 129/01a background, ensuring the co-isogenic nature of these mice with wild-type 
129/01a. This controls for the effects of non-PrP genes and enables changes in incubation 
time and pathology to be attributed to the specific effects of gene targeted PrP codon 
108 and 189 alterations. 
The level of PrP mRNA and PrPc  in the brains of uninoculated mice was 
investigated and confirmed the expression of the targeted Pm-p a[108F_189V]  allele in brain 
but also demonstrated that mice encoding a Pm-p a(108F_189V}  allele expressed PrP at levels 
indistinguishable from non-targeted co-isogenic Pm-p a  littermates. The PrPc  SDS-
PAGE banding pattern was unaltered in mice homozygous for the Pm-p a[108F_189V]  allele 
and expressing the gene targeted PrP gtB allotype, indicating that manipulation of 
codons 108 and 189 has no deleterious effect on PrP structure at this level of analysis. 
These studies argue that differences in incubation time and neuropathology 
between wild-type 129/01a mice and mice encoding the gene targeted Pm-p 
a[108F_189V] 
allele are not due to differences in PrPc  expression level but to the specific effect of 
The gene targeted allele has been named Pm-p a[I08F_189V]  to distinguish it from wild-type Pm-p a 
and Pm-p b  alleles. 
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modified PrP codons 108 and 189. This enabled a formal test of the proposal that PrP 
codon 108L/F and 189T/V dimorphisms control incubation time. 
Section 8.3: 301V challenge of 129/01a PrP co-isogenic mice 
Section 8.3.1: PrP codons 108 and 189 control the response of mice to 301V 
challenge and demonstrate the congruence of Prn-p, Pm-i and Sinc 
301V challenges revealed a critical role for PrP codons 108 and 189. 129/01a PrP 
gtBlgtB mice homozygous for the targeted Pm-p a[108F_189V]  allele had incubation times of 
133 days -more than 110 days shorter than wild-type 129/01a PrP A/A mice encoding 
the wild-type Pm-p a , Pm-i N  and Sinc s7 alleles. The 133 day incubation time was very 
similar to the 119 day incubation time of VM/Dk PrP B/B mice encoding wild-type Pm- 
b  and Sinc p7 alleles. This demonstrates that PrP codon 108 and 189 dimorphisms are 
the major molecular determinants of incubation time in the mouse and that homozygosity 
for the Pm-p a[108F_189V]  allele can convert incubation times from those of wild-type 
129/01a mice encoding Pm-p a  Pm-i N  and Sinc s7 alleles to those characteristic of 
VMIDk mice encoding wildtype Pm-p b  Pm-i 'and Sinc p7 alleles. 
This confirms that Sinc/Pmn-i and Pm-p are congruent, validating long standing 
observations that a single gene exerts a major control over incubation times for a number 
of mouse adapted scrapie, CJD and BSE isolates (Dickinson, Meikle and Fraser, 1968; 
Carlson et al., 1986, 1988, 1993; Kingsbury et al., 1983; Bruce et al., 1991,1994). 
Although the role of PrP codons 108 and 189 are demonstrated here with a 
single mouse adapted BSE strain (Bruce et al., 1994) it is expected that mice bearing the 
gene targeted Pm-p aI108F_189v1  allele will respond to challenge with other strains in a 
manner characteristic of the wild-type Pm-p b  allele. Preliminary observations from ME7 
challenge experiments indicate that this is the case. 
129/01a PrP gtB/gtB mice had 301V incubation times that were 14 days longer 
than VMIDk mice. This small difference may be attributable to the differing genetic 
backgrounds of 129/01a and VMDk or to the effects of non-coding Pm-p 
polymorphisms. Indeed, a 14 day difference is well within the range of incubation times 
observed between different inbred mouse lines encoding the same Pm-p allele. 
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Although a number of non-coding Pm-p polymorphisms have been described, 
the dramatic alteration in incubation times reported here in 129/01a mice encoding a 
common Pm-p a  allele, which differs by only two amino acid alterations, indicates that 
Pm-p coding polymorphisms have the major role in the control of incubation time. 
Nevertheless, it is possible that non-coding Pm-p polymorphisms are responsible for the 
14 day difference between the incubation times of 129/01a PrP gtB/gtB and VMIDk 
mice. 
Previous 301V challeneges of Fl [C5 7BLxVM] (Pm-p ) mice revealed that 
they have incubation times which were 20-30 days shorter than C57BL (Pm-p ) mice. 
This indicates that the Pm-p a  allele, or rather the PrP A allotype, is almost completely 
dominant in conferring long incubation times with 301V. It was therefore expected that 
301V challenges in 129/01a PrP A/A and PrP A/gtB mice would reproduce this 
incubation time ranking. 129/01a PrP A/gtB mice had incubation times that were 15 days 
longer than 129/01a PrP A/A mice. It is possible that there are small differences in 
expression levels from these alleles which are below the level of sensistivity afforded by 
PrP immunoblotting. If this were the case, it could provide an explanation for the slightly 
longer incubation times of both 129/01a PrP gtB/gtB and 129/01a PrP A/gtB mice. It is, 
however, likely that genetic differences between 129/01a and VM/Dk are responsible for 
this slight deviation from the predicted incubation time ranking. 
Section 8.3.2: PrP allotype controls 301V neuropathology 
Although it is well established that agent strain is one of the main determinants of 
neuropathology (Fraser and Dickinson, 1967, 1968; Fraser, 1976; Bruce et al., 1989, 
1991; Hecker et al. 1992; Carlson et al., 1994), the extent to which PrP A and B 
allotypes control neuropathology remains controversial. Studies with S/nc and Pm-p 
congenic lines suggest that PrP allotype can modify pathology, but such studies cannot 
exclude the possibility that linked genes, rather than Prn-p, are responsible. Indeed, 
Carlson has described a Pm-p linked gene which influences neuropathology in a number 
of brain areas (Carlson et al., 1994). 
129/01a PrP co-isogenic mice provided an opportunity to make comparisons 
between mice expressing different PrP allotypes whilst controlling for the effects of non- 
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PrP genes. 301V challenge of these mice indicated that PrP allotype controls the extent 
and distribution of vacuolar change in many brain areas and the extent of neuronal loss in 
the hippocampus. Evidence based upon a smaller number of mice indicates that PrP 
allotype controls the extent and distribution of PrP deposition in the hippocampus and 
thalamus. 
Areas of common vacuolar change between 129/01a PrP gtBlgtB and VMIDk 
mice suggest common lesion targeting sites for the PrP B allotype. Together with the 
dramatic effect of codon 108 and 189 alterations on incubation time, the alterations to 
pathology described here argue that the gene targeted Pm-p a[108F_189V]  allele can 
reproduce important features of the Pm-p b  allele or PrP B allotype. Minor differences in 
129/01a PrP gtB/gtB and \TMIDk  incubation times and lesion profiles indicate that genes 
other than the Pm-p influence the pattern and extent of vacuolation in some brain areas. 
It is also possible that non-coding Pm-p polymorphisms can influence incubation time 
and neuropathology. 
Section 8.4: Future studies in mice with PrP codon 108 and 189 alterations 
Future studies with 129/01a co-isogenic mice bearing gene targeted alterations to 
PrP will enable the exploration of the role of PrP sequence in the control of many aspects 
of prion disease in the absence of PrP gene dosage effects and the confounding effects of 
other genes. Although the 301V challenges reported here demonstrate that PrP codon 
108 and 189 dimorphisms control incubation time, it is not known whether these 
dimorphisms act singly or together. Future challenges will examine incubation times and 
neuropathology in gene targeted mice encoding Pm-p a[108F]  and Pm-p a[189V]  alleles 
expressing PrP molecules with individual 108F and 189V alterations. This may reveal 
whether incubation time is controlled by one or both positions. Challenge of these mice 
with a variety of strains may also determine whether the relative importance of each PrP 
codon is fixed or whether it is strain dependent. 
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Section 9A: Materials 
Section 9A.1: Suppliers of laboratory reagents 
Section 9A.1.1: Restriction endonucleases and other nucleic acid modifying 
enzymes 
Boehringer Mannheim PLC. 
GIBCO BRL Life Technologies. 
New England Biolabs Inc. 
Pharmacia LKB Biotechnology. 
Section 9A.1.2: Standard laboratory reagents 
BDH Chemicals Ltd. 
Fisons Chemicals. 
GIBCO BRL Life Technologies. 
ICN Flow Ltd. 
Sigma Chemical Co. 
Section 9A.1.3: Bacterial media reagents 
Becton-Dickinson U.K. Ltd. 
Difco Laboratories. 
Section 9A.1.4: Reagents for mouse embryonic stem cell culture 
GIBCO BRL Life Technologies. 
ICN Flow Ltd. 
Sera-lab Ltd. 
Sigma Chemical Co. 
Section 9A.1.5: Radioactive reagents 
[a-32P]dCTP 	3000 Cilmmol, Amersham Redivue 
[y- 32P]dATP 	3000 Ci!mniol, Amersham Redivue 
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Section 9A.1.6: Antibiotics 
Aminopterin, Sigma Chemical Co. 
Ampicillin, Beecham Research Laboratories. 
Chloramphenicol, Sigma Chemical Co. 
Penicillin G, Sigma Chemical Co. 
Section 9A.1.7: Antisera 
1A8 rabbit anti mouse PrP 27-30 polyclonal antiserum (Farquar et al., 1994), a gift 
from the BBSRC/MRC Neuropathogenesis Unit, West Mains Road, Edinburgh. 
Section 9A.2: Media, antibiotics and miscellaneous 
Section 9A.2.1: Bacterial media 
Luria Broth (LB): 	lOg Bacto-tryptone (Difco), 5g bacto-yeast extract (Difco), 5g 
NaCl per litre adjusted to pH 7.2 with NaOH. 
Luria Agar: As Luria broth with 15 g per litre Difco agar. 
Terrific Broth (TB): 12g bacto-tryptone, 24g bacto-yeast extract, 4m1 glycerol per 
900mls plus 100 mls sterile solution of 0.17 M KH2PO4, 
0.72M K2HPO4 after autoclaving. 
2xYT: 16g Bacto-tryptone, lOg Yeast extract, 5g NaCl, d.H20 to 1L. 
BBL top agar: lOg trypticase (Baltimore BioLabs), 5g NaCl, 6.5g bacto-agar 
(Difco), 10mM MgSO4, per litre, adjusted to pH 7.0 with NaOH. 
M9 minimal agar: 15g bacto-agar, 1 OOml 1 Ox M9 salts, 20ml 20% (w/v) glucose, 
lOml 0. 1M MgSO4, lOmi 1mg/mi Vitamin Bi, lOmi 0. 1M 
CaCl2 to 1L with d.H20. 
lOx M9 salts: 60g Na2HPO4, 30g KH2PO4, 5g NaCl, lOg NH4C1 to 1L with 
d.H20. 
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Section 9A.2.2: Antibiotics 
Ampicillin to a final concentration of 100 mg/ml in d.H20 stored in aliquots at -20°C 
Chioramphenicol stock: 30mg/mi in 100% ethanol, used at 30ug/ml. Stored in 
aliquots at -20°C. 
Section 9A.2.3: Miscellaneous 
IPTG: 	(isopropyl-13-D-thiogalactopyranoside) 100mM stock in d.H20. Filter 
sterilised, stored at -20°C. 
X-gal: 	(5 Bromo 4-chioro 3-indolyl 3-D-galactoside) 2% stock in 
dimethylformamide. Stored at -20°C. 
Proteinase K: Smg/ml in d.H20 (Boehringer Mannheim), stored at 4°C. 
HAT (lOOx): 1M hypoxanthine, 100mM thymidine, lOOuM aminopterin, dissolved 
in d.H20 and stored at -20°C. 
gancyclovir: 2uM stock in PBS, stored at -20°C. 
Trypsin: 	0.025% (w/v) trypsin (ICN Flow, Cat No. 043-5090), 1mM EDTA, 
1%(v/v) chicken serum (TCN Flow Cat No.29-501-49) in 0.8x PBS. 
Section 9A.2.4: Standard buffers and solutions 
20X SSC: 	3 M NaCl; 0.3 M tn-sodium citrate, pH 7.0 
lox TBE: 	0.9 M Tris-HCI; 0.9 M boric acid, 20 mM EDTA ,pH 8.0 
50X TAB: 	2 M Tnis, 1 M glacial acetic acid; 50 mM EDTA, pH 8.0 
TB: 	 10 mM Tris-HCl, 0.1 mM EDTA, pH 8.0 
PBS: 	 8 mM K2HPO4; 1.5 mM KH2PO4, 150 mM NaCl 
lOx MOPS: 	200mM MOPS, 50mM sodium acetate, 10mM EDTA pH 7.0 
Phage Buffer (SM): 50mMTris.HC1, pH7.5, lOOniMNaCl, 1OmMMgSO4, 2% 
(w/v) gelatine. 
Denaturing Buffer: 0.5MNaOH, 1.5MNaC1 
Neutralising buffer: 3M NaCl, 0.5M Tris.HC1, pH 7.0 
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Table 9.2: Cloning vectors and plasmid constructs 
Name 	 Description 	 Reference 
I 
pBluescript General cloning vector. 
M13mp18 	Cloning vector for in vitro mutagenesis. 
X DASHII 	Bacteriophage ?. sequence replacement vector. Used for construction of 129/01a HM-1 
genomic library. 
pHPT5 	Full length mouse HPRT cDNA. cDNA insert used as a hybridisation probe for BPRT 
genotyping of mouse tail DNA. 
pUC 18 	General cloning vector. 
pUC18N 	NZW mouse 8.5kb Pm-p Exon 3 BamHI fragment cloned into pUC18. 
pUCPrP 	1.1Kb Sma 1/Eco RI Pm-p exon 3 ORF fragment derived from pUC18N, cloned into 
pUC 18. Used as probe for screening HM- 1 X DASH II for Pm-p exon 3 sequences. 
p129S/E' 	HM-1 Pm-p exon 3 1.1kb Smal/EcoRl ORF fragment derived from pl29PrP cloned 
into pBluescript SK 11+. 
pl29Pst2.0 pl29PrP derived 2.0 kb PstI fragment spanning PrP exon3. 
pBam!RV 	pl29PrP derived 700bp Eco RV/Bam HI probe fragment cloned into pBluescript. 
Thummel, 1988 
Norrander, Kempe and 
Messing, 1983 
Stratagene 
Konecki et al., 1982 
Yanisch-Perron et al., 1985 
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Chapter 9: Materials and methods 
Section 9B: Methods 
Section 9B.1: Bacterial culture 
Section 9B.1.1: Growth of E. coli 
E. coil was grown in liquid culture in Luria or Terrific broth by inoculation 
from a single colony. Cultures with volumes greater than 10 ml were grown in conical 
flasks with a total capacity of 5-10 fold of that of the culture volume to ensure good 
aeration. Cultures were shaken at 37°C for an appropriate length of time, typically 
overnight. E.coii carrying plasmids were grown on L plates supplemented with the 
appropriate antibiotic at 37°C (or 30°C to reduce the growth of satellite colonies). 
E.coli cultures inoculated with M13 bacteriophage were always grown at 37°C 
because pili, required for M13 infection, are not formed below 3 5°C. 
Section 9B.1.2: Storage of E. coli 
For short-term storage (less than 4 weeks), bacterial plates were wrapped with 
paraffin film and stored at 4°C. Bacterial strains were stored at room temperature as 
stab cultures: a fresh bacterial colony was used to inoculate a stab culture which was 
incubated overnight at 37°C with the cap loosened. After overnight incubation the cap 
was tightened and the bacteria stored at room temperature for up to a year. 
For long term storage 900 ml of fresh overnight culture was mixed with 100 ul 
of glycerol, and stored at -70 T. Upon recovery, the surface of frozen culture was 
scraped with a flamed sterile inoculating loop and streaked out onto a Luria broth 
agar plate with antibiotic, if required. After an appropriate length of incubation at 37 
a single colony was picked to propagate a fresh bacterial culture. Bacterial strains 
TG1 and CJ236 were streaked onto minimal agar and chloramphenicol plates 
respectively to maintain the F' episome. DH5cLF' cultures were not plated on minimal 
media because the F' in this strain is integrated into the host chromosome and does 
not require selection. 
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Section 9B.1.3: Transformation of E. coli 
Section 9B.1.3.1: Transformation with plasmid DNA 
The method generally used was a modification of Nishimura et al., (1990). A 
500u1 aliquot of an overnight culture of the appropriate E.coli strain was used to 
inoculate 50m1 L broth supplemented with MgSO4 (10mM) and glucose (0.2%w/v). 
This culture was incubated at 37°C until the culture reached mid-logarithmic phase 
whereupon it was chilled on ice for 10 minutes and pelleted by centrifugation at 
1500g for 10 minutes at 4°C. The cell pellet was resuspended in 0.5m1 of the above 
supplemented medium then 2-5m1 of medium B was added (30% glycerin, 12% (w/v) 
PEG 7500, 12mM MgSO4 in LB medium, filter sterilised) and the cells mixed gently. 
Competent cells were generally split into 1 OOul aliquots and stored for up to 3 months 
at -80°C. 
Cells were transformed by the addition of approximately 100 pg of plasmid 
DNA to a 100 ul aliquot of competent cells, followed by mixing and a 15 minute 
incubation on ice. Cells were heat shocked for 3 minutes at 37°C then placed on ice 
for a further 1 minute. Then 0.4ml of prewarmed (at 37°C) LB medium was added 
and the cells incubated for 1 hour in the absence of antibiotic selection. A number of 
aliquots (usually 100, 50 and 10u!) were then plated to dryness on LB agar 90mm 
petri dishes, with appropriate antibiotic selection and 30u1 of 2% (w/v) X-Gal (in 
dimethylformamide) and 20ul of 100mM IPTG to aid the identification of 
recombinants (when appropriate). Plates were incubated at 37°C for at least 20 hours 
before scoring or picking of colonies. Typical transformation efficiencies were 
between 1x105 and 1x108 transformants per ug DNA. Recombinant colonies appeared 
white and non-recombinant colonies were blue using IPTG/X-Gal. 
Section 9B.1.3.2 Transformation of E.coli with M13 RF DNA and M13 phage 
Many E.coii strains can be transformed with M13 RF DNA using competent 
cells prepared by the method of Nishimura et al., (1990) (Section 9B.1.31, above). 
Infection with intact M13 phage is achieved by mixing an aliquot of phage suspension 
with 200ul of a fresh overnight culture, incubating for 5 minutes and adding 2. 5m1 of 
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50°C top agar prior to pouring onto an L-plate. Plaques were picked with a Pasteur 
pipette and transferred to imi TE and the titre determined (.-1O7pfu/plaque). To 
determine M13 titre, several serial dilutions were plated out as described. Titre = (No. 
plaques x 10 x dilution factor) pfu/ml. 
Two main bacterial strains were used for M13 work: DH5aF' and 0236. 
E.coli DH5aF' have an integrated F and do not require any selection for retention of 
the F. However, E.coli CJ236 encode the F on a plasmid (pCJ105(cm')) which also 
encodes a chloramphenicol resistance gene .Therefore CJ236 was streaked out onto 
an L-plate containing 30uglml of chioramphenicol and grown overnight at 37'C. 
To make plating cells for use with M13 phage, a single colony was used to 
inoculate lOml of LB supplemented with 30ugIml chioramphenicol and was grown 
overnight. The OD 600  of the overnight culture was determined and enough cells to 
yield an OD600,= 0.1 was added to fresh medium and grown until OD600 = 0.8-0.8 
('-2hours). Cells were then pelleted by a short spin at 0°C. The pellet was resuspended 
in lml ice cold 50mM CaCl2, mixed gently, then an additional 20ml 50mM CaC12 
added and the cells stored on ice for 20-30 minutes. Cells were harvested by a short 
spin as before and resuspended in 4m1 50mM CaC12. 
Section 9B.2: Nucleic acid isolation 
Section 9B.2.1: Small scale preparation of plasmid DNA 
Small scale preparations of plasmid DNA were made for screening of bacterial 
colonies for recombinant plasmids. The method used is a modification of that 
described by Ish-Horowicz and Burke, (1981). Typically 2 ml of Luria broth or 
Terrific broth, supplemented with ampicillin to a final concentration of 100 ug/ml, was 
inoculated with bacteria from a single colony and incubated at 37 °C overnight with 
vigorous aeration. The culture was transferred to a 2m1 Eppendorf tube and bacteria 
pelleted by centrifugation for 2 minutes at 13K rpm and resuspended in 300 ml of 
solution P1 (see below). Bacterial cells were lysed by the addition of 300 ml of 
solution P2 and incubated at room temperature for 5 minutes. Next, 300 ml of 
solution P3 was added and mixed by gentle inversion. The precipitated complex of 
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chromosomal DNA, SDS and protein was sedimented by centrifugation (17,000 x g) 
in a microcentrifuge for 5 minutes. Contaminating proteins in the clarified supernatant 
were removed by extraction with 1 volume of phenol: chloroform (1:1), vortexed and 
spun at 13K r.p.m for 2 minutes. The upper, aqueous phase was recovered and 0.6 
volumes of isopropanol added and the nucleic acids precipitated with a 10 minute 
spin. The DNA was washed with 70% ethanol, air dried and resuspended in 50 ml 
sterile distilled water or TE. Plasmid "miniprep" DNA was then stored at -20°C. 
Solution P1: 50 mM Tris-HC1 pH 8.0, 10 mM EDTA, 100 mg/mi RNase A 
Solution P2: 20 mM NaOH, 1% (w/v) SDS 
Solution P3: 2.55 M potassium acetate, pH 4.8 
Section 9B.2.2: Large scale preparation of plasmid DNA 
A single bacterial colony was used to inoculate 50m1 of TB containing an 
appropriate antibiotic and grown overnight at 37°C with vigorous aeration. The 
bacterial cells were pelleted by centrifugation for 15 minutes at 4 °C in an HB4 rotor 
in a Sorval RC5 centrifuge at 10,000 rpm. The bacterial pellet was resuspended 
thoroughly in lOml of solution P1 (see above) then lOmls of solution P2 was added. 
The sample was stored at room temperature for 5 minutes, then 1 Omis of solution P3 
added and placed on ice for 10-15 minutes. Following the P3 step, chromosomal 
DNA, SDS and protein complexes were sedimented by centrifugation at 13,000 rpm 
in an HB4 rotor for 30 minutes at 25°C. A Quiagen 500 column was equilibrated by 
the addition of lOml of buffer QBT. The supernatant was applied onto a Quiagen 500 
column through a Whatman filter paper funnel. After washing twice with 30 ml buffer 
QC, the DNA was eluted with 15 ml buffer QF. DNA was then precipitated by the 
addition of 15m1 (0.6 volumes) of isopropanol and centrifuged as before at 20°C. 
Pelleted DNA was washed with 70% ethanol, air dried and redissolved in TE or 
sterile distilled water and stored at -20°C. 
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Buffer QBT: 750 mM NaCl, 50 mM MOPS, 15% ethanol, 
0.15% (v/v) Triton X-100, pH 7.0 
Buffer QC: IM NaCl, 50 mM MOPS, 15% ethanol, pH 7.0 
Buffer QF: 1.25 M NaCl, 50 mM MOPS, 15% ethanol, pH 8.2 
Section 9B.2.3: Preparation of bacteriophage X DNA 
Chloroform was added to the lysed 250 ml culture to a final concentration of 
1% (v/v). The culture was transferred to a 250m1 centrifuge tube and incubated at 
room temperature for 30 minutes. Cellular debris was pelleted by centrifugation for 10 
minutes at 5,000 rpm in a Sorval GSA rotor. The supernatant (200m1) was transferred 
to a fresh tube and equilibrated to 37 °C and 400u1 buffer Li (20mg/mi RNase A, 
6mg/ml DNase I, 0.2mg/ml BSA, 10mM EDTA, 100mM Tris.HC1 pH7.5) added and 
the sample incubated for 30 minutes to degrade bacterial DNA and RNA. The 
centrifuge tube was transferred to an ice bucket and SOml of ice cold buffer L2 (3M 
NaCl and 30% (w/v) PEG6000 was added and the sample stored for 1 hour on ice 
(or overnight). Phage were pelleted by a 10 minute spin at 5, 000 rpm in Sorval HB4 
rotor. All of the supernatant was removed and the phage pellet resuspended with 9m1 
of buffer L3 (100mM Tris.HC1, 100mM NaCl, 25mM EDTA, pH 7.5) and transferred 
to a 50m1 Falcon tube. Buffer L4 (4% (w/v) SDS) was added (9mls), the tube mixed 
gently and incubated at 70°C for 20 minutes then placed on ice. When cool, 9m] of 
buffer L5 (2.55M potassium acetate, pH 4.8) was added and mixed immediately. The 
sample was and spun at 10, 000 rpm in a Sorval SS 34 rotor for 30 minutes at 4 T. A 
Quiagen tip 500 was equilibrated with 10 ml of QBT (750mM NaCl, 50mM MOPS, 
15% ethanol, 0.15% Triton x-100, pH7.0) and the supernatant poured onto the 
column through a Whatman 3M filter paper funnel. The column was allowed to empty 
by gravity flow then washed with 30m1 of buffer QC (TM NaCl, 50mM MOPS, 15% 
ethanol, pH 7.0). DNA was eluted with 15ml of buffer QF (1.25M NaCl, 50mM 
MOPS, 15% ethanol, pH 8.2) into a centrifuge tube and 10.5m1 (0.6 volumes) 
isopropanol added and mixed. DNA was precipitated by a 10 minute centrifugation at 
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10,000 rpm at 20°C. Pellets were washed twice with 70% ethanol, air dried then 
dissolved in 1 00-200ul of TE. 
Section 9B.2.4: Preparation of M13 bacteriophage DNA 
Section 9B.2.4.1: Isolation of M13 bacteriophage 
Plating cells were produced by inoculating 20m1 of LB with a single bacterial 
colony and incubating overnight at 37°C with antibiotic selection for the F' if required. 
A 250ml flask containing 50m1 of 2xYT medium was inoculated lml of overnight 
culture and grown to an OD600 = 0.3 (1-4 hours). This approximates to lx108cfu/ml. 
An appropriate volume of phage stock was added to a molarity of infection of 0.2 
phage/cell and incubated with shaking a further 4-6 hours. This culture was 
transferred to a 50m1 centrifuge tube and spun for 15 minutes at 17,000g (12Krpm 
with a Sorval SS-34 rotor) and the supernatant was transferred to a fresh tube and 
recentrifuged. The supernatant was transferred to a polyallomer centrifuge tube and 
150ug of RNAase A added and incubated at room temperature for 30 minutes. Phage 
were precipitated by the addition of 0.25 volumes of 3.5M ammonium acetate/20% 
(w/v) PEG8000, incubated on ice for 30 minutes then centrifuged for 15 minutes at 
17,000g (4 °C). The supernatant was carefully removed and the tube drained 
thoroughly and the phage pellet resuspended with 200u1 of high salt buffer (300mM 
NaCl, 100mM Tris pH8.0, 1mM EDTA), transferred to a 1.5m1 Eppendorf tube and 
held on ice for 30 minutes. Insoluble material was precipitated by a 2 minute 
centrifugation at 13,000k rpm and the supernatant transferred to a fresh tube. The 
phage stock was titred as was generally —5x1011pfu/ml. 
Section 9B.2.4.2: Isolation of single stranded M13 DNA 
Single stranded M13 phage DNA was purified as follows: intact phage were 
precipitated from 1.5m1 M13 cultures by the addition of 300u1 of 20% (w/v) 
PEG6000/2.5 M NaCl followed by a 5 minute incubation at room temperature and 
centrifugation for 10 minutes at 13K rpm. Phage pellets were resuspended in 150ul 
TE followed by the addition of 8ul of 5% (w/v) CTAB (Hexadecyltrimethyl- 
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ammonium bromide) and were heated for 5 minutes at 65°C, centrifuged a further 5 
minutes and pellets resuspended in 1 OOul TE/1.2M NaCl. Following a 5 minute 
incubation at room temperature, 250u1 of ethanol was added and ssDNA precipitated 
by a 10 minute centrifugation. Pellets were washed with 70% ethanol, air dried and 
resuspend in 30u1 of TE. Typically 5u1 of 30ul was used for dideoxy sequencing. 
An alternative method was sometimes used: 200ul of phage stock (Section 
9B.2.4. 1) was extracted twice with an equal volume of Tris buffered phenol (pH 8. 0), 
once with phenol/chloroform (1:1) and several times with chloroform until no 
interphase was visible. M13 ssDNA was precipitated by the addition of 0.1 volumes 
of 7.8M ammonium acetate and 2.5 volumes of ethanol and was stored at -70°C for 
30-60 minutes. The sample was centrifuged 15 minutes and the pellet washed with 
90% ethanol, air dried and resuspended in 20u1 TE. This method typically yielded 
several micrograms of Ml 3 ssDNA. 
Section 9B.2.4.3: Isolation of double stranded M13 RF DNA 
The double stranded replicative form of M13 was prepared from a bacterial 
pellet from an M13 infected culture by following the small scale alkaline lysis method 
routinely used to isolate plasmid DNA (Section 9B.2. 1). Larger quantities of M13 RF 
DNA was prepared using a large scale plasmid prep in conjunction with a Quiagen 
column (Section 9B.2.2). 
Section 9B.2.5: Preparation of genomic DNA from embryonic stem cells 
High quality, high molecular weight ES cell genomic DNA, suitable for PCR 
amplification and Southern analysis was made as follows. A 25cm2 confluent flask of 
ES cells was washed twice with 5 mls of PBS drained and Sml of tissue buffer was 
added (50mM Tris.HC1, pH 8.0, 20mM NaCl, 100mM EDTA, 0.5% SDS, 1mM 
CaC12, 0.5mg/mi Proteinase K, 0.1 ug/mi RNase A). The flask was gently agitated for 
5 minutes whilst the ES cells were released from the flask prior to transfer to a 50m1 
Falcon tube. The tube was incubated at 37 °C with gentle agitation for several hours 
or overnight. The ES cell lysate was extracted twice with 1 volume of 
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phenol/chloroform (1:1), centrifuged at 3000 rpm for 15 minutes. The aqueous phase 
was retrieved and extracted against 1 volume of chloroform. High molecular weight 
DNA was precipitated by the addition of 0.6-1 volumes of isopropanol. The DNA 
precipitate was retrieved with a wide bore pipette then washed in 70% ethanol and 
gently resuspended in d.H20 and stored at 4°C. 
Section 9B.2.6: Preparation of genomic DNA from mouse tail samples 
Mice (>3 weeks old) were anaesthetised by intraperitoneal injection of 
approximately 0. 1 m of Hypnorm-Hypnovel and left for 20 minutes for the anaesthetic 
to take effect. Adequately anaesthetised mice were given an identification mark by 
earmarking and small samples of tail (0.5-1cm) were removed and placed in a 1 .5m1 
Eppendorf tube with 0.5ml tissue buffer (50mM Tris.HC1, pH 8.0, 20mM NaCl, 
100mM EDTA, 0.5% SDS, 1mM CaC12, 0.5mg/mi Proteinase K, 0.1 ug/mI RNase 
A) and incubated overnight prior to processing for DNA using the method described 
in Section 9B.2.5. Preparation of anaesthetic: 2ml of Hypnorm (Fentanyl Citrate 
0.315mg/mi, 10mg/mi Fluanisone, Janssen Animal Health, Grove Oxford, UK) was 
added to 4 ml of water and mixed. Two millilitres of Hypnovel (10mg Midazolam, 
Roche) was added to 4ml of d.H20 and mixed. Both solutions were combined and 
mixed to yield 1 2m1 of Hypnorm-Hypnovel ready for use. Anaesthetic was stored at 
room temperature. 
Section 9B.2.7: Preparation of RNA from embryonic stem cells and mouse 
tissues 
The following method is adapted from Chomoczynski and Sacchi, (1987). 
Fresh cells or tissue were placed in a sterile polycarbonate centrifuge tube containing 
lOml of denaturing buffer (4M guanidium thiocyanate, 25mM sodium citrate pH 7.0, 
0.5% sarcosyl, 20mM DTT), homogenised then acidified by the addition of lml of 
2M sodium acetate, pH 4.0 and mixed prior to the addition of lOmi of water 
saturated phenol and 3m1 of chloroform. The tube was vortexed for 30 seconds and 
stored on ice for 10 minutes then centrifuged for 10 minutes at 10,000rpm in an HB4 
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rotor pre-cooled to 4°C. The aqueous phase was transferred to a fresh centrifuge tube 
and RNA precipitated by the addition of 1 volume of isopropanol pre-cooled to - 
20°C. The sample was stored at -20°C for at least 20 minutes before a 15 minute 
centrifugation as above. The RNA pellet was resuspended in lml of denaturing 
buffer, transferred to a 2m1 sterile centrifuge tube and reprecipitated by the addition of 
imi of isopropanol and stored at -20°C for 30 minutes. RNA was collected by a 
further 10 minute spin and the RNA pellet was resuspended in 75% ethanol, 
centrifuged for 10 minutes and resuspended in sterile TE. RNA was generally stored 
under EtOH at -70°C. 
Section 9B.3: Quantification of nucleic acids 
Section 9B.3.1: Estimation of DNA concentration 
The DNA sample was diluted in 1 ml of distilled water and the OD of 
absorbance at wavelengths 260nm and 280nm was measured by a spectrophotometer 
(Perkin-Elmer, Lambda 15, UV/VIS Spectrophotometer). An OD260 value of 1.0 
represents a concentration of 50 mg/ml for DNA. The ratio OD26onm/OD280nm provides 
an estimate for the purity of the nucleic acid. A value around 1.8 indicates a pure 
preparation of DNA. 
Section 9B.3.2: Estimation of RNA concentration 
The RNA sample was diluted in TE and the OD of absorbance at wavelengths 
260nm and 280nm was measured by a spectrophotometer (Perkin-Elmer, Lambda 15, 
UV/VIS Spectrophotometer). An OD260 , value of 1.0 represents a concentration of 
40 mg/ml for RNA. The ratio OD26omn/OD280= provides an estimate for the purity of 
the nucleic acid. A value around 2.0 indicates a pure preparation of RNA. 
Section 9B.4: DNA manipulation 
Section 9B.4.1: Digestion of DNA with restriction endonucleases 
Most DNA restrictions were performed using BRL, Boehringer Mannheim or 
New England Biolabs enzymes and buffers. DNA was digested with approximately 2- 
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5U of restriction endonuclease per ug of DNA using buffer and temperature 
conditions recommended by the manufacturer. For double digests involving enzymes 
with different recommended buffers, the buffers were checked individually in double 
digests to determine which gave most efficient digestion. If the optimal digestion 
conditions varied for buffers, the DNA was digested with enzyme at lower salt 
concentration, the enzyme reaction stopped by heat denaturation or phenol extraction, 
the DNA precipitated and dissolved in a buffer appropriate for digestion by the next 
enzyme. Digestion reactions were terminated by addition of DNA sample buffer then 
heated for 10 minutes at 65°C prior to electrophoresis. 
Section 9B.4.2: Dephosphorylation of plasmid vector termini 
Calf intestinal phosphatase (CIP) is a phosphomonesterase that hydrolyses 3' 
and 5' phosphates from DNA and RNA. It can be used to remove 5 'phosphates 
before end-labelling and to dephosphorylate linearised plasmid vectors before insert 
ligation. This enzyme can be inactivated by heating for 15 minutes at 75 °C in the 
presence of EDTA and 10 mM sodium salt. Phenol extraction is not required. The 
terminal 5' phosphates were removed from DNA (< 5 pmole) by treatment with 0.1 
U (1 ml) of calf intestinal phosphatase (ClIP) (Boehringer Mannheim) in a reaction 
mixture containing 5 ml lox CTP buffer (lOx: 0.5 M Tris-HC1 pH 9.0, 10 mM 
MgCl2, 1 mM ZnC12, 10 mM spermidine) and d.H20 in a total volume of 49 ml. After 
incubation at 37°C for 30 minutes, the reaction was terminated by inactivating the 
enzyme at 75°C for 15 minutes in a solution containing 10 ul of iox STE (lOX: 100 
mM Tris-HCI, 1 M NaCl, 10 mM EDTA, pH 8.0) and 2.5ul of 20% (wlv) SDS and 
d.H20 in a total volume of 100 ul. 
Section 9B.4.3: Ligation of DNA 
Typically, between 100 and 200 ng of insert DNA was ligated with linearised 
plasmid vector DNA at an insert to vector molar ratio of 5:1. Ligations were 
performed in a 10-20ul reaction volume containing 50 mM Tris-Cl pH 7.6, 10 mM 
MgCl2, 1 mM DTT, 1 mM ATP and 5 % (w/v) PEG8000 and incubated overnight at 
204 	 Chapter 9: Materials and methods 
15 °C (for blunt ends), or for a minimum of 2 hours at room temperature (for sticky 
ends). One unit of T4 DNA ligase was used for ligations. Ligation products were 
then transformed into E. co/i. (Section 9B. 1.3) 
Section 9B.5: Electrophoresis of nucleic acids 
Section 9B.5.1: Electrophoresis of DNA in agarose gels 
DNA was separated in 0.7-2.0% (w/v) electrophoresis grade agarose with 0.5 
mg/ml ethidium bromide in lx TBE buffer (for Southern blotting and routine 
analytical gels) or 1X TAE buffer (for preparative gels). Prior to loading, DNA 
samples were mixed with 1/5 volume of 5x sample buffer (20% (v/v) glycerol, 100 
mM EDTA, 0.1% bromophenol blue). Electrophoresis was carried out horizontally 
across a potential difference of 1-10 V/cm. Bacteriophage X DNA cut with Hindlil 
and X174 DNA cut with HaeIII were used as size markers. DNA was visualised by 
short wave UV illumination. Preparative gels were not exposed to short wave UV as 
this can result in thymidine dimerisation. Instead, the DNA in preparative gels was 
visualised by long wave UV from a hand held lamp. 
Section 9B.5.2: Electrophoresis of RNA in agarose gels 
RNA samples were electrophoresed through 1.4 % (w/v) agarose gels made 
with lx MOPS, 0.66M formaldehyde and 0.5ug/ml ethidium bromide. Samples were 
prepared by the addition of lOug of total RNA (in 20u1 d.H20) to an equal volume of 
FSB (lOOul lOx MOPS, 200u1 formamide, 120u1 de-ionised 37%(w/v) formaldehyde) 
and one quarter volume of standard sample buffer (20% glycerol, 100 mM EDTA, 
0.1% bromophenol blue) was also added and the sample heated for 5 minutes at 65°C 
then cooled on ice prior to electrophoresis for 300-400 V/hours. 
Section 9B.5.3: Recovery of DNA from agarose gels 
DNA was electrophoresed using low melting point agarose in 1X TAE, 0.5 
mg/ml ethidium bromide, the desired fragment was visualised by long wave UV 
illumination. The band of interest was excised and recovered from the agarose by 
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phenol extraction. The gel slice volume was estimated then 0.5 volumes of TE, lul 
glycogen (Boehringer Mannheim) and 5u1 20% SDS was added to the gel slice and 
heated to 70°C until the agarose melted (5 minutes). Liquified agarose was extracted 
three times with 1 volume of tris buffered phenol (pH 8.0) and once with 1 volume of 
chloroform. The aqueous phase was retained and DNA precipitated by the addition of 
0.1 volume 3M sodium acetate and 1 volume of isopropanol. DNA was pelleted by a 
10 minute centrifugation at 13Krpm and the DNA pellet resuspended in d.H20. 
Section 9B.6: Transfer of nucleic acids 
Section 9B.6.1: Transfer of DNA from agarose gels to membranes 
The transfer of DNA from agarose gel onto filters for the detection of specific 
sequences among DNA fragments was initially developed by Southern, (1975) and 
modified by Smith and Summers, (1980). Genomic DNA was digested with the 
appropriate restriction enzyme in a total volume of 50-100 ul overnight at 37°C (with 
the exception of BstEII which was digested for 5 hours at 60 °C under mineral oil) 
and separated according to size on a 0.7-1% agarose gel (w/v) in 1X TBE and 0.5 
mg/ml ethidium bromide. Routinely, genomic DNA was electrophoresed for 
800Vhours then photographed. The gel was then soaked in denaturation buffer (0.5 
M NaOH, 1.5 M NaC1) with gentle agitation for 15 minutes. The DNA was 
transferred to Genescreen Plus nylon membrane (Du Pont; Stevenage, U.K.) by 
capillary action using denaturation buffer as the transfer medium (Reed and Mann, 
1985). Transfer was performed for 12-24 hours then the membrane was neutralised 
and adherent agarose washed off by incubating for 10 min in 3 M NaCl, 0.5 M Tris-
HC1 pH 7.0 on a rocking platform. Filters were air dried before use. 
Section 9B.6.2: RNA transfer 
Following electrophoresis, gels were washed three times for 20 minutes in 
1OxSSC at room temperature to remove formaldehyde and ethidium bromide. 
Transfer conditions were similar to DNA except that 1OxSSC was used as the transfer 
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buffer. On completion of transfer the membrane was washed in 2x SSC for 10 minutes 
then baked at 80°C for 2 hours. 
Section 9B.7: Nucleic acid hybridisation 
Section 9B.7.1: Labelling DNA probes 
DNA labelled to high activities was obtained using the randomly primed DNA 
labelling method (Feinberg and Vogelstein, 1983). DNA probes were denatured, 
annealed to random hexamer primers and extended by the Kienow fragment of E.coli 
DNA polymerase I in the presence of [a-32P]dCTP. Oligonucleotide labelling buffer 
(OLB) containing nucleotides and random primers is required for this method. It is 
made by mixing 50 ml Solution A (1.25 M Tns-HC1 pH 8.0, 0.125 M MgCl2, 25 MM 
3-mercaptoethanol, 0.5 mM each of dGTP, dTTP and dATP), 125 ml Solution B (2M 
HEPES buffer adjusted to pH 6.6 with NaOH) and 75 ml Solution C (random 
hexanucleotides OD260 , = 90 in TE). Probes were labelled as follows: 100 ng of d.s 
DNA was made up to 32 ul with d.H20 then denatured by boiling for 5 minutes and 
allowed to cool at room temperature for 10 minutes. The following reagents were 
then added: lOmi of OLB, 2ul of 10mg/mi BSA 5u1 of [a-32P] dCTP (3000Ci/mmol) 
and 10 units of Kienow enzyme. The reaction was incubated at 37°C for 40 minutes 
or overnight at room temperature. 
Section 9B.7.2: DNA and RNA hybridisations 
Pre/hybridisations were performed in a hybridisation oven (Hybaid Limited) in 
a total volume not exceeding 30 ml of prehybridisation buffer (6X SSC, 1% SDS, 
10% (w/v) dextran sulphate, 100 mg/ml of denatured herring sperm DNA). Blots 
were prehybridised for a minimum of 1 hour at 65 °C for Southern transfer and at 60 
°C for northern transfer. DNA probes were heat denatured in 300u1 of 10mg/mi 
herring sperm DNA and added directly to the prehybridisation solution. Following 
hybridisation overnight at 65°C, the hybridisation solution was discarded and the blots 
were rinsed for 5 minutes in 2 X SSC/ 1 % (w/v) SDS at room temperature, followed 
by a 30 minute wash in 2x SSC, 1% (w/v) SDS at 65°C then a 30 minute wash in 
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1xSSC, 1% (w/v) SDS at 65°C. Membranes were sealed in a plastic bag and 
autoradiographed at -80°C, typically overnight. Northern blots were hybridised and 
washed as above but at 60°C. 
Section 9B.7.3: Autoradiography 
Autoradiography was performed using Cronex X-ray film (DuPont) in a 
cassette with intensifying screens (Cronex Lightning Plus; Du Pont). Cassettes were 
exposed at -70°C to facilitate fluorographic enhancement. 
Section 9B.7.4: Stripping probes from membranes 
Radiolabelled probes were stripped from Southern blots by boiling in 0. 1X 
SSC, 1% (w/v) SDS for 10 minutes with gentle shaking. The solution was decanted 
from the membrane, and the boiling procedure was repeated twice. Blots were 
autoradiographed to confirm that probe stripping was complete. The membrane was 
then incubated in pre-hybridisation solution and hybridised as above (Section 9B.7.2). 
Northern blots were stripped by washing them 4 times for 5 minutes in boiling 
0.Olx SSC, 0.01% (w/v) SDS. 
Section 9B.8: Allele specific oligonucleotide hybridisation 
Section 9B.8.1: 5' Labelling of oligonucleotides 
Oligonucleotide (lopmol)was 5' labelled in a 50u1 reaction by the addition of 
5u1 polynucleotide kinase buffer (Promega), lul lOmg!ml acetylated BSA (NEB), lul 
(IOU) T4 polynucleotide kinase and 5u1 [y-32P]dATP (3000Cilmmol). The reaction 
was incubated for 1 hour at 37°C then added directly to the prehybridisation solution 
and incubated with the membrane. 
Section 9B.8.2: Detection of 108F mutants by differential hybridisation 
Membranes were prehybridised for 30 minutes at room temperature in 1 OmI 
prehybridisation buffer (6x SSC, 5x Denhardts solution, lOOug/ml herring sperm 
DNA). The 5' end labelled 108F oligonucleotide was added directly to the 
208 	 Chapter 9: Materials and methods 
prehybridisation solution and hybridised to the membrane for 1.5 hours at room 
temperature. The membrane was washed for 15 minutes at room temperature in 
6xSSC and exposed for 15 minutes at room temperature to provide a control 
autoradiograph showing the relative signal intensities before washing at raised 
stringency. The membrane was placed in 6x SSC and washed twice at 62°C for 5 
minutes then exposed to X-ray film at room temperature for 15 minutes. 
Unambiguous determination of differential hybrids required both positive and 
negative controls on the membrane. Controls were either PCR products or plasmids: 
PrP exon 3 ORF PCR product from HM-1 provided a negative control whilst VM/Dk 
PCR product from the same region provided a positive control for the 108F signal. 
108F mutants were characterised by unaltered signal intensities at raised stringency 
whilst non-mutants had dramatically reduced signals under the same conditions. 
Denhardt's solution (50x): 1% (w/v) Ficoll (type 4001), 1% (w/v) 
polyvinylpyrrolidine, 1% (w/v) BSA (Fraction V, Sigma) in d.H20. 
Section 9B.9: X DASH H mouse genomic DNA library screening 
Section 9B.9.1: Growth of E.coli K802 plating cells and titration of phage 
A single colony of E.coli K802 from an LB plate was picked and placed in a 
sterile 250m1 conical flask containing 20 mis of terrific broth supplemented with 0.2% 
(v/v) maltose. The culture was incubated overnight at 37 °C with vigorous aeration. 
The following day the culture was decanted into a 50m1 Falcon tube and the cells 
pelleted and resuspended in 20ml 10mM CaCl2, 10 MM MgSO4. Plating cells were 
stored at 4 °C for a maximum of three weeks. To titrate phage, 1 Out of an appropriate 
dilution of phage in LB medium or SM solution (50mM Tris.HC1, 100mM NaCl, 
8mM MgSO4, pH 7.5) was added to lOOul of K802 plating cell in a plastic tube, 
mixed then incubated for 20 minutes at room temperature to allow adsorption of 
phage by bacteria. Following this, 3n-As of molten BBL top agar (50 °C) was mixed 
with the phage/cells and poured evenly onto an L-agar plate. The plates were left for 
10 minutes for the agar to set and plates were incubated overnight at 37°C. Plate 
lysate stocks were prepared as above but with a phage/bacteria MOl adjusted to 
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achieve confluent lysis. To lift phage from the L-agar plate, 5mls of SM was added to 
each plate and placed on a gently shaking table for 30 minutes. The supernatant was 
poured into a fresh tube, a few drops of chloroform were added to the stock which 
was then titred. 
Section 9B.9.2: Preparing fitter replicas of ? library pates 
Nylon Membranes (Hybond N, Amersham) were placed on the surface of 
library plates (precooled to 4 °C) for 5 minutes and asymmetrical marks made in the 
membrane made with an ink soaked needle to facilitate the localisation of positive 
plaques. Membranes were carefully removed and placed (DNA side up) on Whatman 
3M paper pre-soaked with denaturing solution (0.5M NaOH, 1.5M NaCl) for 5 
minutes then transferred onto filter paper pre-soaked with neutralising buffer (0.5M 
Tris.Cl, 1.5M NaCl, pH 8.0) for 5 minutes then transferred onto filter paper pre-
soaked with 2xSSC. Filters were air dried for 30 minutes then baked at 80 °C for 1 
hour. 
Section 9B.9.3: Pre/hybridisation of filter replicas 
Baked filter replicas were rinsed briefly with d.H20 and 6xSSC then placed 
into a sealed plastic hybridisation container and incubated with 1 OOml prehybridisation 
buffer (50% formamide, 5xSSC, 50mM NaPO4, pH 7.2, 1% (wlv) SDS, 10 ml 
lomglml yeast tRNA or lOml lOmgIml sonicated herring sperm DNA) for a minimum 
of 1 hour at 37°C. Following prehybridisation the DNA probe was added and 
hybridisation carried out for 18 hours at 37°C. Hybridised filters were washed three 
times for 30 minutes at 55°C in prewarmed 0. 1xSSC, 0.1% (vlv) SDS then exposed 
overnight at -70°C. 
Section 9B.9.4: Picking X bacteriophage plaques 
Well separated plaques corresponding to putative positive hybridisation signals 
were picked from L plates with an inverted sterile pipette tip and placed in 1 ml of SM 
into which 1 drop of chloroform was added to inhibit bacterial growth during storage. 
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To ensure that the phage had diffused out of the agar the plaque suspensions were left 
for at least 1 hour before further use. 
Section 9B.9.5: Lysis of medium scale ? bacteriophage liquid culture 
Prewarmed LB medium (250 ml) was supplemented with 0.2% maltose (w/v), 
10mM MgCl2 and lOmi CaC12 and inoculated with 500u1 of a fresh overnight K802 
culture. Several cultures were set up in parallel and inoculated with different amounts 
of recombinant bacteriophage clones, typically lxl09pfu of plate lysate stock 
completely lysed a 250m1 culture in 6 hours. X DNA was isolated as described in 
Section 913.2.3. The yield from a 250m1 culture was generally 1 50-200ug ? DNA. 
Section 9B.9.6: Mapping recombinant ? bacteriophage clones 
A FLASH Nonradioactive Gene Mapping Kit (Stratagene, Cat No. #200381) 
was used to generate a high resolution restriction map of A. DASH II recombinant 
inserts. This method makes use of the T3 and T7 RNA polymerase promoters which 
flank the polylinker sites of A. DASH II. Following Not I digestion, lOOug of each 
digested A. DASH II clone was resuspended in d.H20 to a final concentration of 
lug/ul. Then lug was digested with 1U of restriction enzyme in the appropriate buffer 
in a total volume of lOul. Aliquots of-250ng (2.5u1) were withdrawn at 2, 5, 10 and 
20 minutes and placed on ice and 3u1 of 0.5M EDTA added to stop the digestion. 
Sample buffer was added to all of the samples and they were electrophoresed and 
transferred to Genescreen+ nylon membrane, neutralised and air dried. Membranes 
were prehybridised for 10 minutes at 37'C. The AP conjugated T3 or T7 
oligonucleotide probe was added to a final concentration of 2nM and hybridised for 1 
hour at 37°C. The hybridisation solution was discarded and the membranes washed 
for 10 minutes with prewarmed (37°C) wash buffer #1 (2xSSC, l%(wlv) SDS). This 
wash was then discarded and the membranes were washed for 10 minutes with buffer 
2 (2xSSC, 1% (v/v) Triton X-100) for 10 minutes at 37°C. Membranes were then 
washed twice for 5 minutes at room temperature with assay buffer (0.0096% (vlv) 
diethanolamine, 1mM MgCl2, pH 10.0) then incubated 10 minutes with substrate 
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buffer (assay buffer with 0.6% (v/v) CSPD). The membrane was sealed in a plastic 
bag and exposed to X-ray film for 10 minutes at room temperature. 
Section 9B.10: In vitro mutagenesis 
Section 2B.10.1: The Kunkel method 
Oligonucleotide directed mutagenesis was performed on the M13 clone 
ml29PrP"t using the method described by Kunkel (Kunkel et al., 1987) in 
conjunction with a Muta-gene M13 In Vitro Mutagenesis Kit version 2 (Biorad, 
Richmond USA) and dut - ung - mutant E.coli strain 0236. Briefly, this method 
enables the generation and rapid isolation of mutants without the requirement for the 
subcloning of each mutant. Single stranded template is isolated bearing the PrP ORF 
region to be mutated and a mismatch primer is annealed and extended by T7 DNA 
polymerase in the presence of T4 DNA ligase. The heteroduplex is used to transform 
E. coil, plated and plaques picked and screened for the presence of the desired 
mutation. The efficiency of this method is increased by biological selection for the 
daughter strand of the heteroduplex. This selection system requires an initial passage 
of the parental M13 clone in CJ236, a dut - ung - mutant strain of E.coii which lacks 
both dUTPase and uracil N glycosylase (Kunkel et al., 1987). Following passage in 
0236, ssDNA from ml29PrPWt  was used for in vitro mutagenesis. 
The dut - mutation in CJ236 inactivates dUTPase and results in elevated 
intracellular levels of dUTP which compete with dTTP for incorporation into DNA. A 
small number of dUTP bases are incorporated into the parental DNA instead of 
thymine. The ung - mutation results in cells which lack uracil N glycosylase -an 
enzyme which normally removes uracil from DNA. When an M13 clone is passaged 
through the double mutant strain 0236, uracil is incorporated into DNA but is not 
removed. Selection for the daughter strand of the heteroduplex following in vitro 
mutagenesis exploits the semi-conservative nature of DNA replication and was 
achieved by transforming dut + ung + E.coii strain NM522 with an aliquot of this 
reaction product. NM522 will not replicate the uracil containing parental strand 
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efficiently and M13 plaques are preferentially derived from the daughter strand 
bearing the engineered mutation. Mutation efficiencies are usually between 60-80% 
and screening by dideoxy sequencing is adequate to isolate mutants. The wildtype 
clone bearing the PrP A coding region, m129PrP\t,  was titred in a wildtype E.coli 
strain (NM522) before and after passage through CJ236 -a large difference in titre 
was noted confirming selection against dUTP DNA derived from 0236. 
Section 9B.10.2: Phosphorylation of the mismatch oligonucleotide 
HPLC purified oligonucleotide (200pmol) was phosphorylated using 4.5 units 
of T4 polynucleotide kinase in lx phosphorylation buffer (100mM Tris.HC1 pH8, 
10mM MgC12, 5mM DTT, 0.4mM ATP) and incubated for 45 minutes at 37°C. The 
reaction was stopped by heating at 65 °C for 10 minutes and diluted with TE to a 
oligonucleotide final concentration of 6 pmollul. 
Section 9B.10.3: Annealing of the mismatch primer and synthesis of the 
complimentary strand. 
200ng of dUTP M13 ssDNA template was mixed with 3 pmol of 
phosphorylated mismatch primer in the presence of lx annealing buffer (20mM 
Tris.HC1 pH 7.4, 2mM MgC12, 50mM NaC1) in a total volume of lOul. This gives a 
primer:template ratio of approximately 20:1 to 30:1 -higher ratios can result in 
significant levels of mispriming. A control annealing reaction was performed without 
primer to determine the rate of endogenous priming. The reactions were placed in a 
beaker of water prewarmed to 70°C and allowed to cool on the bench to 30°C. 
Reactions were placed on ice and the buffer was adjusted by the addition of lul of 
synthesis buffer (25 mM dNTP's, 10mM ATP, 100mM Tris.HC1, pH 7.4, 50mM 
MgCl2, 20mM DTT) followed by 0.5 units of T7 DNA polymerase and 5 units of T4 
DNA ligase. The primer was stabilised by the initiation of DNA synthesis on ice for 5 
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minutes then the primer extended and the complimentary strand synthesised by 
incubation at 25°C for 5 minutes then 37°C for 30 minutes. Following this the reaction 
was terminated by the addition of stop buffer (10mM Tris.HC1, 10mM EDTA, pH8). 
Analysis of the reaction products was performed by gel electrophoresis and an aliquot 
used for transformation of E.coli NM522 to select for the daughter strand of the 
heteroduplex. Following transformation, 10 well isolated plaques less than 24 hours 
old were picked and plaque purified to ensure that each plaque derived from a single 
M13 bacteriophage clone. Plaques were picked and used to inoculate small scale 
liquid cultures to generate ssDNA template suitable for sequencing and RFII d.s DNA 
for restriction analysis and subcloning. 
Section 9B.11: DNA sequencing 
Section 9B.11.1: Annealing of primer to double stranded DNA template 
Template (1-2ug) was denatured for 10 minutes in 40u1 of 400mM NaOH 
then precipitated and resuspended in lOul of dH20. Primer (5-10 pmol) was mixed 
with the denatured template in a total volume of 14ul in 140mM Tris.HCI (pH7.6), 
14mM MgCl2 and 23mM DTT and the primer annealed by heating to 65°C for 10 
minutes followed by a 10 minute incubation at 37°C. 
Section 9B.11.2: Annealing of primer to single stranded DNA template 
Primer (1-2 pmol) was added to 1.5-2 ug of ssDNA template in 140mM 
Tris.HC1, 14mM MgCl2 and 23mM DTT, pH7.6 in a total volume of l4ul. The primer 
was annealed by heating to 60°C for 10 minutes and allowed to cool for 10 minutes at 
room temperature. 
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Section 9B.11.3: DNA sequencing reactions 
Annealed primer/template in a volume of 14u1 was incubated for 5 minutes at 
room temperature following the addition of 3u1 of labelling mix (1.375uM dCTP, 
dGTP, dTTP and 333.5mM NaCl), lul of [a-35S]dATP and 2ul of lU/ui T7 DNA 
polymerase (diluted with 20mM Tris.HC1 pH7.5, 5mM DTT, lOOug BSA/ml, 5% 
glycerol). Following the labelling reaction, 4.5ul aliquots were transferred to each of 
four tubes containing 2.5ul prewarmed (37°C) termination mixes, mixed gently and 
incubated at 37°C for 5 minutes. Termination reactions were stopped by the addition 
of 5ul each of stop solution (0.3% (w/v) bromophenol blue, 0.3% (w/v) xylene 
cyanol, 10mM EDTA (pH7.5) and 97.5% deionised formamide). Reactions were 
stored at -20°C. Prior to electrophoresis, sequencing reactions were heated to 75-
80°C for 2 minutes. 
Sequencing reactions were run on 0.2mm 8% (w/v) polyacrylamide gels using 
a BioRad SequiGen Sequencing Cell at 55-60°C. Gels were transferred to Whatman 
3MM blotting paper, covered with Saran wrap and dried for 2-3 hours at 80°C under 
vacuum. For autoradiography the Saran wrap was removed from the dry gel and 
placed in a cassette with an intensifying screen and exposed overnight at -80°C. For 
higher resolution, gels were exposed without fluorographic enhancement at room 
temperature for 3-4 days. Gel mix: 8% (w/v) polyacrylamide was made by adding 50g 
of urea to 30m1 of H20, lOml of lOx TBE and 20m1 of 40% (w/v) acrylamide/2. 105% 
bis-acrylamide (Easigel, Scotlab). The gel mix was stirred at 37°C for 30 minutes 
with 50g of Duolite ion exchange resin and filtered through a 0.2uM vacuum filter 
(Sartorius) and stored at 4°C in foil wrapped bottles until use. 
Section 91112: Embryonic stem cell culture and gene targeting 
Section 9B.12.1: HM-1 culture conditions 
HM-1 ES cells, a feeder independent line (Magin et al., 1992), were cultured 
in lx Glasgow's modified Eagles minimum essential medium (GMEM BHK21, Gibco 
BRL Life Technologies) supplemented with 5% foetal calf serum (Sera-lab, Gibco 
BRL), 5% newborn calf serum (ICN Flow), non-essential amino acids, 1 mM sodium 
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pyruvate, 0.1 mM 3-mercaptoethanol and recombinant mouse LIF at 1000U/ml as 
described (Melton, 1997). 
Section 9B.12.2: ES cell culture 
ES cells were passaged by aspirating off the medium, rinsing the bottom of the 
flask with 1-2m1 of trypsin (ICN Flow), aspirating off the trypsin and adding a further 
1-2nls of trypsin and placing the flask in a 37°C incubator until the cells had lifted off 
of the flask (2-3 minutes). ES medium was added to a total volume of 1 Oral and the 
ES cells pelleted by a 5 minute spin (13Krpm) at room temperature. The medium was 
removed and the cells resuspended gently in an appropriate volume of ES medium 
and an aliquot transferred to a gelatinised (0.1% (vlv) gelatin) tissue culture flask. ES 
cells were grown in a humidified tissue culture incubator (Forma Scientific water 
jacketed incubator) at 37°C with 4-8% CO2. 
Cells were stored long term in liquid nitrogen. The culture to be frozen was 
trypsinised as above, spun down, medium removed and placed on ice. Ice cold 
freezing medium (10% DMSO, 20% (v/v) FCS in LIF supplemented ES medium) was 
added and the cells gently resuspended in the medium. Cells were frozen at a high 
density (to maximise cell survival) and 3ml of freezing medium was routinely added to 
a confluent 25cm2 flask and the cells frozen in imi aliquots at -20°C for several hours 
then transferred to -70°C overnight, then moved into liquid nitrogen for long term 
storage. ES cells (imi aliquots) were thawed rapidly by placing them in a 37°C 
waterbath then quickly transferred to 9mls ES medium and resuspended. The ES cells 
were pelleted and resuspended in 3-5mls of ES medium and placed in a 25cm2 flask 
and grown at 37°C as described above. 
Section 9B.12.3: Electroporation of ES cells 
Targeting vector DNA was linearised with an appropriate restriction enzyme 
prior to electroporation using a BioRad Gene Pulser (BioRad; Richmond, U.S.A.). 
Cells were suspended in 0.8m1 electroporation buffer (21mM F1EPES, 5mM D-
glucose (dextrose), 8mM Na2HPO4, 5mM KC1, 140mM NaCl) with 200ug linearised 
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targeting vector DNA and pulsed with 3 mF, 800 V (Thompson et al., 1989) using 
Biorad cuvettes (BIO-RAD Gene Pulser Cuvette 0.4cM electrode, gap 50). Cells 
were incubated at room temperature for 10 minutes before plating. 
Section 9B.12.4: PCR screening ES colonies for targeting events 
Single well isolated ES colonies were removed from culture dishes with a 
micropipette and placed in a 1 .5m1 centrifuge tube containing 500u1 of ES medium. 
The colony was broken into a single cell suspension by thorough pipetting and 200-
300u1 of this cell suspension was placed into a single well of a gelatinised 24 well 
microtitre dish and 1 ml of ES medium added. The remainder was processed for PCR 
detection of targeting events. 
PCR screening for targeting events was performed on crude ES cell lysates as 
follows: the ES cell sample was spun for 30 seconds at 13,000 rpm on a benchtop 
microcentrifuge. Supernatants were discarded and 40u1 of lx PCR buffer and 
proteinase K (10mg/mi) was added and incubated for 1 hour at 65°C. Proteinase K 
was denatured by heating the samples to 90°C for 25 minutes in a waterbath. The 
moisture was spun down and 20u1 of the heat inactivated ES cell lysate was included 
in a 50u1 PCR reaction. The PCR cycling conditions were adjusted for each 
primer/template combination. Standard conditions were as follows: 20u1 ES cell 
lysate, 3u1 lOx PCR buffer (50mM KCI, 1.5mM MgCl2, 0.01% (w/v) gelatine, 10mM 
Tris pH8.3, 0.005% (v/v) Triton X-100, 0.005%(v/v) Tween 20), 1.9ul 10mM 
EDTA, lul 5mM dNTPs, lul oligo 1 (OD=20), lul oligo 2 (OD =20), sterile d.H20 
to 50u1, and overlaid with 50 ul mineral oil. PCR was performed for 35 cycles of 
94°C, 30 seconds, 65°C 30 seconds, 72°C 1 minute. 
Section 9B.13: Generation of chimeric mice from gene targeted ES cells 
All procedures performed were as described by Hogan, Constantini and Lacey, 
(1986). C5 7BL/6J and Balb C blastocysts were obtained by timed mating females and 
blastocysts were retrieved 3.5 days after plugging by flushing the uterine horns. Well 
formed, fully expanded blastocysts were injected with approximately 10 targeted ES 
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cells following the method described by Wassarmann and Pamphilis, (1993). Injected 
blastocysts were transferred into the uterine horn of pseudopregnant recipient MF 1 
females. Pseudopregnant females were obtained by mating them with vasectomised or 
genetically sterile males. 
Chimeras were detected by the appearance of chinchilla coat colour on the 
background of the coat colour of the recipient blastocyst. Coat colour alleles of the 
recipient blastocysts were matched with those of the 129/01a HM-1 ES cells to 
provide an easily identified coat colour chimaerism (Thompson et al., 1989) as 
described in Figure 1.7 (p37). 
Section 9B.14: PrP immunoblotting 
PrP' was detected by immunoblotting with crude brain homogenates in 
conjunction with rabbit anti mouse PrP27-30 polyclonal antiserum 1A8 (Farquar et 
al., 1994). Homogenates were prepared as follows: brains were dissected cleanly, 
weighed and homogenised in a sufficient volume of 0.32M sucrose/20mM PMSF to 
10% (w/v). Total brain protein content was determined by the bichinchonic acid 
method (Pierce) -10%(w/v) homogenates had protein contents close to 1mg/mi. 
Samples were stored at -70°C prior to use. 
Brain homogenates and PrPSC  samples were boiled for 5 minutes with Laemmli 
sample buffer before separation by 12% SDS PAGE with a 3.3% stacking gel 
(Laemmli, 1970). NEB broad range pre-stained markers were run with all gels to 
assess separation and electrotransfer efficiency. 
Proteins were electroblotted from acrylamide gels onto PVDF membrane 
(Immobilon P, Millipore) using a BioRad Transblot SD semi dry electroblotter at 12V 
for 2 hours then rinsed in PBST. Membranes were blocked for 30 minutes to 1 hour 
with 5% foetal calf serum, 1%(w/v) BSA in PBST (0. 1%(v/v) Tween 20), the 
blocking solution was discarded and incubated with PrP primary antiserum (1A8 
1:1000 in PBST) for 1 hour at room temperature. Membranes were washed three 
times for 10 minutes in PBST then the secondary antiserum (Promega alkaline 
phosphatase conjugated goat anti-rabbit IgG 1:7500 dilution) added and incubated for 
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I hour. Membranes were washed three times for 10 minutes in PBST, then developed 
using either a chromogenic method with NBT/BC1P (Promega) or with an enhanced 
chemifluorescent alkaline phosphate substrate (Vistra ECF Amersham) and visualised 
with a STORM fluorimager (Molecular Dynamics). 
Section 9B.15: Analysis of 301V terminal brains 
Section 9B.15.1: 301V Challenge 
Mice were challenged by injection of 20ul of 102  dilution of VMJDk terminal 
301V brain homogenate into the thalamus. All challenges performed during the course 
of this project used the same 301V inoculum derived from clinically sick VMIDk brain 
at its fifth passage. Mice were scored for signs of clinical illness as described 
(Dickinson, Meikie and Fraser, 1968). 
Section 9B.15.2: Lesion profiling 
Terminal mice were sacrificed by cervical dislocation and their brains fixed in 
10% formol saline for 2-3 days followed by decontamination for 1 hour in formic acid 
(98%). All brains were sectioned coronally at four levels: forebrain, thalamus, 
midbrain and medulla. Lesion profiles were performed on 6iM H+E stained sections 
using the method described by Fraser and Dickinson, (1968) in which vacuolar 
degeneration was scored on a scale of 0 to 5 in nine standard grey matter areas and in 
three white matter areas. 
Section 9B.15.3: PrP immunohistochemistry 
Brains were removed at the terminal stage of disease and immersion fixed for 48 
hours with periodate-lysine-paraformaldehyde (2% paraformaldehyde), followed by 
decontamination for 1 hour in formic acid (98%). Brains were then dehydrated with 
alcohols and impregnated in wax during a 7 hour processing cycle. 6iM sections were 
mounted on slides which had been baked at 200°C for 4 hours and coated with 
Vectabond. Mounted sections were immunostained by the standard peroxidase-
antiperoxidase (PAP) method (Sternberger et al., 1970) using PrP antiserum 1A8 at 1 in 
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200 dilution (Farquar, et at., 1994). The reaction product was visualised with 
diaminobenzidine and sections were lightly counterstained with haematoxylin. Controls 
were carried out using preimmune serum in place of primary antibody. 
Section 913.15.4: Isolation of sedimentable PrP from 301V terminal brain 
For the analysis of PrPSC  from infected brains, sedimentable PrP was isolated as 
follows: '/2 brains were homogenised in 2m1 of brain lysis buffer (10%(w/v) sarkosyl, 
0. 14%(w/v) NaH2PO4, pH 7.4) on ice then decanted into 2ml screw capped Eppendorf 
tubes and centrifuged at 4°C on a benchtop microcentrifuge for 15 minutes at 13,000 
rpm. The supernatant was retained and its volume increased to 3ml with BLB prior to 
centrifugation at 100,000rpm in a TL120.2 rotor in a Beckman TL100 ultracentrifuge at 
4°C for 30 minutes. Samples were flash frozen with liquid nitrogen and stored at -70°C. 
Samples were also stored for short periods at -20°C. 
For the detection of PrP27-30, samples prepared as above were treated with 
proteinase K (50ugIml, Boehringer Mannheim) for 1 hour at 37°C and immunoblotted as 
described in Section 9B. 14. 
All procedures involving 301V were performed in a class II laminar flow hood in 
a dedicated room at the BBSRCIMIRC Neuropathogenesis unit, Edinburgh. 
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Double Replacement Gene Targeting for the 
Production of a Series of Mouse Strains with 
Different Pnon Protein Gene Alterations 
Richard C. Moore, Nicola J. Redhead, Jim Selfridge, James Hope', Jean C. Manson' and David W. Melton* 
Institute 01 Cell and Molecular Biology. University of Edinburgh, King's Buildings, Mayfield Road. Edinburgh EH9 3J R Scotland. 'BBSRC and 
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We have developed a double replacement gene targeting strategy which enables the production of a 
series of mouse strains bearing different subtle alterations to endogenous genes. This is a two-step process 
in which a region of the gene of interest is first replaced with a selectable marker to produce an inactivated 
allele, which is then re-targeted with a second vector to reconstruct the inactivated allele, concomitantly 
introducing an engineered mutation. Five independent embryonic stem cell lines have been produced 
bearing different targeted alterations to the prion protein gene, including one which raises the level of 
expression. We have constructed mice bearing the codon 101 proline to leucine substitution linked to the 
human familial prion disease, Gerstmann-Straussler-Scheinker syndrome. We anticipate that this pro-
cedure will have applications to the study of human inherited diseases and the development of therapies. 
Received 24 MO/C/i 1995; w'cep/eI 28 June 1995. 
M
ouse models for human inherited diseases and 
familial cancers can be produced by gene target-
ing in embryonic stem cells. The models can he 
used to study the relationship between the genetic 
lesion and the development and progression of 
disease at the molecular, cellular, and whole 
animal level, to enhance the effectiveness of drug 
development programs, and to evaluate gene therapies (see 
ref. I for a review of gene targeting). 
When DNA is introduced into mammalian cells, it pre-
dominantly integrates at random. In gene targeting, homolo-
gous recombination between an introduced vector DNA and 
the chromosomal target locus is used to make alterations to 
individual mammalian genes. The process is inefficient, so a 
range of selective techniques have been devised to facilitate 
identification of gene-targeted clones2. If targeting is carried 
out in cultured mouse embryonic stem (ES) cells, then strains 
of genetically modified mice can be produced. ES cells are 
derived from the inner cell mass of mouse blastocysts. They 
can be cLtltLtred for extended periods in vitro and still retain 
totipotency so that, when reintroduced into a host embryo, 
they will contribute to development, leading to the production 
of a chimeric animal. If ES cells contribute to the germ line 
of the chimera, then ES cell-derived strains of mice can 
be established-'. 
Targeted gene inactivation (gene knockout) has been used 
to produce mouse models for a range of human genetic defi-
ciency diseases'-'. However, the generation of models for 
many human diseases requires more subtle gene alterations. 
For example, the most common cystic fibrosis mutation. 
SF508, is due to deletion of a single phenylalanine codon 
from the CFTR genes,  while the majority of prion protein 
(PrP) gene mutations associated with inherited transmissible 
prion disorders are single nucleotide substitutions. 
Prion diseases in humans are unique in that they can have 
an etiology which may be both genetic and infectious. 
Although most cases are sporadic, a subset are familial, 
being inherited in an autosomal dominant manner, and 
include familial Creutzfeldt-Jacob disease (CJD), Gerstmartn-
Straussler-Scheinker (GSS) syndrome, and Fatal Familial 
Insomnia. While the majority of sporadic CJD cases are not 
associated with any known genetic lesion, the familial forms 
of these fatal late-onset neurodegenerative disorders are  
tightly linked to more than a dozen different point mutations 
and octapeptide repeat expansions in the PrP gene'". In addi-
tion, PrP polymorphisms are known to modulate many 
features of these diseases in humans and mice: a codon 129 
Met/Val human PrP polymorphism influences the suscepti-
bility to sporadic CJD'' and can influence the phenotype 
of familial prion diseases". Polymorphic residues at codons 
108 and 189 in the mouse PrP protein are associated with 
different experimental scrapie incubation times between 
inbred mouse strains" ''. 
To investigate the role of PrP mutations and polymor-
phisms in prion disease etiology in particular and to facilitate 
the construction of mouse models of genetic disorders in gen-
eral, it is important that current gene targeting technology be 
extended to enable the introduction of subtle alterations. Two-
step gene targeting procedures have previously been devised 
to make subtle gene alterations, and some success has been 
achieved with the "hit and run" method 15,  which involves the 
targeted insertion of a vector containing the gene alteration, 
followed by resolution of the resulting gene duplication by 
intrachromosomal recombination, to leave the alteration 
behind. This method suffers from two disadvantages. First, 
there is no control over the site of the second intrachromoso-
mal recombination, with the result that the alteration, rather 
than the endogenous sequence, is often lost and the locus is 
left unmodified. Second, the whole process must be repeated 
for every individual gene alteration to be introduced. We have 
developed an alternative procedure, termed double replace-
ment, which does not suffer from these disadvantages, and 
have used it to produce mice expressing the human, rather than 
the mouse form of the milk protein, a-lactalhumin". Here we 
demonstrate the flexibility of the method by showing how, 
from a single initial targeting event, double replacement can 
be used to generate a series of mouse strains with different PrP 
gene alterations. 
Results 
Double replacement gene targeting. A double replace-
ment strategy in the HPRT-deficient cell line. HM- I (ref. 17) 
was used to introduce subtle alterations into the PrP locus 
(Fig. 1): in the first step, the entire PrP coding region, located 
in exon 3, was deleted and replaced with an HPRT minigene, 
generating an inactivated allele and conferring a HAT selec- 
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table phenotype. Provision of a Herpes simplex virus thymi-
dine kinase (HSV-TK) gene at the 5' terminus of the inactiva-
tion vector enabled gancyclovir counter-selection and 
enrichment for homologous recombinants. The second step 
re-targeted this inactivated allele, replacing the HPRT mini-
gene with exon 3 sequence and giving rise to a 6-thio01.1anine 
resistant (6-TO') phenotype. Reconstitution of the inactivated 
locus results in a PrP allele indistinguishable from the wild-
type allele, with the exception of the introduction of the 
intended mutation. Multiple second steps were used to con-
struct live ES cell lines bearing different PrP alterations. 
Targeted inactivation of the PrP gene. Following dcc-
troporation of HM- I cells with the inactivation vector, ES cell 
colonies surviving HAT and gancyclovir selection were 
screened by PCR for a targeting-specilic product ol 2.28 Lb. 
Fourteen of 72 colonies gave the targeti ii(,-spcci lie hand and 
positive clones identified by this method were further charac-
terized by Southern analysis (sec Figs. 2 and 3): BamHI diges-
tion and hybridization to a 3' PrP probe yielded a 9.1 kb 
fragment from the inactivated allele in addition to the 8.5 kb 
band derived from the wild-type allele. BamHI-Xhol diges-
tion and hybridization to this probe yielded a diagnostic 5.2 kb 
band from the inactivated allele, in addition to the 8.5 Lb hand 
from the wild-type allele. The 5.2 Lb band is due to the tar-
geted introduction of a novel XhoT site, present in the HPRT 
minigene, into the Pr!' locus. 
Two independent knockout clones were chosen for blasto-
cyst in,ection. Both gave chimeras which transmitted the inac-
tivated allele to their offspring (Table I ). Mice heterozygous 
for the inactivated allele have been crossed to produce PrP 
null animals. 
Generation of subtle PrP gene alterations. Selection for 
the replacement of the HPRT minigene with altered PrP 
sequences was achieved in 6-TG. Prior to the second round of 
targeting, PrP knockout clones were taken out of HAT selec-
tion, grown non-selectively for live clays and then plated in 
6-TO to assess the spontaneous level of 6-TO". Clones 
selected for second step targeting had a spontaneous 6-TG` 
frequency of < 10 ". Following electroporation with the 
second-step targeting vectors, the PrP coding region from 
surviving 6-TO" clones was amplified by PCR. PCR prod-
ucts were analyzed for the appropriate RFLP to detect intro-
duced alterations. 
Detection of targeted PrP allele containing 101Leu. The 
codon 101 point mutation changes CCC-Pro to CTC—Leu. 
creating an additional Ddel site within the PCR product from 
exon 3 (Fig. 4). Eighty-four clones were screened by this 
method and 10 showed the pattern expected for cells contain-
ing one normal PrP allele and one targeted allele containing 
the 101 LeLI mutation. Southern analysis of these targeted 
clones gave the expected wild-type pattern (Figs. 2 and 3). 
One second-step targeted clone containing the 101 Leo allele 
was used for blastocyst injection and chimeras transmitting 
the mutant allele were obtained (Table I ). Mice containing the 
101 Leo allele will be investigated as a model for the human 
prion disease, 055. 
Detection of a targeted allele containing 101Leu and 
the SV40 enhancer. As an initial screen for the replacement 
of the inactivated allele using the p055101 Leu-SV40 vector. 
sixty 6-TO" clones were screened for the codon 10! Leu niuta-
tion (which should he integrated together with the 5V40 
enhancer). Fourteen were bound to he positive and the 5V40 
enhancer was shown to be present in all of these clones by 
PCR with SV40 primers. The structure of the targeted allele 
was confirmed by Southern analysis: the 5V40 enhancer con-
tains an Split site. resulting in a 5 Lb targeting-specilic band 
when hybridized to the PrP coding probe (Figs. 2 and 3d). 
. 	—.....................,_ .., 	•-:. 
EXON3 
STEP 1. 	•-- KNOCKOUT VECTOR 
4 - 
Lee- - 	---- 
+ 
u 	•...................  Null 
101 Leu 
STEP 2. -_.._.c+_.1-  ALTERATION VECTOR 
101 I-eu * 	* ALTEREDG — 	ENE C2SS model 
or 2. 	I 





ALTERED GENE experiments 
or 2. 	f •  IO8Phe -- 	 - ALTEGEDOENE 
or2. ......................AUrEREDGENE 
expression  
sr.LcIrflOu , HPRT'  Er - 2. 22111 	 P110 P011En 
I 21P000RS 	U P,PIIIR 	ffl SV400IKAIICER 
FIGURE 1. Double replacement gene targeting for the intro-
duction of subtle alterations into the mouse PrP gene. Use of 
the double replacement strategy in HPRT-deficient ES cells is 
illustrated. In the first step, the PrP coding exon is deleted and 
replaced with an HPRT minigene, leading to the production of 
PrP null animals. In the second step, a range of mouse lines 
with both subtle PrP coding and transcriptional alterations 
can be generated. The figure is not drawn to scale. The first 
two non-coding exons of the PrP gene are located -18 kb from 
Ul.11Pr2 pIlll I'POIKJ ,s , 4V 
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62 3.4 	Bst Eli 





5.2 " 	Barn HI! 
Xtroi 
<d' 5'\ 41  
505 LELJ :WILO TYPE SOUTHERN +OdeI PCRRFLP 
IORPFIE:WILDTYPESOUTHEIVN ASO SIGNAL 
189 VAL ALLELE 	
1— 9.6 	Bsl Eli 
SV40 ENHANCER 5.0 	Sph I 
FIGURE 2. PrP gene structure in wild-type and targeted lines. 
The structure of the endogenous PrP locus in 129/Ola mice, 
the inactivated allele and corrected alleles bearing various 
mutations are shown schematically, using the same conven-
tions as in Figure 1. The location of probes and the sizes of 
restriction fragments detected in Southern blotting analysis of 
the different alleles are indicated. ASO, allele-specific oligonu-
cleotide hybridizing to the 10813he allele. 
TABLE 1. Gene targeting and germ line transmission frequencies. 
Germ Line Transmission 
PrP Alteration 	Targeting Frequency 	Frequency' 
Knockout 	 14/72 	 4/7 
I) t Lea I 0/84 3/3 
108Ptie- I 8OVaI 	 4/60 	 /4 
l8OVaI 	 4/72 5 
I 08Phe 6/50 
SV4O- 101 Leu 	 8/60 	 ND 
NLIITIber ii) targeted clones containing the IIierLIli,)Il ill the I)0j)LIkIti0Il  
51115 is ag ieIectiOII/tOtiII iiuiuher Of clones screened. "Number ol 
chinteras giving germ line transmission of' the targeted altele/totat 
number, tested. Under test. ND = Not determined. 
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FIGURE 3. Southern analysis of targeted ES lines. (a) BamHl 
digest, 3' PrP probe. Lanes: HM-1, non-targeted ES cell line; ., 
knockout cell line with one PrP allele inactivated; 101Leu, 
108Phe-189Val, 189Val and 10813he, cell lines containing the 
codon alteration(s) specified. (b) BamHI-Xhol digest, 3' PrP 
probe. (c) BstEll digest, coding region probe. (d) SphI digest, 
coding region probe. 5V40-101Leu, cell line with one PrP 
allele containing an SV40 enhancer element and the 101Leu 
mutation. 
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FIGURE 4. Detection of codon 101 Leu targeted allele. (a) Ddel 
restriction map of PCR products from a wild-type PrP coding 
exon (1 01 Pro) and an allele containing the 101 Leu mutation. 
Arrows indicate PrP primers. (b) Uncut and Ddel-digested 
PCR products from PrP wild-type (HM-1) cells, PrP knockout 
(.) cells and cells with one PrP allele containing the 101 Leu 
mutation (101 L). 
Expression of 101Leu alleles. Northern analysis of ES 
cell RNA is shown in Figure 5a. Comparison of the relative 
abundance of the 2.1 kb PrP mRNA shows the expected halv-
ills in the knockout cell line compared to HM- I and restora- 
tion in the 101Leu cell line. The 101Leu-SV40 cell line con-
tained an elevated level of PrP mRNA. Figure Sb shows the 
same filter reprohed with mouse a-actin, confirming the 
matched loadings of total RNA. To demonstrate expression 
from the 101 Leu alleles, eDNA was synthesized and ampli-
fied using primers from mouse exons 2 and 3. PCR products 
were definitively generated from eDNA, rather than any 
genomic DNA contaminating the RNA preparation, because 
the primer positions are separated by approximately 18 kb of 
intron 2 in the gene. Figure Sc shows the 854 hp PCR prod-
uct digested with Ddel. Densitometry indicated equal expres-
sion of the wild-type (657 bp fragment) and 101 Leu alleles 
(514 hp fragnient) in the 101 Leu cell line. In the 101 Leu-
SV4O cell line. densitometry indicated a two-fold increase in 
the level of expression of the mutant allele above wild type. 
Detection of targeted PrP alleles containing codon 108 
and 189 alterations. The detection of different combinations 
of codon 108 and 189 alterations required a coupled screen-
ing method for determining the ES cell PrP codon 108-189 
haplotype of potentially-targeted colonies. PCR product from 
exon 3 (1,327 bp) was first digested with Bst Eli to screen for 
the codon 189 ACC to GTC alteration, which results in loss 
of a unique BsIEII site and the substitution of Thr with Val 
(Fig. 621). In each lane it can he seen that the wild-type allele 
is digested into 630 hp and 697 bp fragments. This acts as an 
internal control for BstEIi digestion. but also allows spatial 
separation of wild-type from targeted allele, to enable the 
demonstration of tile physical linkage of both alterations in the 
I O8Phe- I 89Val targeted allele. The PCR product derived from 
the I 89Val allele does not digest, resulting in three bands: 
630bp and 697hp from the wild-type allele and 1327 bp from 
the I 89Vai allele. The codon 108 CTC to TTC alteration, 
resulting in the substitution of Leu with Phe, was readily 
detected by allele-specific hybridization to a radiolabeiled 
I O8Phe ol igonucleotide (Fig. 6h). 
Detection of the 108Phe-189Val allele. Four of the 60 sur-
viving 6-TG' colonies contained the targeted I O8Plle- I 89Val 
allele in addition to the normal I O8Leu- I 89Thr allele. 
Southern analysis indicated the predicted gene structure, with 
the I 89Val alteration leading to the loss of the BstEll site in 
exon 3 and the generation of a novel targeting-specific band of 
9.6 kb (Figs. 2 and 3c). 
Detection of the 189Val allele. Four of 72 colonies 
screened by PCR had undergone the targeted alteration to 
codon 189, as indicated by loss of a BstEII site on one allele 
(Fig. 621). Southern analysis confirmed this (Fig. 3c). 
Detection of the 108Phe allele. Six of 50 colonies surviv-
ing 6-TG selection had the targeted single nucleotide alter-
ation to codon 108Phe and hybridized to the 108Pile 
oligonucleotide (Fig. 6b). The predicted structure of the tar-
geted allele was confirmed by Southern analysis (Fig. 3c). 
Chimeras have been produced from ES cells containing the 
different codon 108 and 189 alterations. Germ-fine transmis-
sion has been achieved from one I O8Phc- I 89Val chimera. 
while other chimeras remain under test (Table I ). 
Discussion 
We illustrate here a double replacement gene targeting 
strategy and show that multiple subtle alterations call be 
rapidly introduced into a gene of interest. This enables a 
strategic approach to gene targeting programs. It is possible to 
first generate a null mouse to investigate gene function and/or 
to generate a model ofa gene deficiency disorder, and then tar-
get single amino acid or nueleotide alterations into a gene, 
enabling the construction of mouse models of human disor-
ders arising from single anlino acid/nucleotide substitutions. 
This method call also be used to manipulate the level of endoge- 
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nous gene expression. 
The use of gene targeting for the construction of mouse 
models of human prion diseases has a number of advantages 
over pronuclear injection. The latter method is reliant upon 
gene addition, giving rise to the multiple copy insertion ol 
transgenes which are susceptible to chromosomal position 
effects and often results in over-expression. Conventional 
transgenesis has been used to great effect to investigate many 
features of experimental murine scrapic2". However, the 
recent observation that over-expression of wild-type prion 
protein is pathogenic' suggests that gene targeting is more 
appropriate for the investigation of some aspects of prion dis-
ease. A previous conventional transgenic GSS mouse model" 
displayed some of the neuropathology of GSS and suggested 
the pathogenic nature of the Pro 101 to Leu mutation, however 
these mice over-expressed mL!tant prion protein eight-fold and 
were of mixed genetic background. We have constructed an 
inbred mouse strain bearing a gene targeted codon 101 Pro to 
Leu substitution in an attempt to generate a model for human 
GSS in a mouse expressing normal levels of mutant prion pro-
teir in a controlled genetic background. 
Past difficulties in generating it mouse model for 
Alzheimer's disease using pronuclear injection and other 
methods have led us to view the use of targeted mouse mod-
els as potentially a more flexible approach. Although recent 
work with mice overexpressing mutant APP V7 I 7F has 
demonstrated some of the characteristic neuropathology of 
Alzheimer's', it is currently unclear whether overexpression 
of genes bearing mutations is a general prerequisite for neu-
ropathology in a short-lived species such as the mouse. Over-
expression has certainly provided much biologically useful 
information-- . ThLis, we have also developed a means to 
increase expression of mutant PrP protein alleles. The targeted 
101 Leu allele was expressed at a similar level to the normal 
allele and the targeted incorporation of the SV40 enhancer 
resulted in an approximately two-fold increase in expression 
of the 101 Leu allele in ES cells. While the enhancer effect is 
comparatively modest in undifferentated ES cells (the pool-
function 
r
 of viral enhancer elements in ES cells is well estab-
lished), higher expression may occur in the tissues of any mice 
generated from these ES cells. Targeted introduction of 
enhancer elements into an endogenous locus will enable over-
expression of a given gene, further diminishing the demarca-
tion between gene targeting and conventional transgenesis by 
pronuclear injection. 
Targeted gene replacement can he achieved in a single step 
by cotransfer of the altered gene and a positive selectable 
marker""'. However, this neccessarily results in the retention 
of the marker gene adjacent to the gene replacement. which 
cannot he considered a subtle gene alteration and could have 
unforeseen consequences on the expression of the altered 
gene. The same criticism applies to a two-step targeting pro-
cedure involving HPRT selection termed "plug and socket"". 
Alternative two-step procedures are required for the pro-
duction of mice with sLibtle gene alterations. The first of these 
to be described, involving insertion of the targeting vector 
and subsequent excision, has been termed "hit-and-run"'. or 
"in-out". Here a targeting vector carrying the desired gene 
alteration first inserts into the target locus, resulting in a partial 
gene duplication. In the second step, the duplication is resolved 
by an intrachromosomal reconibination, ideally restoring the 
locus to its original state, apart from the retention of the sub-
tle alteration. A variety of individLial ES cell lines hearing a 
single subtle alteration at a particular locus have been pro-
duced by this technique" '', and in one case, mice have also 
been generated. The method does, however, suffer from two 
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FIGURE 5. Expression of PrP targeted alleles. (a) Northern 
analysis with PrP coding region probe. Lanes: HM-1, non-tar-
geted ES cell line; ., knockout cell line with one PrP allele 
inactivated; 101Leu and SV40-101Leu cell lines. (b) a.-actin 
probe on the above filter. (c) Ddel-digested PCR products from 
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FIGURE 6. Detection of codon 108 and 189 targeted alter-
ations by BstEll digestion and allele-specific oligonucleotide 
hybridization to PCR products from ES cell DNA. (a) Uncut 
and BstElI-digested PCR products. Lanes: HM-1, non-targeted 
cells, both alleles encoding 108Leu and 189Thr; 10813he-
189Val, 189Val, 108Phe, targeted cell lines with one allele con-
taining the alteration(s) indicated in addition to a second wild 
type, 1 O8Leu-1 89Thr allele. (b) Allele-specific hybridization of 
the gel shown in panel (a) with an oligonucleotide specific for 
codon 108Phe. 
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second, intrachromosomal recombination event, resulting in 
the frequent loss of the introduced altered sequence. rather 
than its endogenous homolog. and leaving the locus unmodi-
fied: secondly, a completely new round of targeting is required 
for each subtle gene alteration to be introduced. 
The alternative two-step method that we have employed 
here, double replacement by selection for gain and loss of 
HPRT expression in HPRT-deficient ES cells, was first pro-
posed by Reid et al:. We have previously exploited this 
method, utilizing the very efficient HPRT selective systems, 
to produce mice with an a-lactalhumin locus inactivated by 
deletion and, in the second step, mice expressing human 
w-lactalbumin from the marine locus". An equivalent double-
replacement strategy, using the less efficient nco-TK marker 
for double selection, has also been described "' and, in one 
case, animals containing the subtle alteration have been pro-
duced. The double-replacement strategy employed in this 
laboratory and also in the Jaenisch laboratory" involves the 
deletion of part of the target locus in the first step. This maxi-
mizes the likelihood that a complete null phenotype will he 
exhibited in animals produced from ES cells tai'geted in the 
first step, rather than the retention of partial gene activity 
which can sometimes result from conventional insertional 
mutagenesis. In the sitLiation described here, the entire PrP 
coding region was deleted. The key advantage that follows 
from this strategy is the imposition of control over the site of 
the homologous recombination occurring during the second 
targeting step, to maximize the likelihood of the alteration 
being introduced. In this case, the PrP coding region was 
deleted in the first step so, in the second step, there was no 
possibility of recombination between endogenous and vector-
derived PrP coding sequences resulting in gene targeting 
Without the introduction of the PrP alteration. Valuable as 
the above features are, the main attraction of the double-
replacement method is that it can be Lised, from a single initial 
targeting event, to generate a series of mice with different 
subtle gene alterations. Here we have realized that potential. 
The site of linearization of the inactivation vector was 
observed to affect the degree of gancyclovir enrichment in the 
positive-negative strategy employed in the first targeting step. 
Optimal enrichment was achieved following vector lineariza-
tion at a site which ensures that HSV-TK 5' sequence is not 
exposed to exonucleolytic attack. Selection for 6-TG' is the 
basis for the second targeting step in the double-replacement 
strategy. A high level of spontaneous 6-TG" in PrP knockout 
cells from the first step would make it harder to identify 
second-step clones. Such 6-TG" could arise from a carry-over 
of parental HPRT-deficient HM-1 cells during growth of the 
HAT" (HPRT-expressing) knockout clones", or from physical 
loss, or loss of expression of the HPRT minigene at the inac-
tivated PrP locus. Only knockout clones showing a sponta-
neous 6-TG" frequency of <10" were used for the second 
step. Despite this precaution only a fraction of the 6-TG" 
clones generated in the second step contained the desired 
alteration. Of the remainder, some retained HPRT minigene 
sequences, while others were indistinguishable from starting 
HM- I cells and could have arisen either by carry-over or gene 
conversion. A similar situation has been observed in previous 
double-replacement targeting' "". We consider, however, that 
the ability to identify five different subtle PrP alterations, while 
screening only small numbers of clones is proof of the general 
utility of the method. 
Experimental Protocol 
Isolation of isogenic DNA. Cloned PrP sequences from HM- I cells 
(derived from the 129/01a strait) were obtained by screening a genomic 
DNA library (a gill from T. Magin) with a I. 1 Lb Sum I-Eco RI exon 3 
fragment from mouse strain NZW". An 8.5 Rh Ban, HI fragnient span- 
ning exon 3 'a as cloned into pBTII SK(+), to give p 129 PrP. All PrP 
sequcilce in the tareeting vectors was derived from this construct. 
Mutagenesis. A 934 bp KpnI EcoRI exon 3 fragtneiit, contain-
ing most of the PrP coding legion, was cloned into Ml 3mp 18 
to 	generate a convenient mutage nes is cassette. UI igon Licleot ide- 
di reeled mutage nesis - was carried out using a M ula-gene M I 3 Kit, 
Version 2 (B ioRad ). Mutant coding regions were sequenced to confirm 
the pres-cricc of only the desired alteration(s) and used to construct 
the replace-ment targeting ectors (see below). The oligonucleotides 
used to introduce the mutations were as follows: codon It) I Pro 
to Lei (GGAACAAGCTCAGCAAACCA). codon 108 Len to Phe 
(CCAAAAACCAACTTCAAGCATGTGGC) and codon 189 Thr to Val 
(GCAGCACACGGTCGTCACCACCACCAAGGG ). Oligonucleotides 
were dens ed from sense strands, with the alterations underlined. 
Construction of targeting vectors. The knockout sector was con-
structed in three steps. lit the first step. a 1.8 Lb Pstl-EcoRI restriction 
fragment and a 3.7 Lb EcoRl -EcoRV restriction fragment, serving as 5' 
and 3' flanking PrP honiol ogous sequences respectively, were ligated 
together into Pst I/EcoR\' linearized pBTl I SK(+). to produce Vector A. 
An HPRT minigene. PGK/pDWM I ", isolated as a 2.7 Lb EcoRl frag-
ment. was then inserted into the EcoR I site between the two regions of 
homology in reverse orientation with respect to the PrP promoter. Finally. 
an H SV-TK gene'' was inserted as a Not I- Barn HI frallinein flanking the 
5' PrP homology (Fig. I ). The completed 13.2 Lb knockout sector has a 
unique Cl al site, for Ii lean/at ion poor to elect roporation . The exon 3 
replacement vectors were constructed from Vector A, p1 29PrP and the 
mutageilesis cassette. Initially the region of 5' homology was excised 
from Vector A by BamI-I I I(eoR I digestion. The replacement vector was 
reconstructed from the residual Vector A backhoi,e, plus it 3.2 Lb Bar,tHI-
Kpn I 5' homologous fragnient. derived from p I 29PrP. and the K pn I-
[cuRl mutagenesis cassette in a single step ligation. Essentially 1)1 291'rI' 
is reconstructed with the mutation of interest included and a 0.7 Rh 
EcoRV- Bain -II 3' terminal fragment excised. The Ii neari sat ion site  of 
the I I .3 kb replacement plasm ids was also Clal. A replacement vector 
containing the S V40 enhancer was also constructed. Primers, 
CCGGAATTCCTGGTTGCTGACTAATTG AGAT. with an [cuR I 
restriction site or the 5' end and CCCTAAGCTTCCAGC'TGTGGAAT-
GTGTGTCAGTTA, with a Hind III restriction site lor the 3' end of the 
72 hp repeat legion were used to amplify the SV40 enhancer. The cycle 
conditions (25 cycles) used were: 30 sees ,it 94°C. 30 sees at 66"C and 
3(1 sees at 72''C. The 5' B aml-I I Kpn I region of homology from p I 29PrP 
was cloned into pBTI I SK(+). and the S VII) enhancer was cloned into 
the unique EcoRl-HimmdIII sites to replace an 100 bp region ofintron 2 
(Fig. I ). The 5' region of homology containing the SV40 enhancer was 
then used for replacement sector construction as above. Five replace-
ment vectors were produced by the cloning method described above: 
pGSS 101 Leu, 	1 OSPhe- I f)9Val. 	1 f(9Val. 	1 OSPhe and pGSS If) I - 
SV4O. 
ES cell culture. The isolation  and culture conditions of the HPRT-
deficient ES cell line, HM- I. have been previously described'".  
Gene targeting. St 	I: Pr!' gnu' inaciiraiion. HM- I cells (5)< 107 ) 
were electroporated with 200 p.g I inearised knockout targeting, vector 
DNA in 0.8 ml HEPES-phosphate buffered saline at pH 7.05 )BioRad 
Gene Pu I set, Sfft) V.3 1iFd) and then incubated at room temperature for 
10 mins. Cells were plated at 5 )< 10'. 2.5X 10' and 1.25 X  0' cellsl90mni 
dish. Twenty four hours later HAT selection for HPRT expression was 
imposed. Four days after electroporation. counterseleclion ( gancyelovir. 
2 tM) was added to some dishes. Surviving colonies were fixed and 
stained, or isolated I  days after electroporaiion. Targeted clones hearing 
the predicted gene structure were used for second step eleetroporations 
and for blastocyst injection to generate PrP null mice. Prior to the second 
step, knockout cells were removed from HAT selection. Step 2: inlroduc-
tim, of tubule olteroiio,,v. Knockout cells (2.5 Xl)) (cells were electropo-
rated as previously with the voltage at 850 V and plated at 4X 10' cells/75 
ciii: flask. Cells were grown for seven days (passaging once) before plat-
ing at 1-2>( ID' cells/90 mm dish in medium containing 5/ml 6-TG. .ng  
Surviving colonies were isolated twenty one days alter the second dee-
troporation step. 
PCR screening for targeting events. Half the cells (100-1000 cells) 
from surviving colonies were used to prepare DNA for all PCR analyses". 
All PCR conditions were those recommended by the suppliers (Gibeo 
BRL). (i) Deteciio,i of PrP knockout: the primers used to amplify the 
2.28 kh PCR product specific for the PrP coding legion replacement 
by HPRT minigene were: AATCGCCACCTGCATTAGGG (introit 2. sit-
uated in the 80 hp Barn Ht-PsiI fragment, 60 hp doss nsf ream of the 5' Barn 
HI site of pI29PrP) and AGCCTACCCTCTGGTAGATTGTCG (located 
Within exon 9 of mouse HPRT eDNA sequence. positions 942-965, 
Genbank accession number J00423) (see Figure I). The cycle conditions 
(10 cycles) were: I min at 94'C, I inin at 67°C. 2 roin at 
72°C ( Umn igene. Hyt,aid ). (ii) Detection of sit/tile a/Ic/s 000.1: the 
primers used to amplify a 1,327 bp region of the PrP coding exon were: 
GATGTCAAGGACCTTCAGCC (introit 2. positions 38-57 from 
NZW sequence, Geihink- accession number M18070) and TTGC-
CTTCAATCAGCTATCG (exon 3. 3' untranslated region of PrP gene. 
positions 1290-1271 from NZW PrP eDNA. Genhank accession number 
M 3685). The cycle conditions (35 cycles) were: 30 sees at 94°C, 30 sees 
Lit 65 °C. I in in at 72'C. (iii) !)etei-tiotm a! S V40 viral eli//am -er veqiuiice 5: 
the primers and conditions used to detect the enhancer sequences were the 
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same as those used originally, except that 35 cycles were used. 
Allele-specific oligonucleotide hybridization. DNA from ES cell 
colonies was amplified as described above, di pested with B 51 [II, dcc-
trophoresed on it 1.51h, agarose gel and Southet'n transferred to 
Gertcscreen P1 us membrane (New England Nuclear). The Inter was 
prehybrided br 2 hours at 37'C (in IS ml of 6 x SSC, S x Denhardt's 
S0106011. With 100 ig/nil denatured herring sperm DNA). I)) pmol of 
end-labeled (1') mLrtant ol igonucicotide specific or the codon I O8Phe 
mutation. GCCACATGCTTGAAGTTGG was then added to the pre-
hybridization solution. Alter 1-2 hoLrrs of hybridization. the filters 
were rinsed in 6 x SSC at room temperature and, as it control for load- 
i ng and transfer variation between PCR samples, au toradiographed for 
I 5 mins to I hour prior to high stringency washing. Filters were then 
washed at allele-specific stringency: twice or 5 mitts each at 67"C in 
6 x SSC and then autoradiographcd at room temperature for 15 mills to 
I hour. 
Southern hybridization. Ge itomic DNA was prepared and Southern 
hybridization carried out as described". A 0.7 kb EeoRV-Band-1 I restric-
tion fragment front the 3' terminus of the 8.5 kb BamHl fragment 
(3' probe), and it 1.1 kb Smal-EcoRl restriction fragment from the coding 
region of PrP (coding region probe), were used as profies. 
Northern hybridization. Total RNA was extracted from cultured 
cells" and Northern hybridiiation carried out as previously described' 
and reprobcd with mouse 0-actin cDNA. 
Reverse transcription. ID p.g of total ES cell RNA was reverse trait-
scribed as described", except that random hexamers (SOng) were included 
in addition to oligo dT. 
Detection of cDNA sequences. eDNA produced by reverse tran-
scription of total RNA was analyzed by PCR. The primers used were: 
GTCCAATTTAGGAGAGCCAAGC )exon 2. positions 63-84 from 
NZW Pt-P eDNA sequence. Genbank accession number M13685) and 
GCCTAGACCACGAGAATGCG (exon 3. positions 915-896 from NZW 
l'rP eDNA) to give a product of ((54 lip with cycle conditions (32 cycles): 
30 sees at 94'C, 30 sees at 65°C, I inin at 72'C. When this product is 
digested with restriction enzyme ])Lie I. it results in bands of 197 hp and 
657 bp. The 657 bp band containing the 101Leu mutation is further 
cleaved into hands of' 143 lip and 514 hp. 
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Prion diseases are fatal transmissible neurological disorders afflicting a range of mammalian species. Although 
still controversial, a large body of data suggests that the causative agent may be composed entirely of a 
small glycoprotein. The brains of infected animals have accumulations of a pathogenic protease-resistant 
isoform (PrPS9 of a normal host-encoded glycoprotein, PrPC  or prion protein. A number of lines of biochemical 
evidence implicate the disease-specific isoform, PrPSC,  as the transmissible agent and genetic analysis has 
shown tight linkage between PrP gene mutations and polymorphisms and differential susceptibility to prion 
diseases. Perhaps the strongest evidence for a protein-only model of the agent is that PrP gene-ablated mice 
are resistant to scrapie and that mice with a PrP mutation, corresponding to those found in a human familial 
prion disease, spontaneously develop a transmissible prion disease. This review describes the critical role 
that transgenic technology has played in the study of the biology of prion diseases and considers the issues 
raised by this work. 
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Introduction 
Prion diseases are transmissible degenerative disorders of 
the central nervous system and occur in a number of species 
(See Table I). Human prion diseases include Kuru (Gadjusek 
and Zigas, 1957), Gerstmann—Straussler—Scheinker disease 
(GSS; Gerstmann et al., 1936), Creutzfeldt—Jakob disease 
(CJD; Creutzfeldt, 1920; Jakob, 1921; see Creutzfeldt, 1989 
and Jakob, 1989 for recent English translations) and fatal 
familial insomnia (FF1; Gambetti et at., 1993). Kuru is an 
epidemic prion disease transmitted by cannibalism amongst 
the Fore tribespeople in the highlands of Papua New Guinea 
(Gadjusek, 1985). Kuru has been responsible for a large 
number of deaths since 1950, although the incidence of 
disease has declined markedly in recent years as a result 
of government intervention. Creutzfeldt—Jakob disease has 
several epidemiological manifestations: sporadic, familial 
and iatrogenic. Sporadic CJD has an incidence of 10 and 
an average onset age of 65 years. Approximately 10% of 
CJD cases (and all GSS and FF1 cases) are autosornal 
dominant familial disorders with linkage to mutations in the 
prion protein gene (See Table II; for review see Prusiner, 
1994). A small number of iatrogenic CJD cases have arisen 
as a result of transmission from contaminated neurosurgical 
instruments, dura mater grafts (Lane et at., 1994), cornea! 
transplants (Gadjusek, 1985) and contaminated cadaver-
derived pituitary growth hormone and gonadotrophin (Buch-
anan et at., 1991). In the UK, much interest has been 
generated by the possible association between consumption 
of BSE-infected food products and the recent emergence of 
an unusual variant of CJD (nvCJD), with an earlier age of 
onset and a novel clinico-pathological phenotype (Chazot 
et at., 1996; Will et at., 1996). 
The biological properties of the infectious agent 
Clinical signs and pathology of the prion diseases 
The effects of prion diseases are generally limited to the 
central nervous system (CNS). The clinical signs are variable 
but include progressive dementia, cerebellar ataxia and 
behavioural disturbances. Gross neuropathology can include 
reduced brain weight, cortical atrophy and enlargement of 
the ventricles. Histological abnormalities include bilaterally 
symmetrical spongiform degeneration of the neuropil, neur-
onal perikaryal vacuolation, conspicuous neuronal loss, 
amyloid plaques and astroglial hypertrophy (Bell and 
Ironside, 1993). A florid CNS microglial response has been 
described in CJD and scrapie, which may represent a 
modified form of inflammatory response (Ironside et at., 
1993; Williams et al., 1994). Widespread apoptosis has been 
described in the brains of sheep, mice and humans with 
these disorders and may be a major mode of cell death 
(Fairbairn et al., 1994; Giese et al., 1995; Lucassen 
et at., 1995). 
Prion diseases are transmissible following long 
incubation times 
The demonstration of scrapie transmissibility in 1936 (Cuille 
and Chelle, 1936) and subsequent transmission studies in 
sheep, goats and other animals established the main biological 
features of the scrapie agent. The response of all hosts, to 
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Table I. Transmissible spongiform encephalopathies 
Species Disease Comments Geographic Reference 
distribution 
Sheep Scrapie Field scrapie; experimentally transmitted to sheep, goats, Worldwide Cuille and Chelle, 1936 
mice, rats, hamsters and cattle (Gibbs et at., 1990). 
Mouflon Scrapie Naturally occurring case Wood et at., 1992 
Goat Scrapie Natural cases rare Cuille and Chelle, 1939; 
Pattison and Millson, 1960 
Mink Transmissible mink Infection in farmed mink; source of infection probably North America; Marsh and Kimberlin, 1975; 
encephalopathy scrapie infected offal. Experimentally transmitted to hamsters. Europe McKenzie St at., 1996 
Mule Deer Chronic wasting Infection of farmed deer probably from scrapie contaminated North America Williams and Young, 1980; 
disease feed. Experimentally transmitted to other deer. Williams et at., 1982 
Elk Chronic wasting Infection in farmed elk, probably derived from scrapie Williams and Young, 1982 
disease infected feed. 
Cattle Bovine spongiform UK BSE epidemic mostly in Holstein Friesian dairy cattle; UK; Republic of Wells et at., 1987 
encephalopathy scrapie contamination of feed. Experimentally transmitted to Ireland; Europeb 
mice (Fraser el at., 1992), pigs (Dawson et at., 1990), 
monkeys (Lasmezas et at., 1996) 
Arabian Oryxa Infection in a zoo specimen UK Kirkwood et at., 1990 
Nyalaa Infection in a zoo specimen UK Jeffrey and Wells, 1988; 
HMSO, 1987 
Greater Kudua Infection in a zoo specimen UK Kirkwood et at., 1990 
Eland' Infection in a zoo specimen UK Fleetwood and Furley, 1990 
Gemsboka Infection in a zoo specimen UK Jeffrey and Wells, 1988 
Domestic cat' Infection in domestic cats. Transmitted to mice (Fraser UK, Norway Wyatt et at., 1993; 
et at., 1994) 
Cheetaha Infection in a zoo specimen UK Bratberg et al., 1995, 
Puma' Infection in a zoo specimen UK Willoughby et at., 1992 
Human Creutzfeldt—Jakob Sporadic: 10-6  incidence; not associated with prion protein Worldwide Creutzfeldt, 1989; 
Disease (sCJD) (PrP) mutations. Experimentally transmitted to chimpanzees, Jakob, 1989 
monkeys, cats and mice 
iCJD latrogenic: transmission following neurosurgery, corneal Worldwide Gadjusek, 1985; Buchanan 
transplant and dora mater graft et at., 1991; Lane 
et at., 1994 
JCJD Familial: linked to mutations in prion protein (PrP); Worldwide for review, see 
autosomal dominant, some have variable penetrance Prusiner, 1994 
Gerstmann— Familial disorder tightly linked to mutations Worldwide Gerstmann et at., 1936; 
Scheinker— in the prion protein (PrP) Hsaio et at., 1989 
Straussler Syndrome 
Fatal familial Familial disorder linked to germline mutation in prion protein Worldwide For review see Gambetti 
insomnia (PrP) in association with a common PrP polymorphism et at., 1993 
Kuru Sporadic CJD spread and maintained by cannibalism; Papua New Guinea Gadjusek and Zigas, 1957; 
endemic to a remote highland region of Papua New Guinea. Gadjusek, 1985 
Experimentally transmitted to goats, primates and rodents 
CJD variant (nvCJD) Unusual CJD variant in UK (10 cases) and France (1 case) UK; France Will et at., 1996; Chazot 
with early onset (<42 years), unusual clinical presentation et at., 1996 
and neuropathology. Transmissibility to rodents not yet 
demonstrated 
1nfection associated with UK bovine spongiform encephalopathy (BSE) epidemic. 
6BSE cases in Switzerland, Portugal, Germany, Italy, Oman and Canada are associated with imports of UK derived feed and cattle 
= iatrogenic; s = sporadic; f = familial. 
inoculation by a variety of routes, is characterized by a 
long asymptomatic pre-clinical phase, which is followed by 
a short clinical illness and death. An intriguing feature of 
scrapie is that of the long incubation time and precise 
timing of disease onset: if inbred mice are given the same 
dose of agent by the same route, all die within days of 
each other following a prolonged incubation period of up 
to 1 year or longer (Scott, 1993). This has enabled the 
estimation of agent titre by incubation time interval assay 
(Prusiner et al., 1982b) and by endpoint titration (Dougherty, 
1964) in mice and hamsters. There is some evidence that 
this precise timing can be a feature of human prion disease; 
analysis of Kuru victims, whose illness is attributable to 
participation in a single cannibalistic funeral rite, has shown 
that such individuals can develop kuru within months of 
each other following an incubation period of 25-30 years 
(Klitzman et al., 1984). 
Agent propagation 
Following experimental inoculation with a small initial dose, 
the agent can propagate to very high titres, well in excess 
of the original inoculum. The distribution of infectious 
material is determined by scrapie agent strain and inoculation 
route. Following i.p. inoculation the agent first replicates in 
the local lymph nodes and spleen, then spreads to the CNS 
from the spleen via the splanic nerve and spinal cord 
(Elkund et al., 1967). Pathogenesis following intracranial 
inoculation usually results in replication first in the CNS 
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Table II. Human familial prion diseases associated with prion protein mutations 
Disease Mutation Onset/duration 
(years) 
Clinical features Neuropathology Reference 
1UJD 120 bp insertion 31-45/5-15 Dementia with myoclonus Spongiosis, neuronal loss and Goldfarb 
reactive gliosis et al., 1991a 
JD 144 bp insertion 22-52/1-13 Early personality changes Widespread atrophy with PrP Poulter el al., 1992; 
progressing to dementia with amyloid plaques Collinge et al.. 1992 
ataxia and myoclonus 
JCJD 168 bp insertion 23-35/>10 Similar to 144 bp insertion Widespread atrophy with Brown et at, 1992: 
spongiosis Goldfarb 
etal.. 	1991a 
JCJD 196 bp insertion 35-54/3 months-13 
year 
flTJD 216 bp insertion 55/2 
GSS Ataxic 102 Pro-Leu 15-40/2-10 
form 
GSS 105 Pro-Leo 42/9 
GSS 117Ala-Val 35/- 
Atypical 145Tyr-stop 38 yr/death 
Prion Disease [amber mutation] at 59 years 
ICJD I 78Arg-Asn/l 29Val 26-56/9-51 months 
haplolype 
FF1, Fatal 178Arg-Asn/129 Met 20-71/6-32 months 
Familial haplotype 
Insomnia 
CJD 	1 8OVal-Ile 









JCJD 	232Met-Arg and 
l8OVal-Ile 
Abnormal behaviour. ataxia. Widespread atrophy with mild Owen et al.. 1992 
mutism, myoclonus spongiosis. PrP amyloid plaques 
in cerebrum and cerebellum 
Single patient with ataxia. Goldfarb et al., 1992 
dementia and myoclonus 
Cerebellar ataxia, extra! PrP amyloid plaques in cerebral Hsaio et al., 1989 
pyramidal signs with late onset and cerebellar cortex, also in 
dementia white matter of basal ganglia 
and thalamus 
Clumsiness, gait disturbance, Kitamoto et al., 1993 
decline in intellectual function 
Dernenting form (telancephalic 
GSS): no cerebellar pathology. 
Ataxic form: widespread 
cerebellar pathology with PrP 
amyloid plaques 
Slowly progressive Alzheimer's- Numerous Kuru plaques and 
like disease in a single Japanese NFT*  but little spongiform 
woman change. Plaques contained only 
truncated PrP derived from the 
mutant allele 
Similar to sCJD Spongiosis of cerebral cortex, 
little thalamic pathology 
Untreatable insomnia, Minimal cortical spongiosis. 
hallucinations. dysautonomia. Selective thalamic atrophy; 
ataxia, myoclonus, extra/ neuronal loss and gliosis in 
pyramidal signs. Endocrine inferior olive 
abnormalities 
Similar to sCJD Similar to sCJD 
Similar to codon 102 mutation Similar to codon 102 mutation 
but with early dementia but with widespread 
Alzheimer's type NFT*  in 
cerebral cortex 
Similar to sporadic CJD Widespread spongiosis which 
Penetrance estimated at 0.56 extends to deep brain nuclei, 
cerebellum and brain stem. 
Incomplete penetrance. 
PrP amyloid plaques and 
occasional neocortical NFT* 
Two Japanese cases 	Typical sCJD pathology. 
with typical sCJD 
presentation 
Dohura et al., 1989; 
Mastrianni 
etal.. 1995 
Kitamoto et al., 1993 
Goldfarb 
etal., 1991b 
Goldfarb ci al., 1992; 
Gambetti et al., 1993 
Kitamoto ci al., 1993 
Hsaio et al., 1992; 
Dloughy ci al., 1992 
Goldfarb et al., 1990; 
Goldfarb 
et al., 1991c 
Pocchiari ci al., 1993 
Ikeda et of., 1991 
Kitamoto ci al., 1993 
5Neurofibrillary tangles. 
and later in other organs, although there are examples of 
strains which exhibit very little non-CNS replication until 
the clinical stages of disease (Farquar et al., 1996). A 
significant PrP gene dosage effect upon the rate (but not 
the distribution) of PrP accumulation has also been noted 
in transgenic mice (see below). 
There are multiple strains of scrapie 
There is heterogeneity in the clinical presentation of natural 
scrapie in sheep and this has been attributed to the action 
of distinct scrapie variants or strains (Pattison and Millson, 
1960), for example an isolate of sheep scrapie passaged in 
goats gave rise to two distinct clinical syndromes called 
'nervous' and 'itching' which could be serially passaged in 
goats, retaining their distinct biological properties (Pattison, 
1960). Transmission of sheep and goat scrapie to mice and 
hamsters has enabled the investigation and description of 
strain-specific differences in incubation time and neuropatho-
logy; the main characteristics used to differentiate scrapie 
strains. 
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Multiple strains of scrapie have been isolated, indeed 
field sheep scrapie isolates have been shown to contain 
mixtures of strains (Dickinson, 1976). More than 20 mouse 
and hamster-adapted scrapie strains have been catalogued, 
some of which have been cloned by several passages at 
high dilution (Bruce, 1993). Different isolates of human 
CJD brain material also give rise to distinct incubation 
times and pathology in inbred mice (Kitamoto et al., 1990), 
suggesting that different CJD strains exist within the human 
population. 
There is evidence that strain properties can be maintained 
irrespective of the species (and therefore PrP sequence) through 
which the agent is passaged (Kimberlin etal., 1989) and such 
phenomena are cited to support the hypothesis that the scrapie 
agent carries a nucleic acid genorne (Bruce, 1993). In contrast 
there are examples of dramatic alterations in strain properties 
(or 'mutation') when scrapie is passaged between species 
or between mice with different PrP alleles (host-dependent 
alterations). Paradoxically, this 'mutability' is also considered 
by some workers to be strong evidence that the scrapie agent 
has a nucleic acid genome. However there is no direct evidence 
for a nucleic acid component in the agent despite several 
decades of searching (for review, see Liberski, 1994). Indeed, 
artificial scrapie strains with altered host ranges, incubation 
time and neuropathology can be generated in mice with 
engineered PrP transgenes (Scott et al., 1993). Despite the 
undoubted role of PrP sequence differences in the generation 
and maintenance of strain diversity there remains sound 
evidence that distinct scrapie strains can be stably maintained 
in hosts with identical PrP sequences (Bruce et al., 1991; 
Kascsak et al., 1991; Hecker et al., 1992) and that strains with 
dramatically different host ranges (Kimberlin and Walker, 
1978) can arise from a single host species. This evidence, 
together with the insights gained from the use of transgenic 
mice are discussed later in this review. 
The biophysical properties of the agent 
Resistance to inactivation 
One of the earliest indications that the scrapie agent had 
unusual physical properties followed the infection of a large 
number of sheep which had received louping-ill vaccine, which 
was raised in a flock subsequently found to have scrapie. The 
contaminated vaccine retained infectivity despite prolonged 
exposure to formalin (Gordon et al., 1940), and it is now 
known that formalin pre-treatment can actually render the 
agent less susceptible to complete inactivation by autoclaving 
(Bell and Ironside, 1993). Subsequently, resistance has been 
demonstrated to boiling (Brown etal., 1982), UV260 nm (Alper 
et al., 1967), ashing at 360°C (Brown et al., 1990a) and a 
wide range of biocidal chemicals (reviewed by Gadjusek, 
1985). However, efficient agent inactivation can be achieved by 
phenol extraction, sodium hypochlorite and sodium hydroxide 
(Brown et al., 1990b). The resistance to UV260nn,  is good 
evidence that the agent is not reliant upon a nucleic acid 
moitey (Alper et al., 1967; Bellinger-Kawahara ci' al., 1987). 
Estimates of agent size 
The first estimates of agent size demonstrated that it could 
pass though bacterial filters (Wilson et al., 1950), suggesting 
viral dimensions. However, controversy still surrounds the 
issue of the size of the agent, because it is held that a small 
agent of sub-viral size might support a protein-only model of 
the agent. Various size estimates exist and range from 50-150 
kDa, being based upon a number of methods. The agent size 
has been calculated based upon its inactivation by ionizing 
radiation (Lea, 1955) and this experiment has been repeated 
13 times since it was first performed by Alper ci' al. (1966), 
with some investigators contending that the agent is within 
the range of small viruses (Rohwer, 1991), whilst others hold 
that it is of sub-viral size (Bellinger-Kawahara et al., 1987). 
The prion protein 
The discovery of the prion protein 
Rapid progress followed the discovery of unique scrapie-
associated fibrils (SAF) (Merz et al., 1981) and prion rods in 
infected brains (Prusiner et at., 1982a). SAF are composed of 
paired helical filaments of 100-1000 nm in length and are 
quite distinct in ultrastructure from prion rods which are 
heterogeneous 100-200 nm long flattened amyloid rods (Bolton 
et al., 1982). Prusiner et al. (1982a) enriched the scrapie agent 
100-1000-fold and found a protease-resistant protein (PrP) of 
27-30 kDa, co-purifying with infectious fractions. Prolonged 
proteinase K digestion was found to reduce the agent titre and 
this was mirrored by the digestion kinetics of PrP27-30, 
suggesting that this protein was a component of the infectious 
agent (McKinley ci' al., 1983). Further analysis of prion 
rods (Prusiner ci' al., 1983) and SAF (Hope et al., 1986) 
demonstrated that PrP27-30 was a major component of these 
structures and the in-vivo relevance of PrP27-30 was demon-
strated by the observation that antisera raised against PrP 27-30 
stained amyloid plaques in the brain of infected animals 
(DeArmond et al., 1985). 
Purification of hamster PrP27-30 to near homogeneity by 
detergent extraction, proteinase digestion and sucrose density 
gradient sedimentation enabled the N-terminal peptide 
sequence of PrP 27-30 to be determined (Prusiner etal., 1984). 
This led to the cloning of a 2.1 kb PrP cDNA from scrapie-
infected hamster brain (Oesch etal., 1985) and a 2.5 kb cDNA 
from a scrapie-infected mouse brain (Chesebro ci' al., 1985). 
It was subsequently found that both infected and uninfected 
animals have an endogenous gene encoding PrP27-30 (Basler 
et al., 1986). This demonstrated that PrP 27-30 is not the gene 
product of a conventional viral pathogen but is the product of 
an endogenous gene. PrP 27-30 was found to be derived from 
the full length form of PrP (33-35 kDa) by partial proteolysis 
during purification. Thus it became clear that both infected 
and uninfected animals contained a full length PrP but that 
PrP from diseased animals was resistant to protease digestion, 
whilst PrP from healthy animals was completely hydrolysed 
by mild protease digestion. Normal PrP was termed PrPC  and 
the infection specific-isoform was denoted by PrP. PrPSC 
clearly accumulates in the brains of infected animals, but PrP 
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mRNA levels do not change throughout the course of scrapie 
infection (Oesch et at., 1985), suggesting that the accumulation 
of PrPSC  during disease does not occur as a consequence of 
raised rates of transcription or alterations to mRNA levels, but 
from increased protein stability. This has been corroborated 
by in-vitro analysis of prion protein metabolism in scrapie-
infected mouse neuroblastoma cells, which shows that, whilst 
PrPC has a half life of 5 h, PrPsc has a much longer half-life 
(15 h) (Borchelt et at.. 1990) and accumulates within the 
cytoplasm (Taraboulos et at.. 1990). 
The prion protein, PrP 
PrPC is a cell surface glycoprotein expressed at highest levels 
in the brain and at lower levels in a number of non-neural 
tissues (Oesch et al., 1985), including heart, lung and kidney. 
The peptide backbone in all mammalian PrPC  molecules studied 
so far is 252-254 amino acids long and is modified by the 
removal of a 22 amino acid N-terminal signal sequence, 
following translocation into the endoplasrnic reticulum, where 
it is modified by the addition of complex N-linked polysaccha-
rides at two asparagine residues and a single intrachain 
disulphide bond (Turk et al., 1988), in addition to a sialated 
glycosylinositol phospholipid (GPI) anchor C-terminal (Stahl 
et at., 1992), to enable attachment of PrP to the cell surface 
(Stahl et al., 1987). 
Clearly the difference between PrP1  and PrP is critical to 
the understanding of prion diseases. These PrP isoforms differ 
with respect to resistance to protease digestion and PrP1c differs 
with respect to a number of biophysical properties such as 
solubility. However PrPsc does not differ from PrPC  by any 
known chemical post translational modification or amino 
acid sequence (Turk et al., 1988; Stahl et at., 1993). Other 
modifications such as protein splicing or editing have also 
been discounted (Stahl et at., 1993). However, there is good 
evidence that PrPc and PrPSC  differ in secondary and tertiary 
structure. Purification of PrPC  and PrPsc under non-denaturing 
conditions has enabled the structural comparison of normal 
and disease-specific PrP33-35 (i.e. full length PrPSC)  isoforms 
by circular dichroism and infrared spectroscopy. Both methods 
of analysis demonstrate that, whilst PrP' has low levels of 3-
sheet and high levels of a-helix, PrP1c is quite different in that 
it has lowered levels of a-helix and high levels of 3-sheet 
(Pan et al., 1993) and there is evidence that PrP" is an 
aggregated folding intermediate (Safar et al., 1994).These 
observations support the notion that conformational change is 
a fundamental event in the conversion of PrP' to PFPSC.  
Genetic evidence for the importance of the prion 
protein 
Although the role of genetics in the susceptibility to field 
scrapie in sheep had been recognized for some time, the 
transmission of scrapie to mice (Chandler, 1961) resulted in 
the discovery of a single autosomal gene, Sinc. Two alleles of 
Sinc exist, s7 and p7. Mice homozygous for these alleles have 
short and prolonged scrapie incubation times respectively with 
scrapie strain ME7 (Dickinson and Mackay, 1964; Dickinson 
et at., 1968), whilst heterozygotes have an intermediate incuba-
tion time. Sinc alleles also control incubation times with other 
scrapie strains, BSE and CJD isolates. However, the fact that 
the incubation time rankings of animals homozygous and 
heterozygous for different Sine alleles can be reversed with 
some strains (e.g. 22A and 301V) suggests that the relationship 
between Sinc genotype and incubation time is not simple 
(Bruce etal., 1991; Bruce, 1993). There is good evidence that 
the Sinc gene and the prion protein gene in mice are tightly 
linked (Carlson et al., 1986, 1993; Hunter et at., 1987) and 
may be coincident. PrP is also linked to the sheep Sine 
homologue, Sip (Hunter et at., 1989). Mice, hamsters and 
sheep with different experimental scrapie incubation times 
encode distinct prion proteins (Westaway et al., 1987; 
Lowenstein et al., 1990; Goldmann et al., 1994). Mice with 
different scrapie incubation times encode different PrP proteins 
(PrP-A and PrP-B), which differ with respect to codon 108 
and 189 dimorphisms (Westaway et al., 1987). However, the 
formal demonstration that Sine and PrP are identical and that 
these dimorphisms control incubation time is lacking. We are 
currently conducting scrapie challenge experiments on inbred 
Sine s7 129/Ola mice (Moore etal., 1995), in which the codon 
108/189 dimorphisms have been altered by gene targeting. 
This may formally resolve the issue of Sinc/PrP identity and 
determine the relative role of codons 108 and 189 in incubation 
time control. 
A common human prion protein codon 129 methionine/ 
valine polymorphism appears to influence susceptibility to 
sporadic and iatrogenic CJD (Palmer et al., 1991). Further 
evidence for the importance of the prion protein is provided 
by the existence of a number of human prion protein mutations 
which are linked to familial prion disease (See Table II). 
Differences in the frequency of field scrapie in sheep are also 
associated with common PrP gene polymorphisms (Goldmann 
et al., 1994). It is likely that some sheep polymorphisms 
behave like the human codon 129 met/val polymorphism and 
influence susceptibility to exogenous infectious agent. It is 
also possible that some sheep polymorphisms may be similar 
to the PrP mutations found in human familial CJD kindreds, 
i.e. some sheep PrP polymorphisms may give rise to sheep 
scrapie spontaneously in the absence of exogenous agent. 
The transgenic mouse as an experimental model 
of prion diseases 
The remainder of this review deals with the enormous contribu-
tion that mouse transgenesis has made to prion disease research. 
Transgenic mice expressing a variety of PrP genes have 
been generated by both conventional transgenesis (pronuclear 
injection) and gene targeting. The relative merits of each 
method of transgenesis have been elegantly exploited. For 
example, conventional transgenesis has been used to investigate 
scrapie incubation times in mice with different wild type 
hamster PrP gene copy numbers and therefore different PrP 
expression levels. This has identified the importance of gene 
dosage effects in the prion diseases. Gene targeting has been 
used to make PrP-ablated mice, which have demonstrated the 
absolute requirement of PrP expression to confer susceptibility 
to prion diseases and to enable prion propagation (Bueler 
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targeting to produce mice with point mutations in the absence 
of overexpression also promises to be very useful (Moore 
et al., 1995). Future experiments will enable the precise and 
controlled analysis of the effects of engineered PrP structural 
alterations on all features of the prion diseases. 
The species barrier effect arises from PrP amino acid 
sequence differences between species 
Transmission of scrapie between species can be very inefficient: 
typically the incubation time for the first passage is long and 
there may be survivors, but upon subsequent serial passage in 
the new species the incubation time shortens and stabilizes 
(Pattison and Jones, 1968; Kimberlin eral., 1989). The reason 
for the species barrier was unclear for some time, but it was 
apparent that transmission between closely related species such 
as Armenian, Syrian and golden hamsters is more easily 
accomplished than between more distantly related species. 
Minor differences in the prion protein sequence between these 
hamster species (Lowenstein et al., 1990) suggested that the 
species barrier is caused by differences between prion protein 
sequence. Syrian hamster scrapie strain Sc237 was used to 
investigate the hamster to mouse species barrier as it causes 
scrapie in - 77 days in Syrian hamsters, but has low patho-
genicity for mice which have an incubation time in excess of 
600 days (Marsh and Kimberlin, 1975). This effect was thought 
to be a property of the 16 differences in primary amino acid 
sequence between mouse and hamster PrP' and a number of 
transgenic mouse lines bearing the Syrian hamster PrP gene 
[SHaPrP] were constructed and challenged with hamster 
scrapie 5c237 to determine whether they became more suscept-
ible to hamster scrapie (Scott et al., 1989). These mice 
had dramatically accelerated incubation times (Figure 1) and 
exhibited neuropathology characteristic of hamster 5c237 
scrapie, which demonstrated that the species barrier was a 
manifestation of prion protein gene differences between 
species. 
Isologous host-inoculum interactions are favoured 
over heterologous interactions 
All of the mice used in the above challenges expressed 
endogenous mouse PrPC  in addition to transgenic hamster PrPC, 
but produced much larger quantities of hamster PrPc  than 
mouse PrP and also produced much higher levels of hamster 
prions than mouse prions following Sc237 challenge. However, 
if these transgenic mice were challenged with a mouse scrapie 
strain, the transgenic mice developed mouse scrapie and 
produced mouse PrPsc and prions which were more infectious 
to mice than hamsters despite expressing much more hamster 
PrP than mouse PrPC  (Prusiner et al., 1990). This was deter-
mined by immunoblotting with hamster and mouse- specific 
monoclonal PrP antisera and was corroborated by scrapie 
bioassay in non-transgenic mice, HaPrP transgenic mice and 
hamsters. This showed that these mice could propagate both 
mouse and hamster prions, but that the source of the scrapie 
inoculum determined whether mouse or hamster PrP and 
infectivity was generated. This suggests a direct interaction 
between PrPSC  in the inoculum and PrF in the host animal, 
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Figure 1. Transgenic analysis of the mouse-hamster species barrier. 
Brain levels of hamster host-encoded glycoprotein (PrP') in 
Syrian hamsters, non-transgenic mice and a variety of transgenic 
lines expressing different levels of hamster PrP'. Syrian hamster = 
SHa; Mouse = Mo; transgenic mouse bearing Syrian hamster PrP 
transgenes = T.-SHa. PrP levels expressed as j.lg/g brain protein. 
The relative position of each group is maintained throughout Figure 
la,b,c (adapted from Scott et al., 1989 and Prusiner et at., 1990). 
Hamster scrapie Sc237 challenge of hamsters, mice and 
transgenic lines. Syrian hamsters have a rapid incubation time of 
—77 days, whilst non-transgenic mice are resistant to infection. All 
transgenic lines are rendered susceptible to hamster scrapie, with an 
incubation time inversely related to hamster PrPC expression level. 
(C) Mouse scrapie challenge of hamsters, mice and transgenic lines. 
Syrian hamsters are resistant to mouse prions, whilst non-transgenic 
mice and transgenic lines readily succumb to mouse scrapie. 
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favoured over heterologous interactions. It is also notable that, 
following inoculation with a mouse passaged scrapie strain 
incubation times were sometimes slightly prolonged in mice 
which also expressed hamster PrP (see Figure Ic). One 
explanation for this is that non-productive interactions between 
transgene-encoded hamster PrPc and inoculum-derived mouse 
PrPSC slightly reduce the effective dose of mouse PrPSC  in the 
inoculum available for isologous interactions with endogenous 
PrPC i.e. an excess of heterologous hamster PrPC  molecules can 
retard the disease process. 
Prion protein expression levels influence scrapie 
incubation time 
Transgenic mice bearing hamster PrP transgenes also illustrate 
that incubation times are influenced by PrP expression levels. 
Examination of Figure 1 a and b shows that scrapie incubation 
time is inversely proportional to the PrP transgene expression 
level, thus mice with the highest hamster PrP' expression 
levels have a shorter scrapie incubation period than mice 
SHo Mo T0SHx T0MH2M T1MHM2 
01 	92 	321 	205 	294 	Line No. 




SHo Mo TgSHx TgMH2M T51MHM2 
81 	92 	321 	285 	294 
Inoculation with 
Mouse Prions 
S11 	Mo T5SIIa T5MIO2M T5M1OM2 
81 	92 	321 	285 	294 
expressing lower levels. This demonstrates a gene dosage 
effect on incubation time and a similar effect is observed in 
mice overexpressing a mouse PrP-B allele transgene (Westaway 
et al., 1991) and a PrP-A transgene (Carlson et al., 1994; 
Fischer et al., 1996; Telling et al., 1996) in which the scrapie 
incubation time is accelerated. A PrP gene dosage effect is 
also present in mice with reduced PrP expression levels. PrP 
null mice express no PrP and are not susceptible to scrapie, 
whilst heterozygous null mice, expressing only one functional 
PrP allele and producing -50% PrPC  levels, have a prolonged 
incubation time with respect to wild-type litterrnates (Bueler 
et al., 1993; Prusiner et al., 1993; Manson et al., 1995). 
Overexpression of wild-type PrP can be pathogenic 
A number of lines of transgenic mice, bearing high copy 
number wild-type PrP cosmid transgenes from a number of 
mammalian species, develop a late onset neurological disorder 
characterized by spongiform changes in the CNS, a demyelinat-
ing neuropathy of the peripheral nervous system and muscular 
pathology (Westaway et al., 1994b). The myopathy was limited 
to skeletal muscle groups including diaphragm and intercostal 
muscles and appeared before PNS demyelination, suggesting 
that PrP overexpression gives rise to a primary myopathy. 
CNS pathology included mild focal spongiform change in a 
number of brain regions. This pathology is similar in some 
respects to experimental scrapie but differed as follows: the 
pathology was milder than is generally seen in scrapie, the 
course was extended and no PrP11 was detected. The absence of 
PrPSC excludes the simple explanation of scrapie contamination. 
These observations imply that overexpression of wild-type PrP 
is sufficient for scrapie-like neuropathology and preliminary 
transmission experiments indicate that brain material from a 
number of clinically ill transgenic mice can transmit a scrapie- 
Figure 2. The hamster—mouse species barrier is controlled by the 
central region of PrP (a) Transgene expression levels in mice 
bearing full length hamster and chimeric mouse-hamster PrP 
transgenes: all expression levels are relative to hamster brain 
(PrPC)_expression  levels. All mice have endogenous mouse PrP' in 
addition to transgenes (when present). The type of transgene is 
indicated below the transgenic line number by a rectangle: filled 
rectangles represent full length hamster PrP: open rectangles 
represent wild-type mouse PrPC  and partially filled rectangles 
represent chimeric mouse/hamster. Tg(MH2M) has five amino acid 
alterations whilst MHM2 has two alterations (adapted from Scott 
et al., 1993). (b) Hamster scrapie Sc237 challenge of hamsters, 
wild-type mice and transgenic lines shown in Figure Ia. Syrian 
hamsters have a characteristically short incubation time whilst non-
transgenic mice are resistant to Sc237. Mice with full length 
hamster transgenes are those shown in Figure 1. Mice with larger 
hamster regions within the chimeric transgenes encode five hamster 
amino acid alterations and are susceptible to Sc237 whilst mice 
with only two hamster alterations [Tg(MHM2)] remain resistant 
(adapted from Scott et al., 1993). (c) Mouse scrapie challenge of 
hamsters, wild-type mice and transgenic lines. Despite 
overexpression of chimeric PrP' in MH2M and MHM2 lines, which 
have five and two amino acid alterations respectively, the mouse 
scrapie incubation time is not shortened. This suggests that these 
alterations have a dramatic effect upon the ability of the chimeric 
PrP' to be converted to chimeric pathogenic protease resistant 
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like disorder with low efficiency to some hosts. This together, 
with the transmission from mice overexpressing a GSSl0l 
mutant PrP (Hsaio et al., 1990, 1994; Telling et al., 1996) also 
suggests that not all prions are proteinase K resistant and 
constitutes further evidence for the de-novo generation of 
infectious agent in the absence of exogenous prions, good 
evidence for a protein-only model of the transmissible spongi-
form encephalopathies (McKinley et al., 1983). 
Fischer et al. (1996) have also observed a similar phenotype 
in mice overexpressing PrP-B from a Prn pb cosmid transgene, 
but this phenotype is not seen in two independent transgenic 
lines which overexpress PrP-A at high levels (Fischer et al., 
1996; Telling et al., 1996). This suggests that PrP-B and PrP-
A, which differ at codons 108 and 189, have quite distinct 
properties. 
Of course it remains formally possible that the phenotype 
associated with PrP overexpression is actually caused by 
overexpression of non-PrP sequences within the cosmid trans-
genes. It is interesting to note in this regard that both PrP-B 
expressing lines which develop a late onset phenotype were 
constructed from the Prn pb transgene derived from LLnIJ mice 
whilst the two published examples of absence of pathology in 
mice overexpressing PrP-A were in high copy number lines 
constructed with vectors differing in some way from the PrP-
B lines: Fischer et al. (1996) used a transgene derived from 
Prn pb Cos 6.ILn/J-4 but differed from all those used by 
Westaway et al. (1994b) and the PrP-B overexpressing line 
because —12 Kb of intron 2 sequence was removed (within 
which there may be a Purkinje neuron-specific enhancer 
element, see Fischer et al., 1996) and Telling et al. (1996) 
used a Syrian hamster PrP transgene (cosSHa.Tet) modified 
by insertion of the PrP-A ORF. However, modifying effects 
of the vectors cannot account for the overexpression phenotype 
because the cosSha.Tet vector was also used for the construction 
of the high copy number hamster transgenic lines which did 
develop a late onset phenotype. 
The observation of pathology in overexpressing mouse lines 
raises the intriguing issue of whether some sporadic CJD cases 
in humans occur as a result of PrP overexpression and 
whether there is variation within the human population for 
PrP expression levels. It seems reasonable to conclude that, 
given the consequences of overexpression in the mouse, 
humans expressing the prion protein at high levels might 
constitute a group which are particularly susceptible to environ-
mental prion contamination or to sporadic illness. PrPC  has been 
detected in the neuromuscular junctions of normal individuals 
(Askanas et al., 1993) and has been shown to accumulate in 
the muscles of some individuals with sporadic inclusion—body 
myositis, hereditary inclusion—body myopathy (Sarkozi et al., 
1994) and GSS patients with neuromyopathic changes 
(Rosenthal et al., 1976; Kretschmar et al., 1992). However, 
the relevance of PrP in muscles remains unknown as Pm-
p mice have normal muscle electrical excitability (Brenner 
et al., 1992). 
Chimaeric hamster/mouse prion protein transgenes 
generate new scrapie strains 
A higher resolution analysis of the hamster-mouse species 
barrier effect examined the role of five of the 16 amino acid 
differences between hamsters and mice (Scott et al., 1993). 
Transgenic mice, bearing chimeric hamster—mouse prion pro-
tein transgenes with a variety of hamster-specific amino 
substitutions, were generated (Figure 2) and this demonstrated 
that changing five mouse codons (Tg MH2M line: 108/111/ 
138/154/169) to those encoded by the hamster is sufficient to 
render mice susceptible to hamster prions. Mice with only 
two hamster substitutions (Tg MHM2 line: 108/111) remain 
resistant to hamster prions, suggesting that differences at the 
remaining three of the five codons (138/154/169) are respons-
ible for the majority of the species barrier between mouse and 
hamster. Mice overexpressing the complete hamster transgene 
at a similar level [Tg SHaPrP81] develop illness much earlier 
following inoculation with the same scrapie strain, suggesting 
that, whilst these amino acid alterations render the mouse 
susceptible to hamster prions, they synthesize hamster prions 
somewhat less efficiently than mice bearing the complete 
hamster sequence. 
There is strong evidence that TgMH2M mice (i.e. Tg mice 
with five hamster substitutions) generate a new scrapie strain 
(MH2M prions) which has an artificial host range, being 
infectious to hamsters, Tg(MH2M) mice and wild-type mice. 
This suggests that it is possible to generate an artificial scrapie 
strain by manipulating the PrP amino acid sequence, providing 
evidence that differences in scrapie strains may be a property 
of PrP structural variation. 
What have transgenic mice taught us about scrapie 
strains? 
An interesting but rather neglected property of strains is that 
the degree of species barrier can differ markedly between 
scrapie strains (Kimberlin and Walker, 1978). Work with 
hamsters and some transgenic work has brought this issue into 
focus and suggests that there are determinants of prion biology 
other than primary PrP amino acid sequence. If one considers 
transgenic work on the Sc237 hamster—mouse species barrier 
it is clear that the barrier effect is due to non-homologies 
between prion donor and recipient PrP sequences (Scott et al., 
1989; Prusiner et al., 1990). However, there is evidence that 
this is not always the case; Kimberlin and Walker (1978) 
isolated three scrapie strains in golden hamsters, of which two 
are very interesting in this regard, 263 K and 431K. 263K was 
highly infectious to hamsters and propagated to very high 
titres (incubation time of 60-70 days) but mice were very 
resistant to this strain, even after observation for 600 days 
(Marsh and Kimberlin, 1975). However 431K, which was also 
isolated from golden hamsters, transmitted with relative ease 
to both hamsters and mice. 
Work with Sc237 and mice with chimeric hamster—mouse 
PrP genes indicates that the majority of the species barrier 
effect is mediated by three critical PrP residues. One might 
suggest that the absence of a dramatic species barrier effect 
between hamsters and mice with 431K may be because the 
conformation of 43 1 K prions is such that the side chains of 
these three residues are not involved in (or have a minor 
importance in) the interaction between hamster 431K PrP 
and mouse PrPC.  This suggests that the species barrier and 
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Figure 3. The conflicting evidence for Protein-X. A variety of wild-type and transgenic lines of mice, with and without endogenous mouse 
host-encoded glycoprotein (PrP'), are represented by 10 challenge groups. Groups 1-5 represent mice inoculated with sporadic Creutzfeldt—
Jakob disease (CJD: case RG, a codon 129 methionine homozygote). Groups 6 and 7 are challenges with iatrogenic CJD (case 348, a codon 
129 methionine homozygote). Groups 8-10 are challenges with an iatrogenic CJD isolate PDGI70 (129 methionine/valine heterozygote). 
Groups I and 8 illustrate the resistance of wild-type mice to human CJD prions. The response of group 2 indicates that mice encoding a full 
length human transgene remain resistant to the RG isolate of CJD. However the incubation time of mice bearing the same transgene is 
dramatically accelerated by ablation of endogenous mouse PrP genes (group 3). This suggests that mouse PrPC  retards the replication of 
human pathogenic protease-resistant isoform (PrPSC)  in the mouse. The essential regions of human PrP required to overcome the species 
barrier between the mouse and human are within the region delimited by codons 88-167 and is illustrated in groups 4 and 5. Comparison of 
groups 4 and 5 also demonstrates that endogenous mouse PrP no longer retards the propagation of human PrP" if human PrP is limited to 
the central region between codons 88 and 167 by use of a mouse—human chimeric transgene. Group 6 illustrates that challenge with another 
CJD isolate yields similar incubation times in mice devoid of mouse PrP but comparison with group 7 (which express a human PrP 
transgene encoding methionine rather than valine at codon 129) shows that correct matching of the inoculum and host codon 129 met/val 
polymorphism can result in faster incubation times. Indeed, the incubation time in group 7 mice is —100 days shorter despite expressing 
human PrP at only 25-50% of the levels of the other transgenic lines. This suggests that codon 129 mismatches between inoculum and host 
PrP significantly retard the propagation of human prions. The data presented in groups 8-10 is derived from challenges performed on the 
same transgenic mouse lines by Collinge et al. (1995) using a different CJD isolate. Mice encoding endogenous mouse PrP in addition to 
the human transgene (group 9) are susceptible to the iatrogenic CJD isolate PDG 170. This is quite different from the response noted by 
Telling et al. with sporadic CJD isolate RG (group 2). This suggests that the effect attributed to Protein-X does not necessarily hold when 
challenged with a different CJD isolate, although there may be simple technical explanations for this discrepancy. 
between both PrP primary structure and other properties of 
PrP, such as conformation. 
The prion protein may interact with an unidentified 
protein: Protein-X 
Given that hamster transgenes overcome the species barrier 
between mouse and hamster (Scott et at., 1989; Prusiner et at., 
1990), one might predict that a mouse expressing human PrP 
would be susceptible to human prions. A recent series of 
publications suggests that this is not necessarily the case 
(Telling et al., 1994) unless the endogenous mouse gene is 
ablated by crossing the human transgene onto a murine PrP 
null background (Figure 3) (Telling et al., 1995). This shows 
that endogenous mouse PrP can dramatically retard the propa- 
gation of human PrPSC  in the mouse. The authors postulate the 
existence of a second protein, Protein-X, with which PrP must 
interact to propagate prions. If one assumes that interaction 
with Protein-X is essential for the PrPcPrPsc  conversion and 
that mouse Protein-X interacts with mouse PrP with a much 
higher affinity than with human PrP, it is likely that endogenous 
mouse PrP will compete with human PrP for interaction with 
mouse Protein-X, and this will result in highly inefficient 
synthesis of human PrP in the mouse. 
Mice bearing a chimeric mouse—human transgene have a 
rapid incubation time with CJD prions regardless of the 
presence of endogenous mouse PrP (compare Figure 3, groups 
4 and 5). The chimeric transgene is based upon mouse PrP 
but has a central region encoding amino acids 96-167 replaced 
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by the corresponding region of human PrP. This suggests that 
it is likely that the region of interaction between PrP and 
Protein-X lies outside the region bearing the human PrP portion 
of the chimeric transgene. The predicted region of interaction 
between PrP and Protein-X is in the C-terminus. This is based 
upon two pieces of evidence: (i) the chimeric mouse-human 
transgenes contain only a central region of human PrP, but the 
propagation of chimeric prions is not retarded by endogenous 
mouse PrP; and (ii) it has been shown in scrapie-infected 
neuroblastoma cells (Rogers ci' al., 1993) and transgenic mice 
(Fischer ci' al., 1996) that large portions of the PrP N-terminus 
are dispensable for the PrPcPrP conversion event. The C-
terminus between codons 215 to 230 contains a number of 
divergent amino acids, notably a region which is shared by all 
rodent sequences so far determined, but quite distinct from 
other mammalian PrP molecules. The conservation of this 
region between rodents might explain why the effect of Protein-
X was not discovered during earlier work with the control of 
the species barrier between mouse and hamster, i.e. hamster 
and mouse PrP probably have a similar affinity for mouse 
Protein-X and thus the propagation of hamster PrP in the 
mouse is not retarded by competition with endogenous 
mouse PrP. 
The postulated existence of Protein-X explains some other-
wise confusing observations: Tg(MoPrP-P1O1L) mice carrying 
a full-length mouse PrP transgene, with a codon 101 point 
mutation homologous to the human PrP codon 102 mutation 
linked to GSS (Hsaio etal., 1989, 1990), develop a spontaneous 
illness between 50-300 days but mice expressing a full-length 
human PrP transgene with the same mutation at similar levels 
do not develop a spontaneous disease after observation for 
>700 days (Telling et al., 1995). The difference between 
the two transgenic lines is presumably due to the non-
permissiveness of the mouse for the propagation of human 
PrPIc as described above. It would be predicted from this that 
the mice with the mutant human transgene will develop illness 
if the transgene is crossed onto a mouse PrP null background. 
This work is in progress (Telling ci' al., 1995). 
Transgenic modelling of human susceptibility to BSE 
Transmission of BSE to mice is well established (Fraser etal., 
1992; Bruce, 1993; Bruce et al., 1993, 1994) and transgenic 
mice expressing human PrP at high and low levels have been 
challenged with BSE to investigate the species barrier between 
cows and humans to BSE. The preliminary results from this 
experiment suggest that mice expressing human PrP129' are 
not more susceptible to BSE prions than non-transgenic mice 
(Collinge et al., 1995). However, all transgenic mice used in 
this study also expressed endogenous mouse PrP, which has 
been shown to retard the propagation of human PrPs  in mice, 
at least under some circumstances (see legend to Figure 3) 
(Telling ci' al., 1995). In this respect, the BSE challenge 
response of mice which express human PrPC  without endogen-
ous mouse PrP' should resolve this issue, although preliminary 
results suggest that Prn-p/HuPrP129" mice are not dramatic-
ally more susceptible to BSE than mice which also express 
endogenous PrP. 
It should be noted, however, that the codon 129 genotype  
of the BSE inoculum (cows are 129 met homozygotes) and 
the human transgene were not matched and this may reduce 
the efficiency of bovine PrP—human PrF interactions. One 
might predict that if the BSE challenge experiment were 
repeated using a transgenic mouse strain expressing the human 
PrPl29Met allele, such as Tg (HuPrP440) (Telling ci' al., 1995), 
the mice would have a shorter incubation time than mice 
expressing the HuPrP 129Val  transgene and provide a quite 
different picture about the human response to BSE prions. 
Regardless of the outcome of such work, it is important to 
remember that mice are not humans and that the consequences 
of exposure of the human population to BSE prions is difficult 
to predict (Hope, 1995). The emergence of a new variant of 
CJD, nvCJD (Will et al., 1996), with a novel clinical and 
neuropathological phenotype together with the demonstration 
that macaques challenged with BSE have nvCJD-like neuro-
pathology (Lasmezas ci' al., 1996) argues persuasively that 
BSE can be transmitted to humans. PrP'  from BSE cattle 
brain and nvCJD brain has been shown to have similar sodium 
dodecyl sulphate—(SDS—PAGE) banding patterns (Collinge 
et al., 1996) adding further weight to the evidence that nvCJD 
has arisen from BSE infection of humans. However, the value 
of SDS—PAGE banding patterns as a means of strain typing 
prions is controversial not only because very little is known 
of the diversity of SDS—PAGE banding patterns prevalent 
amongst CJD cases but because there are examples of strains 
with very different biological properties which have similar 
banding patterns in the same hosts (e.g. ME7 and 22L: Kascsak 
et al., 1991). 
Mouse models of familial prion diseases 
Pronuclear injection has been used to generate mice transgenic 
for the human PrP codon 102 proline to leucine substitution 
linked to ataxic GSS in humans (Hsaio ci' al., 1989). Mice 
overexpressing a mutant mouse MoPrP101Leu transgene 8-
fold (the homologous mutation is at codon 101 in mouse PrP) 
in addition to endogenous PrP-A develop a spontaneous 
neurologic disorder indistinguishable from scrapie with onset 
between 50-300 days (average 196 days). Clinically ill mice 
had histopathological similarities with GSS including moderate 
astrocytic gliosis, spongiform degeneration of the cerebrum 
and brain stem but few PrP amyloid plaques. Brain material 
from clinically ill PrP101 	mice transmitted a neurodegener- 
ative disease, providing evidence that a PrP mutation is 
sufficient to programme the generation of prions de nova 
(Hsaio et al., 1994) in the absence of exogenous agent. These 
mice transmit disease with low efficiency to both hamsters 
and low copy number lines of PrPbo1Leu  transgenic mice (which 
do not normally develop a spontaneous disease). The failure 
to transmit to wild-type mice suggests that the codon 101 
mutation generates a species barrier-like effect. It is possible 
that the clinical illness was not due to the specific effect of the 
codon 101 pro—leu mutation, but a result of PrP overexpression 
similar to that observed in mice overexpressing wild-type PrP-
B (Westaway et al., 1994b). The effect of PrP overexpression 
has recently been addressed and it appears that overexpression 
of PrP-A (Fischer etal., 1996) at similar levels to the PrP10 1Leu 
mutation, in contrast to PrP-B (Westaway et al., 1994b) is not 
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pathogenic. Breeding the 1011u  transgene onto a PrP null 
background has revealed that endogenous PrP significantly 
modifies the behaviour of PrP 10lJ1  (Telling etal., 1996): PrP 
null mice hemizygous for the 101Leu  transgene have an earlier 
and more synchronous age of onset at 145 days (hornozygotes 
have disease onset at ...-85 days), have more amyloid plaques 
and transmit more reproducibly to low copy number PrP111 eh1 
transgenic mice. 
We have used gene targeting to construct codon 101Lt 
mutant mice in which the mutant allele is under the control 
of the endogenous mouse PrP promoter in order that the 
expression of mutant PrPbOu  faithfully reflects that of wild-
type PrP and allows the consequences of the mutation to be 
determined in the absence of overexpression. In contrast to 
mice which overexpress this mutation we do not observe any 
neurological illness at .-500 days (R.Moore, D.Melton and 
J.Manson, unpublished data), suggesting that overexpression 
of the mutant PrPl0P-' is a prerequisite for illness in the 
mouse, an animal with a short lifetime. The requirement for 
overexpression to gain a phenotype has also been observed 
with attempts to model Alzheimer's disease in mice (Games 
et al., 1995). 
A PrP codon 200 glutamate to lysine mutation, responsible 
for a large number of familial CJD cases in Slovakia (Goldfarb 
ci al., 1990, 1991a,c), has also been introduced into mice as 
a modified mouse PrP-A transgene but only six of 20 mice 
developed illness by 744 (±31) days and none of them showed 
signs of scrapie-like pathology or detectable levels of PrPsc  
(Telling et al., 1996). The reason for the lack of pathology is 
unclear but it would be informative to both breed this transgene 
onto a PrP null background and onto a variety of mouse 
genetic backgrounds as this can have a significant effect upon 
the phenotype of neurological disorders in transgenic mice 
(Hsaio et al., 1995). 
Several mouse lines expressing a premature alteration codon 
(PTC) at mouse codon 143 have been generated (Fischer etal., 
1996) in an attempt to model a 145° mutation found in a 
woman with an Alzheimer's-like illness (Kitamoto et al., 
1993). However, the mice expressed very low levels of PrP 
mRNA and no detectable PrP' and Fischer et al. suggest that 
low levels of PrPC  may be present because the truncated 
peptide may (as it is devoid of the C-terminus GPI anchor) be 
released from the cell surface and be rapidly degraded. An 
alternative explanation might be that the PTC decreases PrP 
mRNA stability as has been described with a variety of human 
genes including CFTR (Hamosh etal., 1991), J3-globin(Baserga 
and Benz., 1988), dihydrofolate reductase (Urlaub et al., 1989) 
and triosephosphate isomerase (Belgrader ci al., 1993). 
PrP knockout mice 
PrP knockout mice have proven to be an invaluable resource 
and four groups have independently generated PrP knockout 
mice (Bueler et al., 1992; Manson ci al., 1994; Moore et al., 
1995; Sakaguchi ci al., 1996) by gene targeting in ES cells. 
The very high amino acid conservation of PrPC  between 
mammals and the presence of a 20 amino acid region that is 
100% conserved in all mammalian species and chickens 
suggests that PrPC  has an essential function in viva. However, 
the first PrP null mice were fertile and had no overt phenotype 
(Bueler et al.. 1992). It is possible that PrPC  function is 
complemented by another protein. However, a growing number 
of abnormalities have been reported recently in PrP nulls. 
An electrophysiological defect has been found (Collinge 
ci al., 1994) which is rescued by human PrP transgenes. 
demonstrating conservation of function between mouse and 
human PrP (Whittington ci al., 1995). However, another group 
have been unable to detect these defects in PrP null mice 
(Lledo etal., 1996), although the authors suggest that this may 
be due to differences in genetic background. The importance of 
genetic background as a major modifier of knockout phenotypes 
is well established amongst workers dealing with the behavi-
oural genetics of organisms such as Drosophila (for review of 
examples in the mouse see Gerlai, 1996). 
Recently alterations in the circadian rhythm and sleep 
patterns have been reported in two lines of PrP nulls (Tobler 
ci al. 1996). Kept in a normal light:dark cycle (12 h light:12 
h dark), wild-type mice display highly reproducible patterns 
of activity which can be recorded on running wheels. Being 
nocturnal, wheel running activity is greatest during the dark 
cycle and indeed the first half of the dark cycle involves a 
period of prolonged exercise which trails off and the mice are 
relatively inactive during the light cycle. When mice are 
maintained in conditions of permanent darkness, prolonged 
recording from wild-type mice shows that, whilst absolute 
activity levels remain the same, the time at which wheel 
running activity initiates in the 24 h cycle progressively drifts 
by several min each day. Presumably this is adaptive and 
enables the mouse to reset (entrain) its circadian activity to 
changing environmental cues, such as seasonal changes in 
day length. PrP nulls demonstrated a significantly prolonged 
circadian period length but even more surprisingly, switching 
the lights off permanently has little or no effect upon the pattern 
of wheel running activity. Additionally, when maintained on 
a normal 12 h dark:12 h light cycle, PrP nulls were more 
active in the second half of the dark cycle than wild-type 
mice, whilst electroencephalogram (EEG) analysis suggests 
that PrP nulls have fragmented sleep patterns and are less 
tolerant to sleep deprivation. This suggests that a normal 
function of PrPC  may be the control of sleep continuity or 
intensity. In rodents, lesions in the suprachiasmatic nucleus 
are known to have an effect upon circadian activity and this 
area is considered to be the site of the mammalian circadian 
clock, however there is no published data suggesting that the 
PrP nulls have a morphological defect in the suprachiasmatic 
nucleus. 
These observations have a number of similarities to FF1, a 
variant of CJD. FF1 has intractable insomnia and selective 
thalamic atrophy as a major feature (Gambetti et al., 1993). 
Could it be possible that at least some of the effects of prion 
diseases are due to loss of normal PFPC  function as it is 
converted into PrP? It is more likely that this parallel is 
conincidental and that the insomnia phenotype in FF1 is due 
to the severe thalamic pathology and endocrine abnormalities 
found in these cases. 
A late onset cerebellar ataxia has been reported in one PrP 
knockout line (Sakaguchi ci al., 1996) which develops at -70 
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weeks of age, suggesting that PrP may be required for the 
long-term survival of cerebellar Purkinje neurons. Given that 
this phenotype has not been reported in other lines of 
PrP knockout mice, it is important to exclude a number of 
alternative explanations other than loss of PrPC  function, as 
the cause of the phenotype. There is the remote possibility 
that the cerebellar phenotype is due to the inactivation of an 
unknown gene immediately 5' to PrP exon 3. The null allele 
generated by Moore et al. (1995) is very similar to that of 
Sakaguchi et al. (1996) and analysis of appropriately aged 
mice should provide a good comparison. 
PrP null mice (Bueler et al., 1992) overexpressing PrP-A 
from a modified Prnpb  transgene in which intron 2 had been 
removed had PrP expression levels and distribution similar to 
mice bearing the full length transgene (Fischer et al., 1996) 
with the notable exception that PrP was no longer expressed 
in cerebellar Purkinje neurons, a cell type which normally 
expresses PrP abundantly and suggests that Pm-p intron 2 bears 
a Purkinje enhancer. These mice do not have an endogenous PrP 
allele and therefore could be considered to be a Purkinje-
specific PrP knockout: the fact that these mice do not develop 
a late onset cerebellar disorder following observation for >600 
days suggests that the loss of PrP expression in cerebellar 
Purkinje neurons is not the cause of the PrP null phenotype 
described by Sakaguchi et al. (1996). 
PrP nulls enable experiments in which the restricted expres-
sion of PrPC  from a PrP transgene can help determine the 
relative roles of various CNS regions and cell types in the 
propagation of scrapie. The recent demonstration of convincing 
in-situ hybridization evidence for PrPC  expression in glial cells 
(Moser et al., 1995) has raised issues about the role of non-
neuronal CNS cell types in prion propagation. A PrP null 
mouse carrying a hamster PrP transgene driven by a neuron 
specific enolase promoter (Race et al., 1995) developed scrapie, 
showing that glial expression of PrP is not critical for scrapie, 
although other experiments will be required to exclude the 
possibility that non-neuronal CNS cell types may propagate 
low, but significant, levels of prions or indeed that there are 
some strains that do propagate in glials. 
There is some evidence that glial fibrillary acidic protein 
(GFAP) is a PrP ligand (Oesch et al., 1990) and is therefore 
a candidate co-factor for prion propagation in vivo. However, 
GFAP null mice do not have altered scrapie susceptibility 
(Gomi et al., 1995), suggesting that whilst GFAP may engage 
in some sort of interaction with PrP', it is not essential for 
prion propagation. 
The means by which PrP11 accumulation results in cell death 
is beginning to yield some clues. For instance, primary rat 
hippocampal cell lines have been shown to die by apoptosis 
after chronic exposure to a synthetic peptide corresponding to 
PrP amino acids 106-126 (Brown et al., 1996); a region 
completely conserved within mammals and also in chicken. 
This data is particularly interesting because apoptosis seems 
to be an important means of cell death in viva during prion 
diseases. The role of PrPC  in this effect is critical because PrP 
null primary cultures are not susceptible to the toxic effects 
of this peptide. A similar phenomenon has been shown in viva 
with brain grafting experiments (Brandner et al., 1996): if  
brain grafts from PrPC  expressing donors are introduced into 
the brains of PrP null recipients and the mice inoculated with 
scrapie, the host mice do not get scrapie but the PrPC  expressing 
graft does. The characteristic scrapie pathology is clearly 
evident in the graft but the PrP null host brain is apparently 
normal. Pathology is strictly limited to graft cells expressing 
PrP. PrP migrates long distances from the graft into the host 
PrP null brain but does not cause any pathology despite 
forming PrP amyloid plaques. Thus, there is both in-vitro and 
in-vivo evidence that PrP' expression is required for cells to 
be susceptible to scrapie induced pathology. 
Conclusions 
Prion disease research has come a long way in the last 8 years 
since the first use of mouse transgenesis was reported (Scott 
et al., 1989). It is now known that the species barrier is 
controlled in large part by differences in PrP amino acid 
sequence (and probably structure) between the inoculum and 
host animal (Scott et al., 1989, 1993; Prusiner et al., 1990). 
This has been corroborated by in-vitro work which shows that 
heterologies based upon single amino acid alterations can 
dramatically alter the efficiency of PrP synthesis (Priola et al., 
1994; Priola and Chesebro, 1995). 
The variable copy number in transgenic mice have shown 
that scrapie incubation time is not only determined by PrP 
gene sequences but also by PrP expression levels: mice with 
reduced PrP expression levels have prolonged experimental 
scrapie incubation times (Bueler et al., 1993; Manson et al., 
1994; Sakaguchi et al., 1996), whilst mice with raised PrP 
expression levels have shorter incubation times. The extreme 
end of this spectrum is manifest in a spontaneous scrapie-like 
(note however that no PrP is produced) illness in mice which 
grossly overexpress wild-type prion protein (Westaway et al., 
1994b). The crucial role of PrP is demonstrated by the complete 
resistance of PrP null mice to prion infections (Bueler et al., 
1993). The discovery of the first human prion protein mutation, 
in a kindred with Gerstmann—Straussler—Scheinker disease 
(Hsaio et al., 1989), was followed by a transgenic model 
which developed a similar disease spontaneously which was 
subsequently shown to be transmissible (Hsaio et al., 1990, 
1994). However mice overexpressing a codon 001ys  mutant 
PrP do not develop neurological symptoms (Fischer et al., 
1996). 
PrP knockout mice have provided clues to the normal 
functions of PrP, suggesting a role in neurotransmission 
(Collinge et al., 1994), in the control of some aspects of sleep 
and circadian rhythm (Tobler et al., 1996) and possibly a 
role in the long-term survival of cerebellar Purkinje neurons 
(Sakaguchi et al., 1996). 
Much of the mouse transgenesis has provided further weight 
to the biochemical evidence suggesting that an abnormal 
isoform of the prion protein, PrP', is a major component of 
the transmissible agent (Prusiner et al., 1982a). The prion 
hypothesis has gained widespread, but not universal, accept-
ance. Familial prion diseases are linked to PrP germline 
mutations and it is presumed that mutations can adversely 
affect the structural stability or the behaviour of mature and 
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nascent mutant PrF peptides to the extent that misfolding 
events give rise to infectious prions (i.e. PrPsc)  within the 
carrier of the mutation. The spontaneous development of a 
transmissible scrapie-like disorder in a mouse model of the 
GSS 102 Leu  mutation supports this view. However, sporadic 
CJD represents 85% of all CID cases but is not associated 
with PrP mutations or exposure to infectious material, sug-
gesting that sCJD is the result of rare spontaneous PrPC 
misfolding events to form prions de novo in the absence of 
exogenous contamination. 
The future 
One of the major problems facing proponents of the prion 
hypothesis is to account for scrapie strain diversity, stability 
and mutability. The current paradigm of molecular genetics 
holds that heritable biological information is transmitted by 
nucleic acids. How can an infectious agent which has distinct 
strains or isolates encode information in the absence of nucleic 
acid? There is a growing body of evidence that PrPC  and PrP 
differ in conformation and it is possible that strains may be 
conformational isomers of PrP5<. One approach may be to 
correlate strain specific properties with distinct biophysical 
differences between PrPSC  molecules. Ideally each strain might 
represent a distinct conformer (or mixture of conformers) of 
PrP. There are a number of examples of PrPsc  from different 
strains with distinct biophysical properties such as differences 
in protease resistance and SDS—PAGE mobility (Kascsak et al., 
1991). As with all things in this field the story is complex and 
there are examples of PrP11 with similar properties in different 
strains. It is not understood how different strains may target 
different cells types. There are numerous PrF glycosylation 
variants and it may be possible that the different lesion profiles 
found with each strain may arise from the differential infection 
of neurons which express certain PrP glycoforms. The propaga-
tion of PrPsc within such neuronal subtypes may enable the 
glycosylation patterns to 'breed true' and enable the stable 
maintenance of the biological properties of a given prion 
isolate or strain. A good test of this hypothesis is to generate 
gene targeted mice which have had the glycosylation sites 
removed, however in vitro analysis of glycosylation mutants in 
neuroblastoma cells suggests that the prion protein accumulates 
intracellularly (Rogers et al., 1990) and may therefore have a 
deleterious phenotype in mice, precluding analysis by scrapie 
challenge. 
Clearly, three-dimensional analysis of PrPsc  structure should 
resolve this issue by demonstrating whether different prion 
strains possess distinct conformations, but progress has been 
thwarted by technical difficulties crystallizing PrP and PrP'. 
However, a partial NMR structure of PrPc has been recently 
published (Rick et al., 1996) and offers some rational basis 
for the investigation of structural modifications to PrPC.  
Prion diseases and modifier genes 
It is clear that, for the foreseeable future, the prion field will 
focus upon the structural analysis of PrP and, as knowledge 
accumulates, the in-vivo relevance of structural alteration to 
PrP will have to be determined in transgenic mice. New 
prion diseases such as familial progressive subcortical gliosis 
(Petersen et al., 1995), in which PrPSC  is found in the absence 
of coding region mutations, but with linkage to chromosome 
17, point towards a role for other genes in prion diseases. 
Indeed, several decades of genetic analysis of mouse scrapie 
incubation time control has shown that there are clearly non-
PrP genes involved in the determination of incubation time 
length and pathology (Kingsbury et al., 1983; Bruce and 
Dickinson, 1985; Carlson etal., 1994; Westaway etal., 1994a). 
Similarly, the penetrance of some familial prion diseases 
associated with protein mutations is significantly <100% and 
some individuals within a kindred can present with quite 
different clinical symptoms and neuropathology despite bearing 
the same germline PrP mutation (Dohura et al., 1989; 
Hainfellner et al., 1995; Mastrianni et al., 1995), indicating a 
role for modifier genes. The identity of PrP ligands such as 
Protein-X (Telling et al., 1995) and others will also be 
interesting and their relevance to prion diseases will be tested 
by gene ablation in mice. 
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Appendix II 
Restriction maps of targeting vectors 
p108F and p189V 
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Appendix H a: Restriction map of targeting vector p108F 
Map of the completed PrP exon 3 108F targeting vector. This vector was linearised at 
a unique 3' Cia I site prior to electroporation. 
Restriction enzyme abbreviations: B, Barn HI; E, Eco RI; H, Hind III; K, Kpn I; P, 
Pst I; S, Sma I; X, Xba I. 
I 	I PrP coding region I 	I PrP UTR 




7.8 (+3.0=10.8) BamHT 
(1.9) 	 2.1 	 3.7(+3.0+1.9 = 8.6) 
I 	 EcoRI 
1.8 (+3.0=4.8) 	 2.5 	 0.34 	 1.9 	 1.3 
I 	 I 	I I 	 I 	 Hind III 
3.2 (+3.0=6.2) 	 6.4 
I 	 KpnI 
80bp 	 2.3 	 2.0 	 1.6 	 1. 1(+3.0=4. I)* 	
Pst I 
2.0 	 3,5 	 1.7 	 0.7(+3=3.7) 
I 	 I 	 I 	 XbaI 
(3.5) 	 3.3 	 0.6 	0.4 (+3.0+3.5=6.9) 
I 	 I 	 I 	 BstEII 
6.4 (+3.0=9.4) 	 1.4 
	
I 	 I 	 SalT 
7.8 
1 	 EcoRV 
(3.0) 	 4.8 (+3.0+3.0=10.8) 
I 	 Smal 
7.8 (+3.0 = 10.8) 
I 	 CIaI# 
* there is one unmapped Pst site within this region 
# unique I mearisation site 
Appendix II b: Restriction map of targeting vector p189V 
Map of the completed PrP exon 3 189V targeting vector. This vector was linearised 
at a unique 3' Cia I site prior to electroporation. 
Restriction enzyme abbreviations: B, Barn HI; E, Eco RI; H, Hind III; K, Kpn I; P, 
Pst I; S, Sma I; X, Xba I. 
I 	I PrP coding region I 	I PrP UTR 
252 	 Appendices 
a 
	
liii iii 	 189V 	 - 	.o 	c 	liii liii 
L. P 	 HEX p 	SK 	 E HPH 	 x 	p 	H P X 	 J 
I 	DB7'S'.[TI./'f 	 I I II 	II 	I I 
7.8 (+3.0=10.8) 	 Barn HI 
(1.9) 	 2.1 	 I 	
3.7 (+3.0+1.9=8.6) 	
Eco RI I  
1.8 (+3.0=4.8) 	 2.5 	 0.34 	 1.9 	 1.3 	
Hind HI 
3.2 (+3.4.2) 	 6.4 
I 	 KpnI 
OObp 	 2.3 	 2.0 	 1.6 	 * 	 1.1 (+3.0=4.1) 
I 	 I 	 I 	 I 	 PstI 
2.0 	 3.5 	 1.7 	 0.7 (+3=3,7) 
I 	 I 	 I 	 XbaI 
(6.8) 	 0.6 	0.4 (+3.0+6.8=10.2) 
I Bst Ell 
6.4 (+3.0=9.4) 	 1.4 
I 	 Sail 
7.8 
I 	EcoRV 
(3.0) 	 4.8 (+3.0+3.0=10.8) 
I 	 Smal 
7.8 (+3.0 = 10.8) 
CiaI# 
* there is one unmapped PsI site within this region 
# unique linearisation site 
